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Chapter I: Introduction 1
Chapter I: Introduction 
Over the last two decades peptide and protein pharmaceuticals gained 
significant importance in the treatment of several severe diseases including 
autoimmune diseases, memory impairment, hormonal disorders and different 
cancers. Major advantages of protein pharmaceuticals are both their extremely 
specific activity and their high tolerability. With the advance of recombinant DNA 
technology the large scale production of peptides and proteins for pharmaceutical 
purposes has become feasible, but the number of protein pharmaceuticals available 
on the market still lags behind this achievement. 
The reasons for that are multiple: an inherent physical and chemical instability of 
most proteins, which is associated with relevant difficulties in purification, storage and 
delivery, and the problem of making protein drugs access their target sites at the right 
time and for adequate duration [213; 184]. 
Though a number of innovative oral protein delivery approaches have been 
developed – i.e. drug entrapment within liposomes and nanoparticles or the covalent 
coupling to carriers like vitamin B12 - , one major technical challenge for the 
pharmaceutical scientist still is to overcome the enzymatic barrier of the 
gastrointestinal tract [118]. In other words, protein pharmaceuticals are administered 
traditionally through parenteral injection. Unfortunately, most of these proteins are 
only therapeutically useful when following a therapeutic regimen of frequent 
injections or intravenous infusions throughout a long period. This leads to poor 
patient compliance, side effects, and cost-consuming hospitalisation [184]. 
In this realm, non-invasive administration methods such as the pulmonal route [196] 
as well as the transdermal and the nasal application ways could provide major 
benefits [10]. Nevertheless, the development of injectable, sustained and controlled 
release systems can be regarded as the most promising strategy in protein delivery. 
By slowly releasing the protein, these systems virtually act infusion-like. 
Thus, key advantages of those systems can be [150; 42]: 
• reduced injection frequency, associated by an improved patient compliance 
• increased efficiency due to long-term blood levels 
• decreased adverse reactions and side effects 
• passive and/ or active targeting  
• cost savings 
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Injectable depot delivery systems can be divided into four major groups: implants, 
microspheres, nanospheres, and injectable depot solutions, many of them based on 
various matrix materials. The research on synthetic biodegradable polymers such as 
poly(D,L-lactide) (PLA), copolymers of lactide and glycolide (PLGA) and 
polyanhydrides led to FDA approval of several sustained release formulations for 
peptides [184]. Though, the delivery of proteins proves to be more difficult. Despite a 
considerable amount of research only one protein-containing polymeric device 
gained FDA approval in 1999. However, this year Genentech and Alkermes 
announced their decision to discontinue the commercialisation of Nutropin DepotTM, 
which is composed of PLGA microparticles loaded with recombinant human growth 
hormone [99]. This limited success may be caused by drawbacks synthetic polymer-
based systems can inhere. During manufacturing and after administration, 
parameters like shear forces, interface formation, acidification and protein-polymer 
interactions can result in protein denaturation and aggregation [130; 68; 176; 198]. 
Besides, the issue of residual organic solvents remains unsolved [219]. 
By these latest scientific findings, interest in the evaluation of biocompatible natural 
materials as alternative to synthetic polymers increased [104; 188; 211]. 
Nonetheless, the effort to establish lipids such as triglycerides and monoglycerides 
as controlled delivery systems for protein drugs has been neglected in the last years. 
Lipid matrix materials exhibit several potential advantages in comparison to 
polymers, i.e. high biocompatibility, simple manufacture by compressing or moulding. 
Furthermore, the slower water uptake after administration may result in a less 
detrimental environment for incorporated proteins [153; 201]. Consequently, this 
somewhat shadowy existence should not persist any longer. 
1. Fundamentals of protein stability  
1.1 Protein structure 
In spite of the enormous number of naturally occurring proteins, a mere of 20 
amino acids construct proteins. The vast difference in the three-dimensional structure 
and, therefore, also in protein function originates solely from a different amino acid 
sequence, i.e. the unique structure of a protein is determined by the chemical and 
physical properties of the amino acids aligned within the protein sequence. 
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Protein structure can principally be described at four different levels. The primary 
structure refers to the linear arrangement of amino acid residues along a polypeptide 
chain and to the location of covalent bonds, such as disulfide bonds, between chains 
or within a chain. The secondary structure describes the folding of parts of these 
chains into regular, ordered structures like α-helices and β-sheets. Furthermore, 
areas with increased flexibility – the so-called turns or loops – are to be subsumed in 
this level of protein structure. The domains of the secondary structure and all non-
covalent interactions such as hydrogen bonds and hydrophobic, electrostatic, or van 
der Waals interactions generate the intrinsic, three-dimensional arrangement of a 
protein, the tertiary structure (Fig. 1). The association of secondary structures shield 
a substantial fraction of the non-polar amino acid residues from solvents due to an 
embedding within the protein molecule interior. Some proteins consist of several 
polypeptide chains. Finally, the quaternary structure characterises the non-covalent 
interactions binding these chains into a single protein molecule. For example, 
haemoglobin consists of four polypeptide chains, which are associated by one Fe2+ 
ion. 
The retention of the tertiary structure is deemed the primary requirement for the 
biological activity of protein molecules [41]. However, the biochemical and structural 
complexity of these molecules is the reason for proteins to react sensitive to even 
marginal changes in their natural environment. 
1.2 Chemical instability 
Some amino acid side chains are chemically reactive, whereas others are 
chemically inert. It has been demonstrated that “labile” amino acid residues are 
susceptible to covalent modifications via bond formation or cleavage through non-
enzymatic reactions, including [119] 
• hydrolysis 
• deamidation 
• oxidation 
• racemisation 
• ß-elimination 
• disulfide exchange. 
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1.3 Physical instability  
Mentioning physical instability of globular proteins denotes that these super 
structured molecules can undergo changes independent of any chemical 
modification. The loss of tertiary structure, and frequently also of secondary structure 
is generally referred to as denaturation of the protein. 
1.3.1 Denaturation, aggregation and adsorption of proteins 
The folded state of proteins is connected to conformational stability, which is 
expressed as the free energy change G during the unfolding/denaturation reaction 
under physiological conditions [142]. The higher the G value, the greater the 
stability of the protein. However, the reported G values for proteins of 45 +/- 15 
kJ/mol [92] indicate that the folding state is only marginally more stable than the 
denatured state. As a matter of fact, the conformational stability of a protein in 
aqueous solution tallies with only a few H-bonds or ion pairs [213].  
Simplified, protein denaturation can be described as:  
 
Figure 1: Equation of the native and denatured state of a protein [176]. 
The native state N exists in an equilibrium with a partially unfolded state pU. This 
unfolding of the native protein can be reversible, e.g. an increase of the temperature 
causes unfolding, which can be reversed by a subsequent temperature decrease 
[123]. Generally, the loss of the tertiary structure implies an increase in the protein 
molecule’s reactivity. Hydrophobic regions, which were accumulated in the core of 
the folded protein, are then exposed to surrounding solvents. As a consequence, 
side reactions can now lead to an irreversible, denatured state D. Alternatively, 
partially unfolded proteins may encounter irreversible aggregation (pU)n. Constantly 
elevated temperatures, extreme pHs, the formation of interfaces during shaking, 
shearing, adsorption to hydrophobic surfaces, high pressure, and denaturants such 
as urea and GdnHCl foster irreversible transitions [197; 91; 63; 122]. 
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Protein aggregation is defined as the association of at least two denatured protein 
molecules. Non-covalent aggregation is caused by interactions between the exposed 
hydrophobic residues of denatured protein molecules. Initially, the formation of 
soluble aggregates occurs. With increasing numbers of molecules the solubility of 
these species will decrease, eventually resulting in the precipitation of the protein. 
Covalently linked protein aggregates are due to chemical reactions, e.g. ß-
elimination, disulfide exchange or transamidation.  
Protein aggregation is to be considered as major event of physical instability and 
consequently as major problem during the development of protein pharmaceuticals 
[213]. Several human diseases such as Parkinson’s or Alzheimer’s are linked to 
protein aggregation [1]. The presence of aggregates in therapeutic protein 
pharmaceuticals can cause adverse effects within patients, ranging from immune 
response to anaphylactic shock [20]. Since 1998, there has been a significant 
increase of the number of kidney patients who developed pure red cell aplasia during 
the course of epoetin α treatment (EprexTM/ErypoTM), a version of human 
recombinant erythropoietin, due to neutralising antibodies. The increase in reported 
cases coincides with the removal of human serum albumin from the original 
formulation. It has been proposed that the new formulation is less stable, allowing 
aggregates of erythropoietin molecules to form, which increases the probability of 
antibody formation [33]. 
A further particularity playing a key role in the formulation of protein pharmaceuticals 
is the adsorption of proteins upon various surfaces and interfaces, e.g. container 
surfaces, membrane filters or air-water interfaces. Proteins are large amphiphilic 
molecules, meaning they are intrinsically surface-active. Once adsorbed, proteins 
can undergo different levels of orientation/conformation changes resulting in a protein 
loss and/or in unfolding and aggregation processes [4]. Here, one major parameter 
influencing the extent of adsorption seems to be the protein concentration, reaching a 
maximum above a certain concentration-surface ratio [80]. 
2. Polymeric systems 
The first controlled-release technology was developed in 1962 and was based 
upon diffusion of small molecules (< 500 – 1000 Da) through the wall of silicone 
rubber tubing [65]. More than a decade later, Davis et al. reported the sustained 
Chapter I: Introduction 6
release of various peptides and proteins from polymeric devices. Crosslinked 
polyacrylamide and polyvinylpyrrolidone gels have been subcutaneously implanted 
into hamsters to deliver immunoglobulins, luteinizing hormone, bovine serum 
albumin, or insulin over a prolonged period. It was shown that the release rate 
declined with increasing polymer concentrations, enabling the sustained release of 
luteinizing hormone in vivo for over 50 days [52]. However, the use of those polymers 
was accompanied by a high inflammatory potential in animal tissues [114]. 
In 1976, Langer and Folkman published that proteins and other large molecules with 
molecular weights up to 2 x 106 Da can be liberated from hydroxyethylmethacrylate 
(Hydron) and ethylene-vinyl acetate polymeric devices, respectively. The 
development of so-called “sandwich” pellets facilitated a three months steady release 
of soybean trypsin inhibitor, lysozyme and catalase. Furthermore, the biological 
activity of the delivered proteins was verified [114; 115; 66]. In the next years Langer 
and his co-workers improved the reproducibility of the protein delivery by new 
incorporation techniques, e.g. solvent casting or sintering. Furthermore, 
mathematical models were established in order to clarify the underlying release 
mechanisms [182; 88]. However, one major problem persisted: the polymer systems 
were non-biodegradable and required a surgical removal after drug delivery was 
complete. A non-removal often went along with toxicological problems.  
As a consequence the search for appropriate materials in the past two decades was 
focused on biodegradable polymers. Biodegradable means that the polymer device 
degrades over time due to hydrolysis (non water-soluble polymers) or solubilisation 
(water-soluble gels). Concomitantly, the drug is released. Potential degradation 
products can be absorbed by the body, obviating the need for surgical removal. 
In this respect, biodegradable matrices must meet the following characteristics: high 
tolerability by the body, no interaction with the incorporated protein, reproducible in 
vivo degradation, constant drug diffusion rates, no toxicity, and rapid metabolism of 
the degradation products [159]. Table 1 lists natural and synthetic polymers that have 
been investigated for the delivery of proteins and peptides. 
Chapter I: Introduction 7
 
Table 1: Biodegradable materials for controlled delivery of proteins or peptides [42].  
Natural polymers like alginate materials are water-soluble, whereby the protein drugs 
can be embedded without the use of organic solvents or elevated temperatures. 
These mild conditions can reduce degradation or inactivation effects on protein 
molecules during manufacturing. However, the risks of immunogenicity and 
contamination often restricts a broad use of these materials as drug delivery matrices 
[42; 184]. 
Scanning the literature on the field of synthetic, biodegradable polymers used as 
controlled release systems reveals that in recent years research has been focused 
on polyanhydrides and especially on polyesters. In other words, polyesters, in 
particular esters prepared from poly(lactic acid) and/or poly(glycolic acid) – i.e. 
poly(D,L-lactide) (PLA), poly(glycolic acid) (PGA) and copolymers of lactide and 
glycolide (PLGA) – are the biodegradable polymers investigated most widely for 
controlled drug delivery. 
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2.1 Controlled release systems based on PLGA 
Polymer devices for controlled protein delivery can be configured in several 
forms, including small microspheres or implants of various shapes and sizes. 
Microparticles are usually defined as spherical devices within a 1 - 1000 µm range. 
For parenteral use it is aimed for sizes ideally less then 125 µm. In a general sense, 
microparticles can be further divided into microcapsules, i.e. microparticles 
containing the drug in a central core, surrounded by a polymeric membrane, and 
microspheres, i.e. microparticles containing the drug in a polymeric matrix. 
Microparticles can be injected readily subcutaneously or into the target site. The 
standard encapsulation method for protein drugs is the double (multiple) emulsion 
technique including a subsequent evaporation or extraction step. Further established 
techniques are phase separation (coacervation), spray drying, or microparticle 
formation using supercritical fluids [93]. 
Implants are cylindrical, monolithic devices implanted by a minor surgical incision or 
injected through a large bore needle (trocar) into the subcutaneous tissue. Implants 
are commonly manufactured by extrusion or solvent casting techniques, generating 
implants with millimetre and centimetre dimensions. Implants cannot be applied in 
therapy regimen which require a weight-based dosing, e.g. x milligrams of drug per 
kilogram of body weight. 
The family of homo- and copolymeric systems based on lactic and glycolic acid has 
gained considerable attention due to the ease of fabrication, the FDA approval for 
use in humans and due to the successful use for several decades in biodegradable 
sutures [78]. However, the availability of these polymeric delivery systems for protein 
drugs was not accompanied by a corresponding output – meaning the work invested 
does not mirror in a huge number of products marketed in pharmaceutics (Tab. 2). 
This allows the conclusion that the polymers available hitherto are deemed a 
restricted-use stock where the scientists can choose from when needing device 
materials for protein delivery.  
In the past few years incomplete release of native protein as a result of protein 
instability phenomena was identified as a major problem. Considerable drawbacks 
synthetic polymer-based systems can inhere will be outlined in detail in the following 
parts. 
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Drug Trade name Company Polymer Route Application 
buserelin 
acetate 
ProfactDepot, 
SuprefactDepot 
Hoechst 
Marion 
Roussel 
PLGA s/c implant prostate cancer 
goserelin 
acetate Zoladex
Depot Astra Zeneca PLGA s/c implant 
prostate 
cancer, 
endometrioses
leuprorelin 
acetate 
Lupron Depot,  
Enantone Depot, 
Enantone Gyn 
Depot 
 
Trenantone 
Takeda-
Abbott 
 
PLGA 
 
 
 
PLA 
3-month depot 
suspension,  
1-month 
suspension 
 
3-month 
suspension 
prostate 
cancer, 
endometrioses
octreotide 
acetate 
Sandostatin 
LARDepot 
Novartis 
Pharma PLGA s/c suspension 
GH 
suppression, 
anti cancer 
triptorelin Decapeptyl
® 
Depot Debiopharma PLGA 
s/c depot 
injection 
LHRH agonist, 
prostate 
cancer 
recombinant 
human 
growth 
hormone 
NutropinDepot, 
[discontinued 
commercialisation 
since 06/2004]  
Genentech-
Alkermes PLGA 
monthly s/c 
injection 
growth 
hormone 
deficiency 
Table 2: Overview of peptide/protein controlled, release systems based on PLGA. 
2.1.1 PLGA microspheres: manufacture and protein stability issues  
2.1.1.1 Double (multiple) emulsion technique 
During the past 25 years considerable work was spent on the investigation of 
microencapsulation of pharmaceutical compounds with PLGA via solvent evaporation 
technique (conventional O/W encapsulation). However, for water-soluble drugs like 
peptides and proteins this method appeared to be insufficient. In other words, the 
formation of an O/W emulsion leads to a rapid diffusion of the drug from the organic 
phase into the aqueous phase resulting in microspheres with low or even no drug 
loading at all [135]. In case the solvent evaporation technique is modified by the 
formation of multiple W/O/W emulsions (Fig. 4), the preparation of PLGA 
microspheres with higher drug loads and a more efficient encapsulation is rendered 
possible [85]. This was demonstrated for leuprorelin acetate - PLGA microspheres, 
where the application of the double emulsion method led to FDA approval in 1992; 
and Lupron depot became the first peptide microparticulate depot product entering 
the U.S. market [137; 42]. 
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Figure 2: Schematic illustration of the double (multiple) emulsion method, a technique widely 
used for the PLGA microspheres preparation. 
As illustrated in Fig. 2, an aqueous protein solution (2) is added to an organic 
polymer solution (1) – i.e. polymer dissolved in methylene chloride or ethyl acetate - 
followed by an emulsification step using either high speed homogenisers or 
sonicators (3). This primary W/O-emulsion (4) is then rapidly transferred in a second 
aqueous phase containing a stabiliser, usually polyvinylalcohol (5). The formation of 
the W/O/W emulsion is obtained by stirring or vortexing (6). To ensure the 
entrapment of the protein and to remove the organic solvent (7), additional water is 
added resulting in hardened microspheres (8). Another possibility for organic solvent 
removal is the extraction with a water-miscible solvent (solvent extraction). The 
washed and collected microparticles are dried by vacuum drying or lyophilisation. A 
modified technique implies the addition of the protein in solid form – then, the 
suspension is transformed to an S/O/W system. 
At first glance this method appears simple, but scrutinising the technique clearly 
indicates that several complex procedures own potential to imperil protein stability 
during microparticles manufacture. 
 
Effect of the formation of large water/organic solvent interfaces 
As surface active molecule, a protein tends to adsorb at water/organic solvent 
interfaces. This adsorption step can induce protein unfolding, inactivation, and 
irreversible aggregation during the first emulsion step [165; 147; 49]. Morlock et al. 
demonstrated the formation of the primary emulsion being mainly responsible for the 
occurrence of erythropoietin (EPO) aggregates during manufacture. All the following 
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steps did not increase the total amount of detected EPO aggregates [130]. These 
findings were substantiated by van de Weert et al., revealing the non-covalent 
aggregation of lysozyme by means of Fourier-Transform Infrared Spectroscopy 
(FTIR), whereby the non-recovered lysozyme was found at the water/organic solvent 
interface as white precipitates [197]. The extent of protein loss due to interface 
adsorption and subsequent aggregation mainly depends on the protein per se, e.g. 
38 % recovery was found for ovalbumin, 72 % for lysozyme, and 99 % for bovine 
serum albumin (BSA), applying identical emulsion conditions [166]. 
During the microparticle formation interfacial stress may be detrimental to protein 
molecules positioned at the surface of the growing particles [198]. In addition, a 
potential protein loss due to diffusion of protein from the inner aqueous phase into 
the outer aqueous medium can be observed [14]. 
 
Effect of the emulsification process  
During the emulsification process protein molecules are exposed to shear and 
cavitation stress. The way how the primary emulsion is prepared – for instance via 
homogenisation or ultrasonication - can have a considerable impact on the protein 
denaturation rate. Morlock et al. showed the aggregation of erythropoietin being more 
pronounced when ultrasonication or vortexing is used for the emulsification. The ratio 
of EPO aggregates could be substantially reduced by the application of 
homogenisers [130]. Also, sonication may induce an increase in temperature (hot 
spot) and the formation of free radicals resulting in protein impairment [198; 108]. 
Generally, hydrophobic interactions between protein and polymer during 
emulsification may foster protein unfolding and aggregation [102]. 
 
Effect of Organic solvents 
After the addition of the aqueous protein solution to the organic polymer 
phase, organic solvent molecules diffuse into the aqueous phase to a certain extent, 
e.g. 2 % of methylene chloride migrate into an aqueous phase. The organic solvent 
can bind directly to the protein by hydrophobic interactions or can alter the ionic 
strength conditions inside the aqueous medium, fostering the destabilisation of 
protein molecules [109]. Cleland et al. showed that the destabilising effect of the 
organic solvents mainly depends on two factors: (1) how is the protein incorporated 
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(aqueous phase or solid protein?) and (2) which organic solvent is chosen for the 
dissolution of the polymer. The recovery of human growth hormone was noticeably 
increased by using ethyl acetate rather than the commonly applied methylene 
chloride as dissolution medium or by adding solid protein to the methylene chloride 
phase. In solid form, the conformation of a protein is severely restricted, and the 
protein can be stabilised in a water-free organic solvent. However, even a small 
amount of water within the organic phase results in an increase of protein mobility, 
thereby inducing protein denaturation tendency. In other words, the detrimental effect 
of organic solvents on protein stability mainly depends on the amount of water 
present inside the organic medium [45; 109]. 
A further critical parameter to be outlined is the content of residual solvents within the 
microspheres after drying. Methylene chloride is classified by the international 
conference of harmonisation (ICH) as toxic organic solvent whose application should 
be constricted. The concentration in pharmaceutical products is limited to 600 ppm 
[219], and a pharmaceutical product can suffer FDA rejection due to an exceeding 
residual organic solvent content. 
2.1.1.2 The phase separation technique (coacervation) 
Generally, the protein is suspended into a dilute polymer solution, e.g. 
methylene chloride. Silicone oil is usually added to the suspension acting as phase 
inducer. As a result the polymer is subjected to phase separation, encapsulates the 
drug and `embryonic` microspheres are formed. This system is then transferred into 
a second non-solvent to harden and form the final microparticles. After repeated 
extraction steps, microparticles are collected and dried. 
The major advantage of the phase separation technique is the avoidance of the 
contact between protein molecules and an aqueous phase. For instance, the non-
aqueous microencapsulation procedure revealed a significant decrease in bovine 
serum albumin (BSA) covalent aggregation [31]. However, the additional solvents are 
often difficult to remove and their residue limits within pharmaceutical products are 
often exceeded. 
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2.1.1.3 (Cryogenic) spray drying 
Spray drying is a rapid, convenient technique which can be conducted under 
aseptic conditions. First, a polymer – prevalently PLGA is applied - is dissolved in a 
volatile organic solvent such as methylene chloride or acetone. The protein is 
suspended as solid or emulsified as aqueous solution in this organic solution by 
homogenisation. After that, the resulting dispersion is atomised through a (heated) 
nozzle into a heated air flow. The organic solvent evaporates, thereby forming 
microparticles with dimensions of typically 1 – 100 µm. The microparticles are 
collected in a cyclone separator. For the complete removal of the organic solvent, a 
vacuum drying or lyophilisation step can follow downstream. 
Morlock et al. demonstrated the successful use of a modified spray drying technique 
for the encapsulation of EPO within PLGA microspheres. By this, a reduced amount 
of EPO aggregates was detected when compared to EPO microspheres prepared by 
a standard W/O/W emulsion method. Moreover, the encapsulation efficiency rose 
due to obviating protein diffusion processes during emulsification [14]. 
One variation of the conventional spray drying method, which is subsumed to the 
cryogenic technique, uses very cold temperatures for freezing biologically active 
agents into polymeric microspheres (Fig. 3). A protein/PLGA organic solvent 
dispersion is atomised into a vessel containing a liquid non-solvent such as ethanol 
that is overlaid with a liquefied gas phase, usually nitrogen, at temperatures below 
the freezing point of the protein/polymer mixture. During evaporation of the liquid 
nitrogen, the non-solvent melts, followed by an extraction of the organic solvent from 
the formed microparticles [76; 75]. Besides the advantage of low temperature 
conditions, this method completely avoids the use of water during manufacture (non-
aqueous encapsulation). 
 
Figure 3: Cryogenic spray drying process [195] 
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This technology has been effectively applied to the encapsulation of zinc-complexed 
human growth hormone in PLGA microspheres, resulting in a one-month effect after 
one single injection [99; 100]. The investigations in that realm yielded FDA approval 
of one unique protein-containing PLGA formulation. However, the commercialisation 
of Nutropin Depot is discontinued since June 2004. 
2.1.1.4 Techniques using supercritical fluids 
Generally, the application of supercritical (SC) fluids for the encapsulation of 
peptides and proteins has been fueled by the recognition that the established 
methods implicate some drawbacks. The application of supercritical fluids, especially 
of supercritical carbon dioxide, can minimise or even eliminate the use of organic 
solvents and renders work at moderate temperatures possible [155]. The term 
“supercritical” defines the area above the critical point, which specifies the final point 
of the liquid-gas phase transition curve. Beyond that critical point, isobar/isotherm 
alterations of pressure or temperature alter the density of the critical phase, but do 
not lead to a separation into two phases. A density change is directly associated with 
a change of the solvent power, thus the method features a high variability. Usually 
carbon dioxide is used as supercritical fluid due to its critical point (Tc = 31.1 °C, Pc = 
73.8 bar), which can be easily reached. That allows a moderate working temperature 
and leaves no toxic residues since it returns to the gas phase at ambient conditions. 
Two SC CO2 based processes have been reported for the preparation of drug-loaded 
polymeric microspheres: first, the rapid expansion from supercritical solutions (RESS) 
process, whereby a SC CO2 solution of an active agent and a polymeric carrier is 
rapidly expanded. This quickly transforms the SC CO2 into a liquid that is a much 
poorer solvent, thereby precipitating the active agent/carrier mixture as small 
particles [53; 222]. Second, the aerosol solvent extraction process, also referred to 
as antisolvent process. Here, a solution of the active agent and the polymeric carrier 
is sprayed into a chamber loaded with SC CO2. The SC CO2 extracts the solvent from 
the spray droplets, and induces co-precipitating of the active agent and the polymeric 
carrier in form of small, solvent-free particles [215; 15]. However, the use of organic 
solvents can not be avoided, which is to be deemed as a major disadvantage of both 
techniques. 
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In protein pharmaceutics, the antisolvent technique is predominantly applied for the 
preparation of microparticulate protein powders as an alternative to common drying 
processes. However, Winters et al. reported an increase of ß-sheet aggregates 
during the precipitation of lysozyme, trypsin and insulin as a consequence of stress 
parameters such as organic solvent, pressure and shear forces [218]. One reason 
why these methods were not credited as encapsulation techniques for protein within 
PLGA may be the tendency of several polymers to rapidly precipitate and 
agglomerate during the process [18].  
2.1.2 PLGA implants: manufacture and protein stability issues  
While countless publications are describing the manufacture of 
microparticulate systems, literature dealing with PLGA implants delivering proteins is 
yet sparse. 
With the solvent casting method, the polymer is dissolved in a volatile organic 
solvent, e.g. methylene chloride or acetone, and the solid protein is suspended within 
the solution by homogenisation. This mixture is poured into moulds with a definite 
size, and the organic solvent evaporates slowly. Garcia et al. reported the 
development of biodegradable laminar implants for recombinant human growth 
hormone (rhGH) using the solvent casting technique. Thereby, a PLGA solution in 
methylene chloride was poured onto the lyophilised cake of rhGH and methylene 
chloride evaporated slowly at 4 °C during 48 hrs. The resulting rhGH polymer-film 
was vacuum dried and then cut into discs of 6 mm in diameter [70].  
A modified solvent casting technique was established by Zhu and Schwendeman, 
who filled a BSA/PLGA suspension in a syringe and extruded the mixture into a 0.8 
mm silicone tubing at a rate of about 0.1 mL/min [226; 225]. 
An injection-molding process was exemplified by Rothen-Weinhold et al.. The 
peptide/polymer mixture was heated at 110 °C for plasticising, followed by injection at 
100 °C and 130 bar pressure. The obtained implants revealed a diameter of 4.6 mm 
and a length of 2.8 cm [161].     
Extrusion processes are the most convenient way for implant manufacturing. Screw 
extruders consist of single or twin helical rotating screws inside a stationary 
cylindrical barrel. By definition, the extruder is divided into three sections: feed zone, 
transition zone, and metering zone. Both, the polymer and solid protein are 
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transported to the transition zone where they are mixed, pressed, melted and 
eventually plasticised. In the metering zone the plasticised mixture is extruded 
through a die, and simultaneously the temperature decreases. By using ram 
extrusion, the protein/polymer mixture is filled into a barrel into which a piston rod is 
inserted and then moved further into the barrel with apt pressure. The extrusion 
temperature is usually set at 80 °C – 110 °C and the mixture is compressed through 
a die with diameters around 1.5 mm [190]. 
The manufacture of the goserelin acetate implant (Zoladex®), available on the market 
since 1987, is realised by an extrusion technique. The drug and the polymer material 
are dissolved in a capable solvent followed by a lyophilisation step. This 
protein/polymer cake is then formed into implants by extrusion and the implants are 
sterilised by γ-irradiation [89; 90].   
Deghenghi et al. described the extrusion manufacture of polymeric implants 
containing bioactive peptides as follows: the sterilised and ground PLGA copolymer 
is wetted with a sterile aqueous slurry of peptide. Then, this composition is 
homogenised and dried at reduced pressures and at temperatures below 25 °C. 
Subsequently, the peptide/polymer mixture is extruded at temperatures between 70 
and 110 °C and the obtained cylindrical rods are cut into the pharmaceutical implants 
[54]. A similar extrusion technique was shown by Marion et al.. The solid peptide and 
dry PLGA were mixed homogeneously and then granulated by adding a suitable 
liquid such as ethanol. This mixture was extruded at a temperature profile ranging 
from 30 °C at extruder entering up to 110 °C at extruder leaving. Under these 
conditions the PLGA melts, and forms a continuous matrix which coats the peptide 
particles [124].                    
 
Effects of the manufacturing processes 
During implant preparation, peptides and proteins are exposed to various 
unfavourable conditions. The exposure to high temperatures, shear forces, or high 
pressures may cause protein unfolding and irreversible aggregation. Rothen-
Weinhold et al. showed the purity of the somatostatin analogue vapreotide rapidly 
decreasing at high temperatures during ram extrusion. This effect is increased with 
process time [160]. In a later work, they demonstrated the main peptide impurity 
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being a lactoyl lactyl-vapreotide conjugate that originated due to a covalent bonding 
between free lactide and a phenylalanine residue [162]. 
2.1.3 Protein stability issues during release 
Two mechanisms control the release of proteins from biodegradable polymeric 
devices, e.g. PLGA. The first mechanism is the simple diffusion of the protein out of 
the polymer matrices. Initially, protein molecules located at or close to the surface of 
the matrices diffuse rapidly out of the matrices (responsible for the often cited “burst 
effect”), then a slower diffusion of the protein from the interior of the polymeric 
system through porous channels follows. The other mechanism is the erosion of the 
polymeric matrix which is initiated by the degradation of the polymer backbone (chain 
cleavage). As the drug surrounding polymer erodes, the drug escapes. An erosion/ 
diffusion controlled release mechanism represents a possible combination of both 
processes [129; 42; 78; 72].  
2.1.3.1 Surface erosion versus bulk erosion 
Polymer erosion is defined as the mass loss of the polymer from one initial 
level. The erosion of “erodible” polymers commences with the degradation of the 
polymer backbone due to hydrolysis of the ester bonds. Erosion is accompanied by a 
decrease of the average molecular weight and an increase of polymer porosity due to 
the release of the degradation products, i.e. oligomers and monomers [72]. 
Degrading polymers are classified into surface-eroding and bulk-eroding polymers 
(Fig. 4). 
 
Figure 4: Pattern of the changes a polymer matrix undergoes during surface and bulk erosion 
[204] 
Erosion kinetics depend on two major factors: the diffusion of the water into the 
polymer bulk and the degradation rate of the polymer backbone. If the degradation of 
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the polymer backbone is faster than the diffusion of water into the polymer, water will 
be consumed mainly on the surface by hydrolysis and will thus be prevented from 
diffusion into the matrix. This phenomenon is defined as surface erosion, though only 
fast degrading polymers such as polyanhydrides and poly(ortho)esters undergo 
surface erosion. 
If the diffusion of water is faster than the degradation rate of the polymer backbone, 
the complete matrix is wetted. The degradation is then not confined to the polymer 
surface, and the matrix system undergoes bulk erosion. Usually, biodegradable 
polymers, especially PLGA matrices, underlie this bulk erosion phenomenon [204; 
72]. 
2.1.3.2 Consequences of bulk erosion on protein stability  
The rapid water uptake of PLGA matrices results in a complete morphology 
change of the polymer from a glassy to a rubbery state by a lowered glass transition 
temperature [78]. In addition, the polymer matrix becomes more hydrophilic, and 
degradation products may alter the pH in the interior of the polymeric system. Thus, 
the incorporated protein is confronted to completely different environmental 
conditions, which may lead to conformational changes followed by irreversible 
denaturation or aggregation. An overview of potential detrimental consequences of 
the bulk erosion is shown in Fig. 5. 
 
Figure 5: Potential sources of protein inactivation after administration [176]. 
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Protein rehydration – moisture-induced aggregation 
As the polymeric matrices become hydrated the solid protein is exposed to 
increasing moisture, which can lead to irreversible aggregation (moisture-induced 
aggregation). The presence of water increases protein mobility, possibly accelerating 
chemical reactions as well as physical instability events [79; 48; 121; 130]. 
The moisture-induced solid aggregation has been described as a result of thiol-
disulfide interchange. This process preferentially proceeds under basic conditions 
[121], implying moisture-induced aggregation being impeded in the acidic 
environment of the hydrated polymer systems. However, the formation of non-
covalent aggregates induced by moisture was documented in the case of insulin also 
under acidic conditions [48]. 
 
Changes of pH and of osmotic pressure within the polymeric matrices 
The degradation products of PLGA are of acidic nature, which leads to a pH 
drop. If these degradation products can not freely diffuse out of the matrices, an 
acidic microclimate within the polymeric devices is generated. In addition, the 
accumulation of monomers and oligomers increases the osmotic pressure within the 
matrices. Both an acidic microclimate and a high osmotic pressure are potential 
sources for unfolding and aggregation of encapsulated proteins [22; 14; 130; 147].  
The evidence of an acidic microclimate has been demonstrated by confocal laser 
microscopy measurements and by electron paramagnetic resonance analyses, 
respectively. pH values between 1.5 and 4.7 were reported [68; 22]. Zhu et al. 
published encapsulated BSA undergoing peptide bond hydrolysis and non-covalent 
aggregation during release due to an acidic environment (pH < 3) [225]. 
 
Adsorption of proteins to polymers 
Non-covalent and ionic interactions between PLGA and encapsulated proteins 
were stated as a reason for an incomplete protein release by Park and co-workers 
[106; 50; 144]. Extraction of non-released protein was performed by separately 
adding 0.5 M sodium chloride, 5 M guanidine hydrochloride (GnHCl), and 5 mM 
sodium dodecyl sulphate (SDS) to the extraction medium. Sodium chloride extracts 
protein molecules which interacted electrostatically with PLGA. GnHCl dissociates 
non-covalent aggregates, and SDS extracts both non-covalent aggregates and 
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proteins adsorbed to PLGA. The difference in the amount of extracted protein allows 
to calculate the loss of protein due to non-specific adsorption to the polymer matrix. 
With this experimental set-up it could be proved that an incomplete release of BSA 
was mainly due to non-specific adsorption, as GnHCl could not extract this protein 
[50]. In comparison, recombinant human growth hormone is largely lost due to non-
covalent aggregation - no higher amount of protein could be extracted when using 
SDS [106]. Lysozyme interacts electrostatically when encapsulated in uncapped 
PLGA microspheres, whereas the incorporation in hydrophobic PLGA results in non-
covalent aggregation and hydrophobic adsorption [144]. 
2.1.4 Protein stabilisation upon encapsulation and release from PLGA polymers 
2.1.4.1 Protein stabilisation during preparation 
During the last years, several straightforward strategies towards protein 
stabilisation upon encapsulation were presented. These approaches are summarised 
in the following table.    
Stress factor Stabilisation approach Mechanism Literature 
water/organic 
solvent interfaces 
 
increase of protein loading 
 
 
addition of other proteins  
 
 
addition of sugars, polyols, 
PEG, salts 
 
 
avoidance of  emulsification, 
addition of the protein as a 
solid (non-aqueous process) 
reduction of 
protein/interface ratio 
 
competition at interfaces 
 
 
mechanism of preferential 
hydration [8] or protein 
hydrophilization [131]  
 
no interfaces, restricted 
protein mobility 
[45;  148;  165] 
 
 
 
 
[197;  166;  130] 
 
 
 
 
[130;  102;  149] 
 
 
 
 
 
[31;  100;  109] 
shear forces 
avoidance of sonication,  
use of other homogenisation 
methods 
absence of cavitation 
stress, no risk of free 
radicals formation 
[130;  108] 
organic solvent 
replacement of methylene 
chloride by ethyl acetate 
 
 
avoidance of the impact of 
water, non-aqueous process 
increased protein stability 
in ethyl acetate, less 
toxicological problems 
 
restricted protein mobility, 
protein mobility depends 
on the presence of water  
[45;  219] 
 
 
 
 
 
[31;  45] 
Table 3: Protein stabilisation approaches during manufacture; table was created in accordance 
to van de Weert et al. [198]. 
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The success of zinc-complexed rhGH in combination with cryogenic spray drying as 
preparation method (Nutropin Depot) offered new potential for protein stabilisation 
during encapsulation. Lam et al. showed that the formation of an insoluble rhNGF-
zinc complex prior to encapsulation into PLGA microspheres stabilised the protein 
during both encapsulation and release [112]. 
2.1.4.2 Protein stabilisation during release 
In addition to general proposals to improve protein stability in aqueous 
formulations [213], specific stabilisation approaches are normally required when 
protein molecules are confronted with the environment of degrading PLGA matrices 
(Table 4). 
Stress factor Stabilisation approach Mechanism Literature
moisture-induced 
aggregation 
general strategy: increase of 
matrix hydrophobicity  
inhibition of the bulk 
erosion phenomenon, 
reduced water uptake 
[147] 
acidification 
addition of basic salts 
 
increase of the porosity of the 
polymer matrices 
buffering 
 
enabling acidic 
degradation products to 
diffuse out and buffer 
components permeate 
into the matrices 
[225; 207;  179] 
 
 
[98; 40] 
protein/PLGA 
contacts 
addition of other proteins 
 
competition for PLGA 
 
[36] 
Table 4: Protein stabilisation approaches during release; table was created in accordance to 
van de Weert et al. [198]. 
2.2 In situ formed devices 
The traditional methods of preparing PLGA microparticles suffer from 
drawbacks such as (i) the need of reconstitution before application, (ii) the hazards 
and the environmental concern using methylene chloride for preparation, and (iii) the 
residual organic solvents remaining in the final product. PLGA implants did not have 
much commercial success, primarily due to requirements of a surgical incision or of a 
special type of injector [93]. 
To improve patient compliance, Shah et al. and researchers from Atrix Laboratories 
described in the 90´s a novel implant system for the delivery of macromolecules, 
which is parenterally administered as a liquid and that subsequently solidifies into a 
gel (matrix) in situ. The drug is released in a controlled manner [178; 59]. The 
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method was first patented as Atrigel system for low molecular weight drugs, and is 
carried out as follows: preferably PLA/PLGA copolymers are dissolved by heating in 
a water-miscible, biocompatible solvent (e.g. N-methyl-2-pyrrolidone NMP, 
dimethylsulfoxide DMSO or triacetin), which may also act as a plasticiser. After 
cooling, the biologically active agent is either dispersed by homogenisation or 
dissolved in a solvent (e.g. PEG 400) miscible with the polymer solution. This 
polymer-solvent-drug system is highly viscous but still syringeable by a convenient 
syringe and needle. When the liquid composition is injected via the intramuscular or 
subcutaneous route, the solution diffuses in the body. After contact with aqueous 
buffer (in-vitro) or with the physiological fluid (in-vivo) the polymer precipitates and a 
semi-solid implant is formed [96; 60]. While later patents mainly addressed the 
variation of the plasticiser solution, Jain et al. demonstrated the preparation of 
microglobules, which form microspheres at the injection site. Fig. 6 illustrates the 
modified process of the in situ production of various biodegradable PLGA devices. 
 
Figure 6: Modified encapsulation process for various biodegradable PLGA devices in situ [96]. 
The preparation of in situ microspheres exhibited a substantial increase in the 
encapsulation efficiency when compared to implant systems. Implants reveal a lag 
period between the injection of the liquid implant and the subsequent hardening, 
leading to a protein loss of about 50 % due to diffusion processes. In contrast, the 
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novel in situ microsphere process exhibited an encapsulation efficiency of 75 % and 
a controlled protein release for a 2 week period [94; 96; 95]. 
Using the Atrigel® technology resulted in the first drug approval a German 
biotechnology company achieved. Leuprogel®, marked by Medigene AG, combines 
standard hormone therapy with the patient-friendly and efficient Atrigel® depot 
system. The delivery device allows extended release of leuprorelin acetate for a 
period of one month [167; 146].           
One other interesting possibility to apply an injectable protein delivery system in situ 
is the use of sucrose acetate isobutyrate (SAIB). Sucrose acetate isobutyrate is a 
highly lipophilic sugar derivative, which is currently used as stabiliser and emulsifying 
agent to human diets in the Food Industry. The so-called SABERTM technology was 
patented by Tipton and Richard (Southern Biosystems, Inc.) in 1995. The high 
viscosity of the liquid sucrose acetate isobutyrate carrier is lowered by the addition of 
a water soluble or miscible solvent such as ethanol or dimethylsulfoxide. After 
addition of the drug, the composition is injected and forms a highly viscous implant in 
situ, which releases the drug over time [194]. A major advantage in comparison to 
the in situ PLGA devices is the possibility to use ethanol as solvent, which is 
approved as co-solvent in parenteral products. In 2002/03, Cleland et al. at 
Genentech transferred the then established SABERTM technology to the field of 
sustained protein release. Zinc-complexed rhGH was suspended in SABERTM 
solutions, containing various portions of PLA and sucrose as additives. By varying 
the sucrose and PLA ratio, a sustained protein release could be achieved in vivo. 
However, histological examinations exhibited a local tissue response 7 days after 
administration which appeared to be very similar to that observed with PLA and 
PLGA systems [138; 46]. 
Other sustained release injectables formed in situ and based on poloxamer, glycerol 
monooleate or PEG-PLGA-PEG triblock polymers are currently under investigation. 
On the other hand, considerable efforts are made in developing marketable 
sustained-injectables formed in situ for the veterinary market [126]. 
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2.3 Hydrogels 
The first application of hydrogels in controlled delivery of macromolecules is 
ascribed to Davis et al. [52]. Hydrogels are three-dimensional, water-swollen, 
polymeric networks composed of hydrophilic homopolymers or copolymers such as 
hydroxyethyl methacrylate, methoxyethoxy methacrylate, vinylacetate and various 
PEG acrylates. Due to a multitude of chemical and physical crosslinks, these 
hydrogels are insoluble systems. Crosslinking provides the network structure and the 
physical integrity of these systems. Numerous biomedical and pharmaceutical 
applications are mainly due to their swollen and rubbery nature which resembles 
natural tissue more than any other class of synthetic biomaterials. In the last years, 
stimuli-sensitive swelling controlled release systems were developed. For example, 
pH-sensitive hydrogels contain either acid or basic pendant groups. In aqueous 
media with appropriate pH and ionic strength, the pendant groups can ionise, adopt 
fixed charges and result in an increased swelling. Temperature-sensitive hydrogels 
have gained in importance in the pharmaceutical field, e.g. for the application of 
biosensors due to their ability to swell or to contract, depending on temperature. A 
further advantage that has been recognised only recently is that hydrogels may 
protect peptides and proteins from the harsh environment in the vicinity of the release 
site. Thus, such carriers may be scrutinised on their applicability for oral protein 
delivery in the future. Furthermore, hydrogels appear to be applicable as targetable 
carriers or as bioadhesive devices for therapeutic agents [145; 116].  
Recently, Hubbell et al. reported the development of a novel proteolytically sensitive, 
biologically active polyethylene glycol (PEG)-peptide hydrogel. This in situ formed 
device facilitates arterial healing, e.g. after balloon angioplasty by temporarily 
protecting the arterial injury from blood contact [177].  
2.4 Surface erosion polymers: polyanhydrides and poly(ortho esters) 
The bulk erosion phenomenon of PLGA systems has been verified as one 
major problem concerning protein stability issues (chapter I, 2.1.3.2). However, the 
erosion process per se, which is confined predominantly to the surface layers, 
inheres some well-known advantages. First, if the drug is well immobilised in the 
matrix, its release is solely controlled by the erosion rate of the matrix. Second, drug 
release and erosion take place concomitantly. As a consequence, no matrix remains 
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if the drug is completely liberated. And third, hydrolysis products, which are 
generated at the surface of the matrix, diffuse away from the devices and do not 
accumulate in the bulk material. Thus, the interior of the matrix does not turn acidic 
as observed in PLGA systems, and, as a consequence, acid sensitive drugs such as 
proteins can be liberated without activity loss. After considerable efforts in the 
development of surface erosion polymers in the last years, two polymer families 
emerged: polyanhydrides and poly(ortho esters) [82]. 
2.4.1 Polyanhydrides 
Medical applications of polyanhydridic compounds were investigated by 
Langer and his group in the 1980`s, and FDA approval was obtained for the 
treatment of brain tumour with the chemotherapeutic carmustine (BCNU), delivered 
by means of a polyanhydride (PCPP:SA) wafer carrier [110]. In that realm, the 
background of Gliadel® is to be framed: while numerous clinical applications of 
ethylene vinyl acetate (EVA) (refer to chapter I, 2) include insulin therapy, asthma 
treatment, and chemotherapy, the EVA polymer has never been approved for use in 
the brain. However, the new generation of PLGA systems (i.e. microparticles and 
implants) seemed not to be suitable for drug delivery of chemotherapeutic agents 
due to a possible sporadic drug dumping as a result of bulk erosion. In 1985, Langer 
and his group developed the polyanhydride poly[bis(p-carboxyphenoxy)] propane-
sebacic acid (P(CPP:SA)), an extremely hydrophobic polymer with surface-controlled 
erosion. Gliadel entered the U.S. market in 1996, and is today approved in several 
countries of the world [209]. 
Polyanhydrides were also investigated as controlled delivery systems for peptides 
and proteins. Principally, countless variations of polyanhydrides (e.g. aliphatic or 
aromatic polyanhydrides, poly(ester)- or poly(ether)-anhydrides, crosslinked 
polyanhydrides or amino acid based anhydrides) could be used for drug delivery, but 
the pharmaceutical research has been focused on polyanhydrides derived from 
sebacic acid (SA), 1,3-bis(p-carboxyphenoxy)propane (CPP) and fatty acid dimer 
(FDA) - (P(CPP:SA) or P(FAD:SA)) [158; 110]. Because the temperature required for 
the fabrication of polyanhydride devices is too high for sensitive drugs such as 
peptides and proteins, a solvent extraction technique derived from the standard 
W/O/W emulsion method for PLGA microspheres is used [81]. When lysozyme, 
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trypsin, ovalbumin, BSA or immunoglobulin were incorporated in 25/75 fatty 
acid/sebacic acid copolymers, a constant release could be achieved for about 2 
weeks. The different proteins exhibited almost identical release rates over this period, 
suggesting the release mechanism being primarily erosion controlled. However, a 
notable drop in the molecular weight of the polymeric microspheres was also 
monitored within the first 90 hours, followed by a continuous erosion rate [191]. 
These results may indicate that bulk erosion can not be completely suppressed when 
using polyanhydride devices. 
A second approach of Langer and co-workers was the development of biodegradable 
poly(anhydride-co-imides), in particular those containing L-tyrosine in their polymer 
backbone. Due to the incorporation of the immunological adjuvant L-tyrosine, these 
polymeric devices seemed to be very promising for the delivery of vaccines. From 
these systems a BSA release closely correlates to microsphere erosion - as indicated 
by polymer weight loss - proposing a release mechanism mainly controlled by 
polymer erosion [39]. 
In recent years, the interest in the development of controlled protein delivery systems 
based on polyanhydrides has been abated. One possible reason may be the difficult 
fabrication process, since both the hot melt encapsulation and the solvent 
evaporation method can lead to inactivation of proteins during manufacturing. 
2.4.2 Poly(ortho esters) 
Poly(ortho esters) are under research since the 70`s and by that time, four 
families have been developed (Fig. 7):  
 
Figure 7: Survey of the chemical structures of the poly(ortho ester) families: POE I- POE IV [84]. 
Though extensive investigations have been carried out, the families of POE I, II and 
III did not lead to the success originally anticipated [84]. Therefore, only the 
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development and potential applications of the poly(ortho esters) IV will be outlined in 
detail in the course of this review. POE IV is a more hydrophilic modification of POE 
II, which has been realised by the incorporation of a short segment based on either 
glycolic acid or lactic acid in the polymer backbone. This very segment reveals a 
rapid hydrolyses after administration, what triggers in turn the catalysis of hydrolytic 
cleavage of the ortho ester linkages. Such polymers have been designated as auto-
catalysed poly(ortho ester) variants [84]. 
Several studies demonstrated the variability in the polymer characteristics, evidenced 
the surface erosion mechanism and in consequence their high potential in controlled 
peptide and protein delivery [163]. The common group of poly(ortho esters) IV 
exhibited three major features of protein release kinetics: there is no burst, even with 
high protein loads, a notable lag time was monitored, and third, the rate of protein 
release is linear to polymer weight loss and protein release occuring concomitantly 
(surface erosion controlled protein release) [164, 38]. A reduced negative lag time 
can be achieved by simple admixing the monomethyl ether of polyethylene glycol to 
the polymer/protein mixture (AB block copolymers). These polymeric extrudates 
liberated the protein for a 2 months period following zero-order kinetics [83; 163].  
One other variation is the development of semi-solid, auto-catalysed poly(ortho 
esters). These polymers feature the advantage of an easy manufacturing process: 
protein can be loaded into the POE matrix by mixing the two compounds without the 
need of organic solvents or elevated temperatures. Release studies from these 
systems also indicate the protein release to be linearly, however the release was 
much more faster terminating after 7 days [83; 199]. 
These studies using poly(ortho esters) for peptide and protein delivery are certainly 
very promising, but often protein stability issues are not reflected adequately in the 
literature. Due to the fact that bulk degradation cannot be completely inhibited [84], 
the question of what exactly happens in the interior of these systems is still to be 
addressed. 
 
The suffered setbacks in the establishment of synthetic, biodegradable 
polymeric devices for controlled peptide and protein delivery, in particular PLGA 
matrices, and the loss of an ultimate solution for overcoming this dilemma, explain 
the mismatch between the number of peptide/protein containing polymeric systems 
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under preclinical and clinical investigation and the number of polymeric devices 
approved by the FDA. Especially in the light of the recent discussion around 
immunogenicity of even a small amount of denatured or otherwise altered protein for 
s.c. use (e.g. immunogenicity of Eprex® [33]), the distinctive rates of protein 
inactivation during manufacturing and after administration can be deemed the main 
problem of PLGA systems.   
Therefore, the following part will specify the potential of lipophilic materials, such as 
fatty acids, glycerides, waxes and cholesterol for the application as controlled protein 
delivery systems. 
3. Lipids as drug delivery systems 
For a long time, lipids have been used for the encapsulation of drugs in the 
field of oral delivery systems. For example, in the product mucosolvan retard 
capsules® (Boehringer-Ingelheim Pharma KG), the drug is encapsulated in wax 
matrices in the form of lipid pellets resulting in an extended drug release. However, 
the use of lipid carriers for parenteral controlled drug delivery, in particular for the 
delivery of peptides and proteins, has been investigated only in a humble range over 
the last years.  
Potential lipid-based carrier systems for a controlled peptide and protein release are: 
• liposomes (including DepoFoamTM technology) 
• solid lipid nanoparticles 
• oily suspensions 
• lipid microspheres 
• lipid implants 
3.1 Liposomes 
Phospholipid vehicles as drug delivery systems were rediscovered as 
“liposomes” in 1965 by Bangham [11]. In the early 90`s, three products for 
intravenous injection entered the market: Ambisome® for the systemic fungal 
treatment, and two chemotherapeutic liposomal formulations (Doxil® and 
Daunosome®).  
The use of liposomes as protein carriers was thought to improve their functioning as 
a circulating microreservoir for sustained release after intravenous administration.  
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For example, the encapsulation of vasopressin within long-circulating liposomes 
extended the bioactivity from 24 hours to 7 days, determined by diuresis 
measurements in rats. Vasopressin entrapped in PEGylated long-circulating 
liposomes even remained bioactive one month after intravenous injection. The 
application of liposomes containing human recombinant IL-2 inhibited the growth of 
intradermal tumours. However, the locoregional administration had to be performed 
three times per week [189].  
A new approach, rather than using unilamellar or multilamellar liposomes, is based 
on the DepoFoamTM system. These multivesicular liposomes (1-100 µm) contain 
multiple non-concentric internal aqueous compartments and lead to an increase in 
the encapsulation efficiency. After subcutaneous injection, the release of 
encapsulated peptide and protein was shown to be prolonged up to 7 days for 
DepoInsulin and up to 3 weeks for the DepoLeuprolide® formulation [221].  
Recently, the company Novosom AG patented a novel liposome-based depot system 
for proteins and peptides. The Cagicles® depots are produced by a two step method: 
first, proteins are dissolved in an aqueous medium and then added to solutions of 
membrane-forming substances, which are selected such that the resulting membrane 
enters into a reversible mutual reaction with the protein. This mild-condition process 
enables to increase the encapsulation rate over 30 % of incorporated protein. 
Furthermore, a one month sustained protein release was feasible after subcutaneous 
or intramuscular injection of the Cagicles® depots [143].  
These studies have proven the basic applicability of liposomes for protein-based 
pharmaceutics in vitro and in vivo. Though, the time period for release out of 
liposomes usually is short, generally less than two weeks, whereas liposomal 
formulations are limited in their use as sustained, controlled protein release carriers. 
However, liposomal dosage forms may be revaluated in drug targeting by the 
possibility of positioning marker proteins such as antibodies or cytokines upon the 
surface of liposomes or due to the potential of being uses as vaccine formulations. 
3.2 Solid lipid nanoparticles 
The concept of solid lipid nanoparticles (SLNs) was coined in the beginning of 
the nineties by Müller et al. [132]. Solid lipid nanoparticles represent a colloidal 
carrier system mainly based on triglycerides for intravenous injection. SLNs are 
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produced by melt dispersion combined with high pressure homogenisation or by 
microemulsion techniques, resulting in particles with a size range of 50 – 1000 nm. 
Due to their hydrophobic nature and their small size, SLNs may be more appropriate 
for incorporation of lipophilic drugs, which can be easily dissolved in the melted 
mixture. For instance, only small quantities of lysozyme (50 - 500 µg protein/g lipid) 
can be incorporated into various lipids, even with the use of a solubilisation technique 
applying a surfactant [5]. A further problem using SLNs as drug carrier is the burst 
release observed for various active agents after intravenous administration [132]. In 
summary, it may be stated that solid lipid nanoparticles own potential for the 
encapsulation of drugs with a low solubility (e.g. paclitaxel), for the application of 
surface-modified SLNs in drug targeting, or maybe for the use as adjuvant for 
vaccines. Furthermore, it can be hypothesised that SLNs can be applied for oral drug 
delivery in the form of aqueous dispersions or that they can alternatively be used as 
additives in traditional dosage forms such as tablets, capsules or pellets. 
3.3 Oil suspensions of peptides and proteins for a sustained release 
Generally, the viscosity of oily media is considerably higher than the viscosity 
of an aqueous phase such as buffer. Therefore, drug release can be prolonged by 
implementing oil suspensions. In addition, the viscosity of the oily carrier can be 
further increased by the addition of gelling agents such as aluminium monostearate – 
thus enabling the control of process parameters like drug solubility and drug transfer 
rate.  
A further important aspect using oils as drug carrier refers to the distribution 
coefficient of compounds in the oily medium and the surrounding tissue. A lipophilic 
drug with a high distribution coefficient will primarily accumulate in the oily medium 
resulting in further deceleration of effective drug actions. 
For several years, various peptides and proteins have been dispersed in oils to 
engineer sustained-release formulations. Nestor et al. patented as early as 1979 the 
development of long-acting injectable depot formulations for super-agonist analogues 
of luteinizing hormone-releasing hormone (LH-RH), applying oils such as peanut oil 
or sesame oil and a gelling agent such as aluminium stearate [134].  
The complexation of bovine somatotropin with zinc and the use of sesame oil and 
aluminium monostearate as suspension medium prepared the ground for FDA 
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approval of Posilac® (Monsanto agro) in 1993. Posilac® bovine somatotropin has 
become one of the leading dairy animal health products in the United States and 
many other countries, despite the general value is discussed controversially. 
Supplementing dairy cows subcutaneously with single-dosed bovine somatotropin 
enhances the milk production for a period of one month after drug administration 
[128].  
Yu et al. reported the in vivo evaluation of an oil suspension of growth hormone 
releasing factor analogue for the enhancement of animal growth. The delivery of the 
growth hormone could be sustained for over 2 weeks. Furthermore, peptide stability 
was substantially increased within the oil solution when compared to the stability in 
aqueous media [223].  
Shan et al. (Amgen Inc.) described protein/polyol/oil suspensions for the parenteral 
application to animals, realising the prolonged liberation of granulocyte colony 
stimulating factor over 2 week period [74]. 
Apparently oil suspensions have been under investigation mainly in the field of 
veterinary pharmaceutics, thereby revealing potential as drug carriers for peptides 
and proteins.  
3.4 Lipid microparticles 
Several techniques have been proposed for the manufacture of lipid 
microparticles. Primarily those methods are related to the techniques established for 
polymer microspheres [47]. For example, Reithmeier et al. encapsulated 
somatostatin, thymocarpin and insulin within glyceryl tripalmitate using a solvent 
evaporation technique. But the same drawbacks concerning encapsulation efficiency 
and protein stability, which has already been described in detail under 2.1.1.1., were 
noted [153; 154].  
However, lipophilic materials such as fats and waxes inhere one basic difference to 
polymers: the processability of low-viscosity melts, thus obviating the need for 
organic solvents. 
3.4.1 Melt dispersion technique 
The melt dispersion technique for the preparation of wax microparticles as an 
alternative to polymeric systems was first described by Bodmeier et al. [16; 19]. In 
that realm, Domb et al. presented a melt dispersion method for the preparation of 
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lipospheres consisting of a solid-lipid core surrounded by a phospholipids layer [57]. 
By vigorous vortex-mixing or stirring the drug is incorporated into the melt as solid or 
an aqueous solution. The dispersion is transferred into an aqueous phase, which is 
tempered above the melting point of the lipid that normally contains also emulsifiers 
such as polyvinylalcohol or gelatine. The formulation is rapidly cooled to room 
temperature by immersing the formulation flask in a cool water bath without ongoing 
agitation. In this context it is to be noted that the term melt “dispersion” technique is 
not to be perceived in absolute sense, since adding protein solutions to lipid melt is 
defined to yield emulsions. Though, both dispersion and emulsion are to be 
subsumed under melt dispersion technique. 
The application of the melt dispersion for the incorporation of somatostatin, 
thymocarpin and insulin led to essentially better encapsulation efficiencies when 
compared to the use of the emulsion methods illustrated above, This may be 
ascribed to the higher viscosity of the lipid melt [153; 154]. However, two factors take 
centre stage in the encapsulation of peptides and proteins in lipid drug carriers, 
especially when a hot melt dispersion technique is applied: one factor deals with 
polymorphic transformations of the lipid, which may occur during preparation and 
subsequent storage of the dosage form. Second, elevated temperatures the protein 
is exposed to during microparticles preparation can cause protein inactivation. 
 
Polymorphic behaviour of lipids 
It is common knowledge that long-chain compounds can show polymorphism, 
and this is the more valid for fats and lipids. For example, saturated triglycerides 
usually can form three polymorphs (α-, β`- and β-form), that differ in molecular 
structure: disordered aliphatic chain conformation is observed in α, intermediate 
packing in β`, and most dense packing in β-forms. This necessitates Gibbs free 
energy values to be highest in α, intermediate in β`, and lowest in β. In other words, 
the α-modification represents the most instable form, whereas the β-modification 
stands for the stable form of a triglyceride. Generally, polymorphism is influenced by 
several external factors such as temperature, pressure, solvent etc. [168]. As a 
consequence, polymorphic transformations may be encountered during the 
preparation of lipid microparticles. This may account for differences in solubility and 
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of melting points of active and excipients, and, moreover, such transformations could 
impact the release profile of incorporated drugs due to conversion after storage [62]. 
Reithmeier et al. reported that glyceryl tripalmitate microparticles - produced by melt 
dispersion - crystallised in the instable α-modification due to a fast congealing. On 
the contrary, microparticles prepared by solvent evaporation reveal the same thermal 
behaviour of the lipid bulk crystallising in the stable β-form. One explanation therefore 
may be the slower solidification of the microparticles within the lipid molecules 
arranging in the thermodynamically most stable β-modification [153]. Steber et al. 
found that microparticles prepared from mixtures of hard fats (e.g. tristearin) and 
liquid fats show an accelerated transition from the instable α-modification to the 
stable β-form within several hours or days when melt-blended and spray atomised. 
Quite the contrary, pure hard fats retained the α-modification for many months [185]. 
A further possibility to accelerate the transformation from α-form in the β-modification 
directly upon manufacturing is the application of a tempering process [168]. 
 
Influence of elevated temperatures during preparation of the dosage form on protein 
stability 
Proteins unfold above certain temperatures. During thermal unfolding, the 
temperature at which 50 % of the protein molecules are unfolded is defined as the 
unfolding or melting temperature Tm of a protein. The higher Tm, the greater is the 
thermal resistance of a protein [213]. For several proteins, an increase of the melting 
temperature Tm was observed [107] as a result of the reduced flexibility of solid 
proteins in anhydrous, organic media [45; 109]. For example, the thermal unfolding 
temperature Tm of bovine pancreatic ribonuclease suspended in the anhydrous 
alkane nonane is 124 °C, whereas that in water is only 61 °C [107]. However, it is at 
least questionable if an increase in the melting temperature Tm within anhydrous 
solvents can be transferred to the situation of a protein within a lipid melt. Literature 
dealing with this question is not too extensive. Yamagata et al. demonstrated that the 
loss of interferon α-2a activity suspended in polyglycerol ester of fatty acids during 
heating up to 60 °C amounted only 5 %. The further exposure to this temperature 
over 5 hrs did not result in a further activity loss [220]. 
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3.4.2 Cryogenic micronization 
An alternative to the standard procedures represents the cryogenic 
micronization described by Del Curto et al. [56]. The drug is either added to the lipid 
melt (co-melting) by stirring or the drug and the lipid are both dissolved in benzyl 
alcohol-ethanol mixture (solvent stripping) before being poured into a petri dish for 
solvent evaporation. The obtained lipid matrices are micronized in a milling apparatus 
with liquid nitrogen providing -80 °C conditions during the procedure. The 
incorporated GnRH antagonist reveals a continuous release over 1 month in vitro 
and in vivo [55]. It still needs to be shown if this method really is a match for melt 
dispersion or the emulsion technique. 
3.4.3 Spray congealing 
Similarly to the preparation of polymeric devices, protein loaded lipid 
microparticles can also be produced by atomisation (or prilling) the molten 
protein/lipid suspension within a cold air stream [188; 27; 185; 125]. This technique 
led to encapsulation efficiencies for insulin and somatostatin of up to 100 %. Stability 
data during in vitro release proved that neither insulin nor somatostatin were 
influenced by the manufacturing process [125]. 
3.4.4 Application of supercritical carbon dioxide 
A novel supercritical fluid process for the coating of protein particles with lipids 
such as trimyristate or Gelucire® 50-02 was patented in 2000/01 by the group of 
Benoit [13; 58]. In contrast to the techniques described in 2.1.1.4, this method 
completely avoids the use of organic solvents by solubilising the lipid carrier directly 
within SC CO2 medium. Furthermore, the microcapsules produced are composed of 
a preformed core of active material surrounded by a shell of coating material. Coating 
material and protein particles are placed in an autoclave equipped with an impeller. 
The autoclave is heated and pressurised with carbon dioxide until the supercritical 
conditions (35-45 °C, 70-200 bar) are provided. Then, the system is equilibrated for 1 
h in order to solubilise the coating material. After this, cooling of the autoclave 
induces a pressure decrease and the transformation of the SC CO2 into the liquid 
phase, therefore insolubilising the coating material that consequently precipitates 
upon the insoluble protein crystals [193]. 
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It was shown that bovine serum albumin was not affected by heat or pressure during 
the manufacturing process. The protein loss was found to be between 34 % and 87 
% depending on the preparation conditions. Furthermore, the release of BSA from 
these microcapsules was sustained over 5 hrs for crystals coated with trimyristate 
and over 24 hrs for crystals coated with Gelucire® 50-02. Advantages of this method 
are the mild manufacturing conditions and the possibility to change the solvent power 
of SC CO2 by varying the temperature/pressure profile. However, a sustained release 
of a protein over 24 hrs is not deemed sufficient in order to replace liquid 
pharmaceutical formulations [155; 157; 156]. 
3.5 Lipid implants 
In contrast to polymeric systems, lipophilic materials such as fats and waxes 
inhere the competitive edge of their high compressibility. Since polymers are to be 
plasticised by extrusion and injection molding at elevated temperatures before 
implant preparation, lipid implants can easily be produced by compacting using a 
tablets press or a hydraulic press. This method provides mild conditions without the 
use of organic solvents and heat. As a consequence, peptides and proteins are not 
exposed to these detrimental effects during the manufacturing process, what may 
result in better protein stability. Due to the fact that most of the studies described in 
the literature prepared lipid implants by mixing and compressing processes, in the 
following these efforts will be outlined in chronological order. 
One of the very first studies dealing with lipophilic materials - mainly with cholesterol - 
as implant matrices for sustained macromolecule release is addressed by the patent 
of Kent et al. from 1984. Thereby - referring to Langer and Folkman [182] – it was 
aimed for the development of a matrix, which functions by simple diffusion through a 
tortuous pore network [104]. In 1987, Wang et al. dispersed insulin in a pellet disk 
made by compressing a cholesterol mixture. The implantation of these pellets within 
rats reduced blood glucose levels for up to 24 days [210]. Another group around 
Opdebeek and Tucker worked with pure cholesterol and cholesterol/lecithin implants 
for use in veterinary vaccines, in particular for disease prophylaxis in livestock [141, 
105; 206]. The implantation of the matrices (5.5 mm diameter, 1.8 mm thick) induced 
an antigen response within mice for 40 days, whereby pure cholesterol implants 
showed no erosion at all. When those cholesterol implants were enriched with 
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amphiphilic lecithin, the devices eroded over time due to a higher infiltration of water 
into the matrices [105]. 
As mentioned above, Wang et al. first used cholesterol as implant system for the 
insulin delivery. Later on, palmitinic acid was presented as promising excipient in 
sustained insulin release. These implants eroded slowly with time reducing blood 
glucose levels in diabetic rats for up to 40 days. In contrast, both lauric acid and 
myristic acid matrices eroded within 3 days causing blisters in the subcutaneous 
areas. Various triglycerides exhibited no apparent changes after 1 month incubation, 
whereas the applied monoglyceride monocaprin was completely adsorbed by the 
body within 20 hours resulting in hypoglycaemic shock of the test animals. These 
studies effectively evidence the influence of the erosion properties of the material - a 
broad variety of lipophilic substances was investigated – on protein release [211; 
212]. 
A completely different work to previous studies was presented at the end of the 80`s 
and the beginning of the 90`s by Cady et al.. A series of C10 - C20 fatty acid salts of a 
synthetic growth hormone releasing hexapeptide (tri-fatty acid hexapeptide salt) was 
prepared and compressed into implants. The implants were partially coated with 
either biodegradable polymers such as poly(L-lactide/glycolide) copolymer or with 
non-biodegradable polymers such as silicone elastomer. The level of daily drug 
release could be varied with the proper selection of the fatty acid salt. The longer the 
fatty acid chain length, the less soluble the hexapeptide fatty acid salt, and thus the 
lower the daily rate of release. Furthermore, implants coated with the non-
biodegradable polymer approached zero-order kinetics over a 42 days period [25; 
26]. 
Steber et al. published in 1989 implant compositions based on triglycerides, aiming 
for the delivery of polypeptides and proteins - in particular for growth factors such as 
somatotropin. In comparison to the work of Wang, the implants contained up to 25 % 
of a salt and up to 15 % of a filler material. In order to achieve a better release 
control, implants were partially coated with methacrylate polymer acting as 
semipermeable membrane. Elevated blood levels of somatotropin in pigs could be 
reached for 1 month, whereby the long release duration from the triglyceride matrices 
can be attributed to the additional water-soluble salt within the matrices [186; 187]. 
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Recent works dealing with triglycerides as matrix material have used gelatin in order 
to adjust release to different time periods by adding varying amounts of gelatin as 
release modifier [73; 202]. Bovine serum albumin was liberated over 20 days from 
matrices containing 1 % gelatin as porogen, and the lion’s share of protein was 
delivered within 5 days. Using higher gelatin quantities led to more pronounced burst 
effects, liberating the protein within 24 hours. Release studies with hyaluronidase 
loaded implants have been cited as evidence that neither the lipid itself nor the 
manufacturing process induced protein instability [202]. 
In order to avoid variations of physico-chemical characteristics, which may occur 
when using natural materials, Yamagata et al. presented polyglycerol ester of fatty 
acids as novel sustained-release dosage form for interferon α-2a. In contrast to the 
other work illustrated above, these implants were prepared by a heat extrusion 
technique, whereby protein activity was not reduced by extrudate manufacture. 
Interferon α-2a could be liberated from these systems over 15 days, and the total 
amount of released protein was mainly depending on the degree of fatty acid 
esterification and the fatty acid chain length. The constant release rate matched well 
to the modified Jander´s equation indicating that the release process from these 
matrices being diffusion-controlled [220]. 
3.6 Lipophilic matrices after administration 
As mentioned above, lipophilic matrices are not as susceptible to erosion 
phenomena as polymeric systems. Although Reithmeier et al. found a degradation of 
triglyceride microparticles after implantation into mice after 7 days [154], the erosion 
of lipophilic systems, and in particular of lipid implants - seems to be virtually 
nonexistent or, if any, very slow. Intensive studies on the water uptake and the 
erosion behaviour of triglyceride implants revealed pure triglyceride implants showing 
no obvious water uptake for more than 6 months in vitro. The constant mass of the 
matrices after drying indicates that no erosion took place throughout the entire 
observation period of 32 days. In vivo data additionally verified that the defined 
geometry of the implants did not change throughout a 15 days implantation time 
[201; 202]. Starting from an inert, water-insoluble matrix, drug liberation from 
lipophilic systems is assumed to be a diffusion-controlled process through pores. The 
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mathematical background of the diffusion process and the principles of controlled 
macromolecule release from these systems will be outlined in the next section. 
3.6.1 Controlled release of macromolecules from lipophilic systems 
The diffusion process is commonly described by the Fick´s laws relating the 
particle current j to the concentration gradient ∇c as the driving force. The first Fick´s 
law (noted by Adolf Fick in 1855) is defined as 
dx
dcDj ⋅−=  
whereby D is the concentration-independent drug diffusion coefficient, j refers to the 
drug molar flux, and dc/dx is the concentration gradient.  
Accordingly, release from an insoluble, inert matrix such as a wax matrix or a non-
biodegradable polymer matrix can be described by Higuchi´s equation [174], 
provided diffusion being the rate-determining process: 
( ) tCCADQ ss ⋅⋅−⋅
⋅
= ε
τ
ε 2  
with Q being the amount of drug released per area of the disk units exposed to the 
solvent, D being the diffusion coefficient of the drug in the solvent, ε the porosity of 
the matrix, τ the tortuosity of the matrix, A the concentration of solid drug in the 
matrix, Cs the solubility of the drug in the solvent, and t representing the time. 
Detailed theoretical studies of the controlled release mechanism of macromolecules 
dispersed in non-biodegradable devices – e.g. in ethylene vinyl acetate matrices - 
were performed by Siegel and Langer [182; 113; 12]. The release of macromolecules 
from these monolithic, polymeric systems was postulated to occur through a porous 
network created by the drug particles. Whereas a high drug loading creates a 
complete interconnected network leading to drug release due to drug dissolution 
followed by diffusion through this very network, the release from low loaded matrices 
is incomplete due to the interconnected network being incomplete. The retardation of 
peptide and protein release through the formed network has been attributed to a 
geometrical feature of the pore structure in the matrix (Fig. 8). 
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Figure 8: Scheme of pores through which a diffusing drug molecule must pass [182]. 
A protein molecule is to traverse through several pores, and it is a prerequisite that 
the pores are directly connected to each other, forming an intact channel network. 
Often, the channel radius is much smaller than the pore radius, and this represents 
the bottleneck of the diffusion-based release. A diffusing molecule is somewhat 
executing random walks, and, as a consequence, the molecule will traverse into the 
pore wall many times before exiting that pore. The confinement of the protein 
molecules in several pores due to these constrictions was hypothesised a reason for 
the decelerated release from polymer matrices [182]. 
Kaewvichit and Tucker confirmed that in fatty acid matrices obtained by compressing 
neighbouring drug particles form interconnecting networks similar to monolithic 
polymeric system (Fig. 9).  
 
Figure 9: Model of release from compressed matrices showing effects of BSA load and stearic 
acid particles size [101]. 
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This - as well as the appending protein release from fatty acid matrices – was found 
to be namely depended on the protein load and the fatty acid particle size. Protein 
particle size and void spaces between particles generated by the compressing 
process are other parameters that are to be discussed in terms of affecting the 
release profile [101]. 
The described studies can be used as theoretical model for the controlled release of 
macromolecules from lipophilic matrices. Though, it is to be clarified inasmuch the 
diffusion-controlled process is influenced or overlapped by other parameters, for 
example impact by slow matrix erosion. 
3.6.2 Biocompatibility and protein stability issues after administration 
A comparative biocompatibility study was performed by Reithmeier et al., 
assessing the biocompatibility of lipid microparticles in comparison to polymeric 
matrices by implanting both forms subcutaneously into mice. The proliferation of a 
connective tissue combined with a slight infiltration of inflammatory cells was more 
pronounced in the polymer group as early as 2 days after implantation. After 7 days, 
the reaction of the connective tissue came to a halt in the lipid group, whereas in the 
polymer group the fibres of the connective tissue were still solidifying, and fibroblasts 
were visible. The lipid microparticles were concluded to be more biocompatible than 
the PLGA polymeric microparticles [154]. Various evaluations of the inflammatory 
potential of lipid matrices after implantation [105; 206; 211] appear to assert that 
controlled release devices which base on lipids as natural materials and which are 
derived from body tissue constituents exhibit a high biocompatibility after 
administration. This advantage may turn the balance for the application of lipophilic 
materials rather than synthetic polymers in the development of controlled protein 
release systems. 
Matrix swelling and the degradation of synthetic polymers like PLGA as result of a 
substantial water uptake during release lead to an increased osmotic pressure and to 
an acidification within the matrices. Both effects often cause protein aggregation 
during in vitro release (see also 2.1.3.2 ) [14; 22; 130; 147; 225].  
Generally, swelling and erosion occur only marginally in lipid implants, if at all [201; 
211; 105]. In that realm, lipophilic matrices might provide a less detrimental 
environment for incorporated proteins after administration. This hypothesis was 
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verified by various research groups demonstrating that protein activity was not 
affected during in vitro release studies [220; 125; 55; 202].  
In the consequence, this major advantage is giving lipids as encapsulation matrix for 
peptides and proteins a competitive edge when compared to the commonly used 
PLGA systems. 
4. Short survey of the pharmaceutical proteins used in this thesis 
4.1 Interferon α-2a (IFN α-2a) 
Investigating basic mechanisms of viral interference in 1957, Isaacs and 
Lindemann exposed chorioallantoic membranes of embryonated eggs to temperature 
inactivated influenza virus. A few hours later, the supernatant fluid recovered and 
was found to prevent infection of other cells by active live virus. This factor 
transferring invulnerability was named “Interferon”. IFN was notified not directly anti-
viral, not an antibody, and obviously to be a protein. Later, IFNs were defined as 
“proteins” which convey virus non-specific anti-viral activity - at least in homologous 
cells - via cellular metabolic processes involving the synthesis of both RNA and 
protein. 
Interferon was the “prototype” member of a class of bioactive compounds which is 
called “cytokines”. Cytokines are proteins or glycoproteins usually smaller than 30 
kDa. Principally, cytokine action is paracrine and/or autocrine and usually not 
endocrine – but high concentrations of IFN (and other cytokines) are found in plasma 
during systemic infections. Interferon can be produced by almost every kind of cells 
in response to most viruses and several non-viral inducers. However, Interferon is 
not a single substance; there are several IFNs which have different physico-chemical 
and biological properties and that can be distinguished by antibody assays. IFN-α 
(produced by leucocytes) and IFN-β (produced by fibroblasts) are known as type I 
IFN. Their production is induced by viruses. IFN-γ is known as type II IFN and is only 
produced by T-cells on mitogenic/antigenic stimulation. 
Interferon alpha-2a is a 19,237 Da immunomodulating cytokine composed of 165 
amino acids. cDNA cloning allows the production in Escherichia coli since the early 
80`s. Recombinant human (Rh) IFN α-2a has shown antitumour and antiviral efficacy 
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and is clinically used in the treatment of patients with hair cell leukaemia, AIDS 
related Kaposi’s sarcoma, and chronic hepatitis B and C.  
4.2 Granulocyte colony stimulating factor (G-CSF) 
In the mid 1960`s, scientists in Israel and Australia attempted to grow mouse 
leukaemia cells in nutrient agar plates. Although not succeeding, they observed the 
spectacular growth of healthy white blood cells in clusters of colonies around other 
tissue fragments in the agar. Number and size of these white blood cell colonies 
were dependent on adding other cells or tissue fragments to the cultures, giving rise 
to the speculation that some factor contained in this material was stimulating 
haematopoietic cells to divide and form these colonies. This still unidentified factor 
was dubbed a colony stimulating factor (CSF). Further detailed studies by an 
Australian group around Metcalf and by the scientists of the Sloan Kettering Center in 
New York led to the identification of several CSFs, including G-CSF. 
Colony stimulating factors (growth factor cytokines) regulate the proliferation and 
differentiation of immature cells to white blood cells (leucocytes), red blood cells 
(erythrocytes) and platelets, which are all produced in the bone marrow.  
A 19.6 kDa glycoprotein composed of 174 amino acids, granulocyte colony-
stimulating factor (G-CSF) is responsible for the proliferation and differentiation of 
neutrophilic immature cells to neutrophilic granulocytes. Since the mid 80`s, 
recombinant G-CSF can be produced either in Escherichia coli (non-glycosilated G-
CSF with an extra N-terminal methionine, Filgrastim) or in chinese hamster ovary 
cells (glycosilated G-CSF identical with the human G-CSF, Lenograstim). 
G-CSF is clinically used for the regeneration of the immune system in parallel to a 
cytotoxic chemotherapy – treatment of neutropenia - or after bone marrow 
transplantation. The first product, Neupogen® - available since 1991 - is marketed by 
AMGEN. The tenor Jose Carreras, who came down with leukaemia at the end of the 
80´s, was one of the first people to be treated with G-CSF. In 2003, sales totalled 
more than $2.6 billions, with an annual growth rate of 15 %.   
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Chapter II: Aim of the thesis 
The successful controlled release of proteins from biodegradable polymeric 
devices – in particular from PLGA systems – is deemed a daunting task. The most 
remarkable obstacle in the development of such polymeric systems for proteins has 
emerged as the instability of the protein during encapsulation and release [45; 130; 
144; 225]. 
For lipophilic sources (e.g. fatty acids, glycerides and waxes) as alternative 
biomaterials used in controlled protein release systems, protein-compatible 
manufacture processes as well as less detrimental conditions for proteins during 
release potentially might cope with the setbacks polymeric systems generally 
suffered in protein stabilisation [202; 155; 55; 125; 105; 211; 188]. 
Despite showing promise, however, the efforts spent in this specific field – 
particularly approaches in the development of lipid delivery systems for 
pharmaceutically relevant proteins – were kept at low levels over the last years. 
It was therefore the aim of this thesis to develop an implantable delivery system for a 
pharmaceutically relevant protein based on lipid materials.  
Commercially available interferon α-2a (IFN α-2a) formulations (i.e. Roferon® A from 
Roche) which are clinically used in the treatment of patients with leukaemia, AIDS 
related Kaposi sarcoma and hepatitis B and C, require a therapeutic regimen of 
subcutaneous administration several times per week. This is why IFN α-2a was 
deemed an interesting drug candidate for use in parenteral depot systems. Besides a 
second pharmaceutical protein (i.e. granulocyte colony stimulating factor) and one 
model protein compound (i.e. bovine serum albumin) were investigated.   
Implants were chosen as delivery system because a reproducible geometry with a 
defined surface area will allow release studies in a more systematic way.  
It was predominantly aimed for 
• the establishment of a manufacturing process which retains protein integrity. 
• the development of a lipid carrier system which allows continuous protein 
release over a 1-month period 
• to achieve a complete and controlled protein liberation from the device, plus 
• to maintain protein stability during the release process. 
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The applicability of various lipid materials such as fatty acids, triglycerides and 
monoglycerides as protein drug carriers as well as the incorporation of different 
release modifiers were to be evaluated. Moreover, specific evaluation work in order 
to assess and to retain protein stability during manufacturing and release were 
considered a cornerstone throughout all experimental studies. 
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Chapter III: Materials and methods 
1. Materials 
1.1 Interferon alpha-2a (IFN α-2a) 
Rh IFN α-2a bulk was provided by Roche Diagnostics, Penzberg, Germany. 
The protein was formulated in a 25 mM acetate buffer of pH 5.0 containing 120 mM 
sodium chloride. Protein concentration was 1.7 mg/mL. 
In contrast to the native protein, rh-IFN α-2a remains non-glycosilated and contains 
an extra N-terminal methionine. The IFN α-2a molecule owes two disulfide bonds, 
one between amino acids 1 and 98, and the second between amino acids 29 and 
138, whereby only the loss of the second disulfide bond induces an activity loss. IFN 
α-2a can be considered as “all-helical” protein with a total of seven α-helices 
arranging the tertiary structure. The isoelectric point of IFN α-2a is around a pH value 
of 6. 
1.2 Granulocyte colony-stimulating factor (G-CSF) 
Rh G-CSF bulk was provided by Roche Diagnostics, Penzberg, Germany. The 
protein (conc. 4.2 mg/mL) was formulated in a 20 mM pH 4.2 sodium phosphate 
buffer. 
The G-CSF molecule features two disulfide bonds between amino acids 36 and 42 
and between amino acids 64 and 74, respectively. G-CSF forms four α-helices in an 
“up-up-down-down” structure. A great part of the G-CSF molecule consists of 
hydrophobic regions resulting in a high aggregation/self-association tendency of the 
liquid formulations during storage. In addition, G-CSF is extremely sensitive to 
elevated temperatures, e.g. the exposure of G-CSF to a temperature of 85 °C led to 
a complete activity loss within 10 minutes [133; 86]. 
1.3 Bovine serum albumin (BSA) 
Bovine serum albumin (Mr 66,300 Da) is extracted by the Cohn fractionation 
process. The hydrophilic BSA molecule features 17 disulfide bonds, restricting the 
mobility of the molecule. Approximately 55 – 60 % of the BSA molecule are arranged 
as α-helices. The isoelectric point of bovine serum albumin is around 4.7 – 4.9. BSA 
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inheres a considerable amount of dimers (~ 9.2 %) and trimers or higher-ordered 
aggregates (~ 2.5 %) [120]. 
Lyophilised bovine serum albumin Fraction V was purchased from Sigma-Aldrich 
Chemie, Steinheim, Germany. 
1.4 Triglycerides 
Glyceride esters of saturated, pair and non-branched fatty acids (Dynasans®) 
were provided by Condea Chemie, Witten, Germany as microcrystalline products in 
stable β-modification with distinct melting points. Dynasans® are physiologically 
harmless. 
 Chemical 
structure 
Acid value 
(mg KOH/g) 
Hydroxyl 
number OHZ 
(mg KOH/g) 
Saponification 
number VZ 
(mg KOH/g) 
Iodine 
number IZ 
(g I2/100g) 
Melting 
area (°C) 
Dynasan 112 triglyceride of 
lauric acid 
max. 3 max. 10 229-238 max. 1 47 
Dynasan 118 triglyceride of 
stearic acid 
max. 3 max. 10 186-192 max. 1 70-73 °C 
Table 5: Characterisation of Dynasan® products. 
1.5 Stearic acid 
Stearic acid (C18H36O2), a hard wax-like saturated acid with a molecular weight 
of 248.47 g/mol was provided by Condea Chemie, Witten, Germany. Stearic acid is 
almost water-insoluble, physiologically harmless, and a basic constituent of several 
animal and vegetable fats and oils. 
1.6 Monoglycerides and mono-diglycerides 
Palmitic acid monoglyceride (Myverol 18-04 K) and palmitic acid mono-
diglyceride (Admul MG 40-04 K) were provided by Quest International, Netherlands. 
Monoglycerides and mono-diglycerides are the most widely used emulsifiers in the 
food industry. 
 
Total 
monoglyceride 
(min. %) 
Free glycerol 
(max. %) 
Acid value  
(mg KOH/g) 
Iodine 
number IZ  
(g I2/100g) 
Source 
Myverol 18-04 K 95 1 max. 3 max.3 palm 
Admul MG 40-04 K 45 1.5 max. 3 max. 3 palm 
Table 6: Characterisation of monoglycerides and mono-diglycerides. 
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1.7 Polyglycerol ester of fatty acids (PEGFs) 
PEGFs (Admul PGE 1415 K) were provided by Quest International, 
Netherlands. PEGFs are obtained by polymerisation of glycerol and subsequent 
esterification with fatty acids of various chain lengths. The polyglycerol moiety is 
predominantly di-, tri- and tetraglycerol. PEGFs are widely used in the food industry.  
 Acid value  
(mg KOH/g) 
Iodine number 
IZ (g I2/100g) 
Saponification number  
(mg KOH/g) Source 
Admul PGE 1415 K < 3 < 3 90-120 palm 
Table 7: Characterisation of polyglycerol ester of fatty acids.  
1.8 Chemicals and reagents 
Acetic acid (100%), p.A., VWR International GmbH, Darmstadt, Germany 
Acetonitrile, gradient grade (LiChrosolv®), MerckKGaA, Darmstadt, Germany 
Bromphenol blue, VWR International GmbH, Darmstadt, Germany 
Dextran 60, VWR International GmbH, Darmstadt, Germany   
Dipotassium hydrogen phosphate, K2HPO4, p.A., VWR International GmbH, Darmstadt, Germany 
1,2-Dioleyl-sn-Glycero-3-Phosphocholine, DOPC, Avanti Polar Lipids Inc., Alabaster, U.S. 
Disodium hydrogen phosphate dihydrate, Na2HPO4 x 2H2O, p.A., VWR Int. GmbH, Germany 
Free fatty acids, Half-micro test, Roche Diagnostics, Mannheim, Germany  
Glycerin, p.A., Merck KGaA, Darmstadt, Germany 
Guanidine hydrochloride, GnHCl, p.A., VWR International GmbH, Darmstadt, Germany 
Hexane, p.A., Merck KGaA, Darmstadt, Germany 
Hydranal®-Coulomat AG, Sigma-Aldrich Laborchemikalien GmbH, Seelze, Germany 
Hydroxypropyl-ß-cyclodextrin (HP-ß-CD), VWR International GmbH, Darmstadt, Germany 
Potassium chloride, KCl, p.A., VWR International GmbH, Darmstadt, Germany 
Potassium dihydrogen phosphate, KH2PO4, p.A., VWR International GmbH, Darmstadt, Germany 
Lowry protein assay, Bio-Rad Dc Protein-Assay, Bio-Rad Laboratories, Hercules, Canada 
Methanol, p.A., VWR International GmbH, Darmstadt, Germany 
Methylene blue, p.A., VWR International GmbH, Darmstadt, Germany 
Methylene chloride, p.A., Merck KGaA, Darmstadt, Germany 
Poloxamer® 188, VWR International GmbH, Darmstadt, Germany 
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Polyethylene glycol 6000 (PEG), Clariant, Gendorf, Germany 
Sodium azide, NaN3, p.A., VWR International GmbH, Darmstadt, Germany 
Sodium chloride, NaCl, p.A., VWR International GmbH, Darmstadt, Germany 
Sodium dihydrogen phosphate monohydrate, NaH2PO4 x H2O, p.A., VWR Int. GmbH, Germany 
Sodium dodecyl sulphate, C12H25NaO4S, p.A., Merck-Schuchardt GmbH, Hohenbrunn, Germany 
Sodium hydroxide, NaOH, p.A., VWR International GmbH, Darmstadt, Germany 
Sodium sulphate, Na2SO4, p.A., VWR International GmbH, Darmstadt, Germany 
Trifluoroacetic acid, p.A., Merck KGaA, Darmstadt, Germany 
Tris (hydroxymethyl) aminomethane, p.A., VWR International GmbH, Darmstadt, Germany 
Triton X-100, C33H60O10,5, p.A., VWR International GmbH, Darmstadt, Germany 
α,α-Trehalose-dihydrate, British Sugar, Peterborough, UK 
Tween® 20 pure, polysorbate 20, Serva, Heidelberg, Germany 
Tween® 80 pure, polysorbate 80, Serva, Heidelberg, Germany 
Ultra pure water, taken from Purelab Plus®, USF GmbH, Ransbach-Baumbach, Germany 
 
1.9 Packaging material 
Borosilicate glass vials (2R), parenteral quality glass I, siliconised and not 
siliconised, respectively, as well as cycloolefin copolymer TopPac® vials (10R) were 
provided by Schott GmbH, Mainz, Germany. Stoppers were teflon covered 
chlorobutyl rubber stoppers. 
2. Methods 
2.1 Freeze-drying process 
Freeze-drying was performed using a freeze-drying apparatus ε12G (Christ, 
Osterode, Germany). Sample volumes were always 1.0 mL; primary package 
materials were 2R glass vials. Samples were frozen to – 45 °C at a rate of 1.6 
°C/min. This temperature was maintained for 90 min. Then, temperature was 
increased by 0.1 °C/min up to -20 °C, and the chamber pressure was reduced to 10-2 
mbar. That primary drying step was applied for 30 hrs. For the secondary drying, the 
temperature was further increased by 0.1 °C/min up to 20 °C. With a chamber 
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pressure of 10-3 mbar, those conditions were maintained for 15 hrs. After chamber 
venting with nitrogen up to a pressure of 800 mbar, the samples were crimp-sealed 
and eventually stored at 4 °C. 
2.1.1 Freeze-dried protein/sugar formulations 
2.1.1.1 G-CSF 
G-CSF was lyophilised with trehalose in a protein/sugar ratio of 1:4. Each 
lyophilisate consisted of 4 mg protein and 16 mg trehalose. 
2.1.1.2 BSA 
BSA was lyophilised with trehalose in protein/sugar ratios of 1:1, 1:2, 1:3, 1:4 
and 1:5. Per each lyophilisate, the relevant BSA portions account for 4 mg of the 
freeze-dried cake. 
2.1.1.3 IFN α-2a 
• IFN α-2a was lyophilised with trehalose in protein/sugar ratios of 1:1, 1:2, 1:3, 
1:4 and 1:5. Per each lyophilisate, the relevant IFN α-2a portions account for 4 
mg of the freeze-dried cake. 
• IFN α-2a was lyophilised with trehalose, dextran 60 and hydroxylpropyl-ß-
cyclodextrin, respectively, in a protein/excipient ratio of 1:3. Per each 
lyophilisate, the relevant IFN α-2a portions account for 4 mg out of the 16 mg 
cake mass. Before lyophilisation, the pH of the stock solutions was adjusted to 
4.2.   
• IFN α-2a was lyophilised with trehalose, dextran 60 and hydroxylpropyl-ß-
cyclodextrin, respectively in a protein/excipient ratio of 1:3. Per each 
lyophilisate, the relevant IFN α-2a account for 16 mg out of the 64 mg cake 
mass. Before lyophilisation, the pH of the stock solutions was adjusted to 4.2.        
2.2 Karl Fischer titration 
Residual moisture in freeze-dried products was determined via coulometric 
Karl Fischer titration (KF 373, Metrohm GmbH &Co, Filderstadt, Germany), with 
generating the I2 electrolytically to keep the Karl Fischer reaction ongoing. Samples 
were dissolved in 1.0 mL anhydrous methanol inside a nitrogen flooded glove box 
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followed by 5 min vortexing step. Per sample, 500 µl were injected into the 
coulometric cell filled with Hydranal® Coulomat AG. At the end of each experiment, 
residual moisture data was calculated as amount of water in %. 
For later studies, an advanced coulometric Karl Fisher titrator with a Head-Space 
oven was used (Analytik Jena AG, Jena, Germany). Sealed freeze-dried samples 
were fixed in the oven chamber and heated up to 110 °C. The vaporised water was 
transported into the Karl Fisher cell via a needle system.  
2.3 Implant manufacturing 
Placebo implants were prepared by using a hydraulic press (Maassen, 
Eningen, Germany). Lipid powder was ground and compressed to 5 mm diameter 
implants by applying a pressure of 2 tons over 30 s. 
For reasons of comparison, placebo implants were prepared by melting the lipid, 
pouring the melt in 96-well plates and freezing the melt with liquid nitrogen. 
Methylene blue loaded implants and protein loaded implants were prepared by using 
the hydraulic press. The components – lyophilised methylene blue or lyophilised 
protein, additive and lipid – were admixed stepwise in an agate mortar and the 
mixture was filled into a compacting tool with 5 mm in diameter (Fig. 10). 
The powder was compressed with a pressure of 2 tons yielding implants with an 
average weight of 50 mg and with 2.3 mm in height. The drug load was calculated 
based on total implant weight (w/w). 
 
Figure 10: Compacting equipment for the preparation of implants with 5 mm in diameter. 
The powder was compressed with a pressure of 2 tons yielding implants with an 
average weight of 50 mg and with 2.3 mm in height. The drug load was calculated 
based on total implant weight (w/w). 
Chapter III: Materials and methods 51
2.4 Microscopic studies 
Microscopic studies of methylene blue loaded tristearin matrices were carried 
out using a SMX-2T microscope (Nikon, Düsseldorf, Germany), equipped with an 
incident light source (Tungsten 6 V, 12 W) . Standard magnifications from 0.5 x to 2 x 
were applied in order to visualise methylene blue distribution on implants surfaces. 
Microscopic pictures were collected with a TK-C1380 colour video camera (camera 
digital – ½ inch CDD, JVC Professional Products GmbH, Friedberg, Germany) 
coupled with Lucia software.          
2.5 Free fatty acids, half-micro test 
The determination of free fatty acids – i.e. non-esterified fatty acids, NEFA - as 
a function of the erosion behaviour of triglyceride matrices was conducted by using 
an optimised enzymatic colourimetric assay (Roche Diagnostics GmbH, Mannheim, 
Germany). At the presence of the enzyme acyl-CoA synthetase, free fatty acids are 
converted by adenosine-5`-triphosphate (ATP) and coenzyme A (CoA) to acyl-
coenzyme A (acyl-CoA) (addition of 50 µl sample to 1.0 mL reagent A followed by 10 
min vortexing). Acyl-CoA reacts with oxygen in the presence of acyl-CoA oxidase to 
2,3-enoyl-coenzyme A (enoyl-CoA). With peroxidase being present, the resulting 
peroxide converts 2,4,6-tribromo-3-hydroxyl-benzoic acid and 4-aminoantipyrine to a 
red dye (start of the reaction by the addition of 50 µl reagent B, followed by 15 min 
vortexing). The dye intensity was measured spectrophotometrically at 546 nm 
wavelength. Solutions of stearic acid (0.3 – 0.7 mM/L) were prepared by dissolving 
the fatty acid in ethanol and Triton X-100 for the generation of calibration curves. 
2.6 Differential scanning calorimetry (DSC) 
Placebo implants and protein loaded implants were ground. DSC 
measurements (DSC 204 Phoenix, Netzsch, Selb, Germany) were performed using 5 
– 10 mg of the sample. Heating and cooling were conducted at a scan rate of 5 K/min 
within a 25 – 100 °C temperature range.  
2.7 X-ray diffraction 
Pure tristearin implants and protein loaded implants were ground. Wide-angle 
X-ray scattering (WAXS) was performed by an X-ray Diffractometer XRD 3000 TT 
(Seifert, Ahrensberg, Germany), equipped with a copper anode (40 kV, 30 mA, 
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wavelength 0.154178 nm). Experiments were conducted at 0.05 ° (2 theta) within a 
5° - 40 ° range. 
2.8 Extraction of protein from the lipid matrix 
2.8.1 Method I 
The protein-loaded lipid matrix was dissolved in 5.0 mL organic solvent (i.e. 
methylene chloride or hexane). The organic phase was overlayed with 5.0 mL of a 
pH 7.4 isotonic 0.01 M phosphate buffer (PBS), and the protein was extracted by 
gentle agitation. Protein concentration was determined by using a Lowry protein 
assay (Bio-Rad Dc Protein-Assay, Bio-Rad Laboratories, Hercules, Canada), and 
protein stability was evaluated by gel electrophoresis (SDS-PAGE). 
2.8.2 Method II 
The protein-loaded matrix was ground in an agate mortar. 30 – 50 mg of the 
mixture were suspended in 2.0 mL of a pH 7.4 isotonic 0.01 M sodium phosphate 
buffer with 0.05 % (w/v) sodium azide and 1 % polysorbate 20 (PBST). After gentle 
agitation over various periods of time, the samples were filtrated or centrifuged at 
5,000 g for 5 minutes. Protein concentration and stability were determined as 
described for Method I.  
2.9 Lowry protein assay, Bio-Rad DC Protein Assay 
The Bio-Rad DC Protein Assay is a colourimetric assay on protein 
concentration similar to the well-documented Lowry assay. The assay is based on 
two steps: (I) the reaction between protein and copper in an alkaline medium 
(addition of 500 µL reagent A to 100 µL protein samples followed by vortexing), and 
(II) the subsequent reduction of Folin`s reagent by the copper-treated protein 
(addition of 4.0 mL reagent B to the samples followed by vortexing) resulting in a 
characteristic blue colour within 15 min, with an absorbance maximum at 750 nm 
wavelength (U-1100 Spectrophotometer, Hitachi, Berkshire. U.K.). Colour 
development is primarily due to the amino acids tyrosine and tryptophane, and, to a 
lesser extent, cystine, cysteine, and histidine. In case of protein samples containing 
detergents, 20 µl of 10 % sodium dodecyl sulphate solution (reagent S) are added 
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per each mL of reagent A. Protein solutions of known concentrations (50.0 – 1000.0 
µg/mL) were used to generate calibration curves. 
2.10 Sodium dodecyl sulphate polyacrylamide gel electrophoresis  
SDS-PAGE was conducted under non-reducing conditions using an XCell II 
Mini cell system (Novex, San Diego, CA, USA). Samples were diluted in a pH 6.8 
Tris-buffer containing either 2 % or 4 % SDS and 2 % glycerin, were stored for 30 
min at 90 °C, and subsequently loaded into the gel wells (NuPAGE® Novex 10 % Bis-
Tris Pre-Cast Gel 1.0 mm from Invitrogen, Groningen, Netherlands). Electrophoresis 
was performed in a constant current mode of 30 mA in a Tris-glycine/SDS running 
buffer (MES running buffer from Invitrogen). After staining with either a coomassie 
blue kit or a silver staining kit (Colloidal Blue Staining Kit and SilverXpress® Stain Kit 
both from Invitrogen), the gels were dried using a DryEase® Gel Drying System 
(Invitrogen). 
2.11 In vitro release studies 
In vitro release studies were conducted by incubating the implants at 37 °C 
either in glass vials or in TopPac® vials (both from Schott GmbH, Mainz, Germany), 
each containing 2.0 mL isotonic 0.01 M phosphate buffer (pH 7.4 with 0.05 % (w/v) 
sodium azide; PBS). The samples were shaken at 40 rpm (Certomat® IS, Braun 
Biotech International, Melsungen, Germany). At predetermined time points, the 
release medium was completely removed and replaced with fresh buffer. The set-up 
of the in vitro release system was designed for comparative development purposes 
only, and not designed for mimicking the conditions at an s.c. injection site. Each 
experiment comprised analysis of three individual samples. Protein concentration 
and protein integrity were assessed either by reversed phase HPLC (IFN α-2a and 
G-CSF) or by size exclusion HPLC (IFN α-2a and BSA).  
In order to further investigate the protein integrity within the matrices, protein was 
extracted from several implants (see chapter II, 2.7.2) after incubation and analysed 
by SDS-PAGE. In addition to that, samples drawn at various times were also 
analysed by gel electrophoresis. 
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2.12 Reversed phase HPLC (RP-HPLC) of IFN α-2a 
Protein concentration and the amount of chemically modified protein - e.g. 
oxidised species - can be assessed by RP-HPLC (Fig. 11), which was performed 
with a Jupiter 5u C18 300 A 250 x 4.60 mm column (Phenomenex, Aschaffenburg, 
Germany). The mobile phase consisted of a 49:51 (v/v) acetonitrile/ultra purified 
water mixture, which was acidified with 1 mL trifluoroacetic acid per L of eluent. The 
flow rate was adjusted to 1 mL/min, UV-detection (UV 1000, Thermo Electron 
Cooperation, Dreieich, Germany) was performed at 215 nm wavelength. IFN α-2a 
solutions of known concentrations (37.5 – 600.0 µg/mL) were used calibration curve 
set-up. 
2.13 Size exclusion HPLC (SE-HPLC) of IFN α-2a 
SE-HPLC of IFN α-2a (Fig. 11) was conducted using a TSKgel G3000SWXL 
7.8 mm x 30.0 cm column (Tosoh Biosep, Stuttgart, Germany). 120 mM disodium 
hydrogen phosphate dihydrate, 20 mM sodium dihydrogen phosphate and 4 g/L 
sodium chloride, adjusted with hydrochloric acid to a pH of 5.0 was used as mobile 
phase. The flow rate was set to 0.6 mL/min, UV detection (UV 1000, Thermo-
Electron) was performed at 210 nm wavelength. IFN α-2a solutions of known 
concentrations (42.0 – 600.0 µg/mL) were used to generate calibration curves. 
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Figure 11: Detection of oxidised and aggregated IFN α-2a specimen by RP-HPLC (left) and SE-
HPLC (right), respectively. 
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2.14 Reversed phase HPLC (RP-HPLC) of G-CSF 
RP-HPLC of G-CSF was accomplished using a Jupiter 5u C18 300 A 250 x 
4.60 mm column (Phenomenex). The mobile phase was made up of acetonitrile and 
ultra purified water 60:40 (v/v), acidified with 1 mL trifluoroacetic acid per L medium. 
The flow rate was set to 1 mL/min, UV detection (UV 1000) was performed at 220 nm 
wavelength. Calibration curves were generated by G-CSF solutions at a range of 
21.0 – 420.0 µg/mL. 
2.15 Size exclusion HPLC (SE-HPLC) of BSA 
In order to assess protein concentration and protein stability, BSA was 
analysed via SE-HPLC (Fig. 12). A TSKgel G3000 SW 7.5 mm x 30 cm column 
(Tosoh Biosep) was used, with the mobile phase consisting of 250 mM sodium 
sulphate and 10 mM potassium dihydrogen phosphate, adjusted to a pH of 6.8. The 
flow rate was set to 0.6 mL/min, UV detection (UV 1000) was performed at 210 nm 
wavelength. BSA solutions of known concentrations (25.0 – 600 µg/mL) were used 
for instrument calibration. 
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Figure 12: Detection of BSA specimen by SE-HPLC. 
2.16 Light obscuration analysis 
Light obscuration technique – often referred to as light blockage - is a state-of-
the-art method for subvisible particle counting in liquid parenterals with a lower 
detection limit of ~1 µm. A proceeding aggregation process within the liquid 
formulation may result in insoluble aggregates/precipitates which can be analysed by 
this technique. Light obscuration measurements were carried out using a SVSS-C40 
apparatus (PAMAS GmbH, Rutesheim, Germany). Analytical sample volumes were 
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consistently 0.3 mL, and each protein sample was measured three times (n=3). Data 
of counted particles were correlated to a sample volume of 1.0 mL. 
2.17 Scanning electron microscopy (SEM) 
For SEM sample preparation, dry implants were coated with gold. Incubated 
implants were dried before coating in a VO 200 vacuum chamber (Memmert, 
Schwabach, Germany) for 48 hrs before coating. Surface morphology of the implants 
was analysed by a Field Emission Scanning Electron Microscope JSM-6500 F (Joel, 
Ebersberg, Germany). 
2.18 Mercury porosimetry 
Incubated implants were dried in a VO 200 vacuum chamber (Memmert) for 
48 hrs. Pore size measurements were performed using a Auto Pore IV Porosimeter 
and a 5 bulb 0.38 stem solid penetrometer (both from Micromeritics, 
Moenchengladbach, Germany). The contact angle used was 141 °. The samples 
were evacuated for 5 min with an evacuation pressure of about 50 mg for low 
pressure runs. The mercury filling pressure was 0.0028 MPa. The equilibration time 
during low and high pressure measurements was set to 30 sec. 
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Chapter IV: Tentative experiments   
Lipophilic materials – e.g. fatty acids, triglycerides, and waxes - reveal a high 
compressibility. As a consequence, lipid implants for use in drug delivery are 
commonly prepared by means of standard compacting equipment like tablet presses 
or hydraulic presses, respectively [211; 25; 187]. In theory, the mild condition process 
is assumed to deliver implants with a reproducible geometry and a definite drug load, 
what should also be exploited in this thesis.  
Thus, a standard hydraulic press in combination with a potassium bromide moulding 
pellet tool (d = 13 mm) was used in pilot surveys in order to verify the compressibility 
of the lipophilic materials. These investigations indicated the manufacture of lipid 
implants by compacting being possible, but due to the required pressure of some 12 
tons as well as due to the fact that the implants stuck on the compacting tool the 
diameter of this tool had to be reduced. Furthermore, implants` dimensions should be 
kept in a feasible range with respect to the demands of parenteral application 
pathways. 
As shown in chapter II, a purpose-built compacting tool (Maassen GmbH) enabled 
the preparation of implants with a diameter of 5 mm by applying a pressure of solely 
2 tons for 30 seconds. Using this set-up yielded implants with weights ranging 
between 30 - 100 mg. Though for reasons of a higher reproducibility during future 
release studies matrices were prepared with weights between 45 – 55 mg and height 
dimensions of 2 - 2.5 mm (Fig. 13A).  
The implants could easily be loosened from the punching tool without sticking. 
Furthermore, the obtained matrices exhibited a high physical stability (e.g. a 27 N 
breaking strength) and the surface appeared smooth with only low ruggedness which 
is ascribed to the compressing process per se (Fig 13B). 
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Figure 13: (A) Triglyceride matrix, (B) surface zoom by SEM. 
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Dissolving the implants manufacture related irritations was the first approach in the 
tentative experiments. Based on the first trouble shooting the next step was to 
characterise the pure lipid implants in terms of polymorphic behaviour, erosion 
properties and basic applicability as delivery systems for protein drugs. 
1. Characterisation of lipid modification 
Generally, polymorphism of long-chain compounds, in particular of fats and 
lipids, is influenced by several external factors such as temperature, solvents and 
pressure (refer to chapter I, 3.4.2). The transformation of the stable β-modification to 
the instable α-form due to melting has been rated a major disadvantage of the melt 
dispersion technique, which is commonly used for the preparation of triglyceride 
microparticles [153]. During storage, this transition can impact the release profile of 
incorporated drugs [62].  
Therefore, the melting points of compressed tristearin -, trilaurin -, and stearic acid 
implants, respectively were investigated by differential scanning calorimetry (DSC) 
and compared to unprocessed bulk materials as well as to implants produced by 
melting and freezing. Data of the thermal behaviour of tristearin material are 
illustrated in Fig. 14. 
The thermogram of tristearin bulk (A) revealed one single endothermic peak at 72.3 
°C originating from the melting of the crystalline β-modification. Implants (B), ground 
prior to DSC measurements exhibited a peak maximum at 74.5 °C. This minor 
displacement of the peak maximum versus bulk lipid is considered an effect caused 
by different particle sizes of the ground implants [23]. However, pure tristearin 
implants obtained by melting and freezing (C) demonstrated modified thermograms, 
like two endothermic peaks. The lower peak (Tm = 56.1 °C) represents the melting 
characteristic of a metastable α-fraction followed by an exothermic peak representing 
the recrystallisation. The higher temperature peak is assigned to the melting of the 
stable β-modification. As expected thermograms obtained from trilaurin samples 
featured identical results (data not shown). 
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Figure 14: DSC analysis of (A) tristearin bulk, (B) tristearin implants obtained by compressing  
exerting a pressure of 2 tons, and (C) tristearin implants obtained by melting and freezing with 
liquid nitrogen. (For better visualisation the plot baselines are displaced vertically). 
Crystal forms of even fatty acids are referred to as A, B and C. For stearic acid, the C 
variant is the most thermodynamically stable form (Tm = 69.6 °C) prevalently obtained 
by the solidification of the melt. Crystallisation from a non-polar solvent usually yields 
either the A-form (Tm = 64.0 °C) or a mixture of the B (Tm = 54.0 °C) and C-forms. 
Though, the A-form preparation also was reported by pressing stearic acid upon a 
glass plate [69; 71; 136]. 
One single endothermic peak at 70.5 °C was detected in the thermogram of stearic 
acid bulk (Fig. 15 (A)), which is assigned to the melting of the stable C-polymorph. 
Implants obtained by compressing (B) feature a displaced peak maximum at 73.8 °C 
[23]. However, the visible shoulder ( ) of this peak may indicate the existence of an 
A-polymorph fraction originating from the compression process [136]. In contrast, 
implants obtained by melting and freezing possessed one sharp endothermic peak. 
This implicates the melt solidification in the thermodynamically stable C-polymorph 
during implant preparation. 
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Figure 15: DSC analysis of (A) stearic acid bulk, (B) stearic acid implants obtained by  
compressing exerting a pressure of 2 tons, and (C) stearic acid implants obtained by melting 
and freezing with liquid nitrogen. (For better visualisation the plot baselines are displaced 
vertically). 
DSC results pointed out the manufacturing process by compressing does not impact 
the lipid modification of triglycerides. Besides, it can be concluded that the implants 
consist mainly of stable β-modification material.  
However, for stearic acid implants the compressing step did generate A-polymorph 
material. This instable form being now present within the matrices may result in 
polymorphic transformation during storage [61]. Therefore, the findings have to be 
taken into account with respect to the evaluation of the applicability of stearic acid 
material as delivery system for proteins. 
2. Erosion behaviour of lipid implants 
The main parameter influencing the stability of incorporated proteins is the 
erosion behaviour of the relevant controlled release systems. Completely changing 
the morphology of polymeric devices, a rapid water uptake also alters the 
microclimate. Given that conditions, the proteins are exposed to acidic degradation 
products within both the matrices and the release media [176; 78].  
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At the beginning of this work only few authors dealt with swelling and erosion 
phenomena of lipophilic matrices [211; 105]. These studies indicated that the water 
uptake and the erosion rate of lipophilic materials is substantially lowered in 
comparison to polymeric systems. However, a saponification of triglycerides was 
assumed to take place during drug release. This triglyceride degradation would 
liberate long-chain fatty acids, which may result in an alteration of the pH within the 
matrices or the release media. Moreover, it could be assumed that the exposure of 
stearic acid implants to aqueous media may result in an increased water uptake and 
eventually an accelerated degeneration rate due to the more hydrophilic nature of 
this material [211]. 
In a first approach, each pure tristearin, trilaurin and stearic acid implants were 
prepared and incubated at 37 °C each in 2.0 mL of a pH 7.4 isotonic 0.01 M 
phosphate buffer (PBS) over a time period of 4 weeks. PBS medium was moderately 
agitated via shaking (40 rpm, Certomat® IS, BraunBiotech International, Germany). 
The pH of the buffer media was measured after 2 weeks and after 4 weeks, 
respectively (Fig. 16). 
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Figure 16: pH alteration within the release medium (pH 7.4 isotonic 0.01 M phosphate buffer) 
due to interaction with added lipophilic matrices. 
In that experiment, triglyceride matrices featured no obvious erosion during 4 weeks 
of incubation and the implants maintained their original geometry in diameter and 
height. Also no mass loss was detectable. Furthermore, measuring constant pH 
values within the aqueous media did not indicate any liberation of free fatty acids In 
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contrary, stearic acid matrices underlie a complete degeneration within 2 weeks of 
incubation, associated with a pH drop of the buffer media down to values around 6.8 
(Fig. 16). 
In order to confirm the poor erosion rate of triglyceride matrices, a half-micro test for 
the determination of the free fatty acids content within aqueous media was set-up. 
For reasons of harmonisation with release studies planned later on, triglyceride 
implants with a 10 % or 20 % trehalose load were manufactured and incubated in 
PBS for a 8 week period (37 °C, 40 rpm).  
Data on free fatty acids content in buffer media are listed below. 
Implant composition Free fatty acids content after 3 weeks [mg/mL] 
Free fatty acids content 
after 8 weeks [mg/mL] 
10 % trehalose/90 % trilaurin  3.20  8.22  
20 % trehalose/80 % trilaurin 2.17  9.36  
10 % trehalose/90 % tristearin 3.13  6.90  
20 % trehalose/80 % tristearin 5.69  6.61  
Table 8: Free fatty acids content in buffer media as a consequence of the degradation of 
various triglyceride matrices. Lipid implants with an average weight of 50 mg were incubated in 
2.0 mL of a pH 7.4 isotonic 0.01 M phosphate buffer (PBS).  
Results obtained by the free fatty acids test clearly proved the degradation of 
triglyceride matrices being negligible. Even for trilaurin implants which appear to 
degrade more during an 8 week incubation period, an average free fatty acid 
concentration of 8.96 mg/L did not indicate pronounced erosion behaviour. The 
detected free fatty acid content corresponded to 0.042 % of implant weights.      
The evaluation of the erosion behaviour of various lipophilic matrices led to the 
following conclusion:  
a) Triglyceride matrices reveal a slow water uptake and poor erosion. As a 
consequence, incorporated proteins may be deemed more stable. On the other hand, 
a chance to control protein release by the erosion process per se – similar to surface 
erosion polymers - has to be jettisoned when using triglyceride matrices as carrier 
material. 
b)  Stearic acid implants exhibit a rapid water uptake leading first to a swelling of the 
matrices, and secondly to a complete degradation of the implants within 2 weeks. 
This erosion behaviour may facilitate protein liberation, but constant protein stability 
could be jeopardised by interaction with eroded lipid material. 
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3. Evaluation of protein stability within isotonic buffer media 
Due to the inherent chemical and physical instability, each protein usually 
requires a unique stabilisation approach. This also includes the adjustment of the 
formulation pH 213].  
G-CSF and IFN α-2a bulk solutions have been provided in slightly acidic buffer media 
because of an increased stability these proteins feature within acidic environments 
[224; 86]. However the optimisation of the buffer media on protein stability 
requirements is only effective in order to guarantee protein integrity within the dosage 
forms prior to administration.  
After application, proteins are exposed to the pH 7.4 physiological buffer medium. 
Consequently, within controlled release systems proteins have to deal over an 
extended time period with the infiltration of this pH 7.4 medium into the release 
device and the incorporated proteins are expected to be stable under these 
conditions. Thus, a better correlation between in vitro release studies and in vivo 
conditions can be obtained when in vitro release buffer media mimic physiological 
conditions. 
In accordance with the aspects outlined above, stability studies of BSA, IFN α-2a and 
G-CSF were performed in solutions formulated either in pH 7.4 isotonic 0.01 M 
phosphate buffer (PBS) or in PBS with 0.05 % (w/v) sodium azide as preservative. In 
order to clarify the influence of protein concentration on aggregation and adsorption 
tendency [213; 80] stock solutions with protein concentrations of 0.05 mg/mL and 
0.25 mg/mL were prepared and each 2.0 mL of solution were incubated at 37 °C over 
7 days (40 rpm). At predetermined points of time the proteins were characterised in 
terms of concentration (Lowry assay) and integrity (PAGE), respectively. 
BSA stock solutions exhibited constant protein concentrations in both buffer media 
(PBS and PBS with 0.05 % (w/v) sodium azide) over 7 days. Independently from the 
original protein concentration and from the addition of the NaN3 preservative 99 % 
protein recovery was obtained (graph not shown). Also gel electrophoresis did not 
demonstrate BSA instability and consequently it was assumed BSA formulations 
being stable at pH 7.4 conditions.   
Contrarily, with the same experimental parameters IFN α-2a - formulated in pure 
PBS - showed a continuous decrease in protein concentration over the time. Adding 
preservatives resulted in constant protein concentrations for 7 days regardless of the 
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original IFN α-2a concentrations (Fig. 17A). These results suggested IFN α-2a 
denaturation due to bacterial growth within the non-preserved buffer medium during 
incubation at 37 °C.  
PAGE was applied for further clarification of that finding (Fig. 17B): a pronounced 
destruction of IFN α-2a molecules was notified after 7 days incubation in non-
preserved media. However, preserved media samples exhibited only a small amount 
of dimer specimen in comparison to IFN α-2a gel standard. For future in vitro release 
studies, conditions enabling a sufficient stability of IFN α-2a in PBS with 0.05 % (w/v) 
sodium azide were applied.  
 
Figure 17: Influence of the addition of a preservative (0.05 % (w/v) NaN3) on IFN α-2a recovery 
and stability in pH 7.4 isotonic 0.01 M phosphate buffer (PBS). (A) Alteration of protein 
concentration over 7 days of incubation - 0.25 mg/mL ( ) and 0.05 mg/mL ( ) IFN α-2a in PBS 
with NaN3, 0.25 mg/mL ( ) and 0.05 mg/mL ( ) IFN α-2a in PBS; (average ± SD., n = 3).  (B) IFN 
α-2a stability in buffer media after 7 days (0.25 mg/mL protein) - lane 1: protein standard, lane 
2: IFN α-2a in PBS/0.05 % (w/v) NaN3, lane 3: IFN α-2a in PBS, lane 4: MW marker.  
In order to investigate stability of G-CSF in solution, similar experiments were 
performed. In PBS, the samples featured a constant recovery over 3 days followed 
by a notable decrease in concentration with incubation continuing for up to 7 days. It 
is worth to be outlined that the addition of 0.05 % (w/v) NaN3 to PBS does not alter 
the profile of the concentration data (Fig. 18).  
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Figure 18: Influence of the addition of a preservative (0.05 % (w/v) NaN3) on G-CSF recovery 
and stability in pH 7.4 isotonic 0.01 M phosphate buffer (PBS). Alteration of protein 
concentration over 7 days of incubation - 0.25 mg/mL ( ) and 0.05 mg/mL ( ) G-CSF in PBS 
with NaN3, 0.25 mg/mL ( ) and 0.05 mg/mL ( ) G-CSF in PBS (average ± SD, n = 3). 
PAGE studies of G-CSF samples formulated in PBS with 0.05 % (w/v) NaN3 reveal a 
solely marginal dimer fraction after 3 days of incubation. Aggregation unambiguously 
became more intense with continuing incubation time, mirrored in the development of 
dimer and trimer aggregates as well as of higher-order oligomer fractions (Fig. 19). 
 
Figure 19: G-CSF stability in PBS media after various time periods (0.25 mg/mL protein). Lane 
1: G-CSF in PBS/0.05 % (w/v) NaN3 after 7 d, lane 2: protein standard, lane 3: G-CSF in PBS/0.05 
% (w/v) NaN3 after 3 d, lane 4: MW marker.  
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These results implicate the stability of G-CSF within neutral buffer media being 
abased over longer incubation [37].  
In summary, those tentative stability studies suggested that future in vitro release 
studies could be conducted using pH 7.4 isotonic 0.01 M phosphate buffer (PBS) 
including 0.05 % (w/v) sodium azide, a buffer medium resembling physiological 
conditions. Here, not all proteins exhibited satisfying stability over a time range up to 
7 days. As a consequence, it is outlined that in future studies release medium will be 
removed completely and replaced by fresh buffer in a three days interval.  
Furthermore, stability appeared to be virtually independent from protein concentration 
- an important point considering that during in vitro release studies varying amounts 
of protein will be liberated from the matrices.  
4. Evaluation of interactions between proteins and lipid matrices 
The adsorption phenomenon of proteins to polymeric matrices after release 
from these systems has been described as a reason for triggering unfolding and 
aggregation. Similarly, direct binding between decomposition products and protein 
molecules can lead to protein inactivation after administration [176]. 
In order to evaluate the possibility of protein/ lipid interactions, pure lipid matrices - 
i.e. tristearin and stearic acid implants - were added to 2.0 mL protein stock solutions 
(0.25 mg/mL) formulated in PBS/0.05 % (w/v) sodium azide. The samples were 
incubated at 37 °C for 7 days (40 rpm). At predetermined points of time samples 
were drawn and assessed in terms of protein concentration and protein integrity. 
Evaluating studies of IFN α-2a featured no substantial difference in protein recovery 
between samples with and without pure tristearin matrices. Almost a 100 % IFN α-2a 
recovery was detectable over 7 days (Fig. 20). Although the average value was 100 
%, a 20 % standard deviation of the applied Lowry assay is to be highlighted. 
Matrices revealed no obvious change in appearance after incubation for one week 
demonstrating again the poor erosion behaviour of this very material. However, 
stearic acid implants revealed visible erosion already after 24 hrs of incubation. The 
erosion went along with a decrease in IFN α-2a concentration over the time, yielding 
a mere 15 % IFN α-2a recovery after 7 days (Fig. 20).  
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Figure 20: IFN α-2a recovery in samples containing pure lipophilic matrices over 7 days of 
incubation (0.25 mg/mL protein). Matrix free samples ( ), samples containing one tristearin 
matrix ( ), and samples containing one stearic acid matrix ( ) (average ± SD, n = 3). 
For G-CSF experimental data were comparable (Fig. 21).  
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Figure 21: G-CSF recovery in samples containing pure lipophilic matrices over 7 days of 
incubation (0.25 mg/mL protein). Matrix free samples ( ), samples containing one tristearin 
matrix ( ), and samples containing one stearic acid matrix ( ) (average ± SD., n = 3).  
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Again, the erosion of stearic acid matrices was accompanied by a low protein 
recovery of 20 % after 7 days of incubation, and virtually no difference was noted 
between matrix free samples and samples containing tristearin matrices.             
In the realm of protein integrity, PAGE analysis of samples containing a stearic acid 
matrix demonstrated extensive protein aggregation after already 3 days of incubation 
(Fig. 22). This suggested interactions between protein molecules and eroded stearic 
acid materials. For G-CSF, almost full protein degradation took place, evidenced by 
almost vanished monomer band and high-molecular weight aggregates, present 
even in the loading nests of the gel. For IFN α-2a, intense aggregation bands were 
also detected, even though the protein degradation appears less pronounced 
compared to G-CSF.         
In contrast, the presence of tristearin matrix material did not substantially impact 
protein integrity. Aggregated species were only humble detected in case of IFN α-2a 
samples, and solely native monomer was detected in G-CSF samples (Fig. 22). 
 
Figure 22: Influence of tristearin and stearic acid matrices on protein stability after 3 days of 
incubation. (A) IFN α-2a - lane 1: MW marker, lane 2: matrix-free sample, lane 3: sample 
containing one tristearin matrix, lane 4: sample containing one stearic acid matrix; (B) G-CSF - 
lane 1: matrix free sample, lane 2: sample containing one tristearin matrix, lane 3: sample 
containing one stearic acid matrix, lane 4: MW marker.   
Based on data and subsequent conclusion, stearic acid matrices appear to be 
inappropriate for further investigations. The existence of multiple polymorphic 
modifications within the implants (refer to chapter IV, 1) and the associated strong 
protein aggregation as a consequence of the rapid erosion rate featured this material 
not being useful in the development of controlled protein release devices. 
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5. Drug homogeneity within lipid mixtures and lipid implants 
The preparation of protein/lipid compositions by mixing may not necessarily 
yield homogeneous mixtures. Consequently variations of implants drug load could be 
possible. Furthermore, it may be argued that a non-uniform drug distribution of the 
lipid implants can also be caused by the compressing forces exerted during the 
manufacture process potentially as a result of sintering processes.  
Due to its colour enabling a convenient visual control, lyophilised methylene blue was 
used as model drug compound for homogeneity evaluations of the manufactured 
implants.  
Mixtures containing 10 % lyophilised methylene blue/sugar mixtures and 90 % 
powdered tristearin were prepared by mixing the components in an agate mortar. 
The mixtures were divided into three identical portions and dissolved in 20.0 mL 
isopropyl alcohol. The solutions were further diluted with isopropyl alcohol for UV 
absorbance measurements at 663.5 nm wavelength. Methylene blue solutions with 
concentrations in a 0.2 – 3.7 mg/mL range were used to generate calibration curves 
for the calculation of methylene blue recoveries (% values, table 9). 
Recovery [%] of  Mixture 
 Portion 1  Portion 2  Portion 3  SD [%] 
I - methylene blue/trehalose lyophilisate A/ 
tristearin 
109.82  111.65  113.46  1.82  
II - methylene blue/trehalose lyophilisate B/ 
tristearin 
79.05  80.42  81.43  1.19  
III - methylene blue/HP-ß-CD lyophilisate/ 
tristearin 
80.20  82.46  83.77  1.81  
Table 9: Methylene blue recovery data from methylene blue/ lipid mixtures portioned into three 
subplots (SD = standard deviation). 
The results of absorbance measurements of mixture 1 led to a higher methylene blue 
recovery in all fractions when compared to the other mixtures. This is addressed to a 
systematic failure during preparation of the methylene blue stock solution prior to 
freeze-drying. However, comparing the standard deviation of recoveries from the 
three fractions of each mixture revealed a sufficient homogeneity of methylene blue/ 
lipid mixtures for subsequent implant manufacture (Table 9). 
In order to evaluate the uniformity of drug distribution within lipid matrices, methylene 
blue loaded implants were prepared from mixtures as described above. Implants 
were portioned into three pieces, which were dissolved in 20.0 mL isopropyl alcohol 
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via 15 minutes ultrasonication. Absorbance measurements were conducted at a 
wavelength of 663.5 nm after further dilution steps. 
Data of the methylene blue incorporated in the three respective pieces of one implant 
exhibited standard deviations in a range of 7 – 8.45 % (table 10), proving 
homogeneity of the methylene blue being unsatisfactorily.  
Recovery [%] of  Implant 
Piece 1  Piece 2  Piece 3  SD [%] 
I - methylene blue/trehalose lyophilisate A/ 
tristearin 
105.79  100.12  116.75  8.45  
II - methylene blue/trehalose lyophilisate B/ 
tristearin 
88.35  76.40  75.38  7.21  
III - methylene blue/HP-ß-CD lyophilisate/ 
tristearin 
86.58  81.16  72.61  7.04  
Table 10: Recovery data of methylene blue from lipid implants, portioned into three pieces  
(SD = standard deviation). 
Microscopic studies (SMX-2T microscope, Nikon, Düsseldorf, Germany) of implant 
surfaces confirmed the non-uniformity of methylene blue distribution after 
compressing. Darker and brighter areas were visible in the different images, being a 
result of different methylene blue contents in these regions (Fig. 23).  
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Figure 23: Microscopic images of (A), (B) and (C) methylene blue/lipid implants I – III. 
Based on these study data it can be concluded that certain variability in release 
curves must be anticipated during release experiments. Despite same manufacturing 
process, implants may differ in (I) their actual drug load, (II) the protein distribution 
between surface and interior and (III) the size distribution of the pores formed during 
compressing.          
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6. Development of a protein extraction method from lipid implants 
Generally, protein aggregation during dosage forms manufacture can be 
induced by a variety of parameters such as shear forces, elevated temperatures, 
organic solvents, pressure etc. [176; 14; 198; 109; 160]. The formation of protein 
aggregates may imperil the safety of the devices by inducing grave adverse effects in 
patients i.e. immune response and anaphylactic shock [33; 20]. Moreover, the 
release kinetics of implant systems may be influenced by a deceleration or even 
restriction of aggregated protein liberation due to a reduced solubility of aggregates 
or because of pore size limitations within the matrices [106; 216]. Therefore the 
successful development of a method for protein extraction was deemed crucial in 
order to clarify whether the manufacturing process by compressing influences protein 
stability.  
Extraction of proteins from microparticulate systems is usually accomplished by 
dissolving the matrices in an organic solvent and yielding the protein by shaking out 
with buffer or by centrifugation [98; 154].  
For the first approaches methods from the literature were adapted for protein 
extraction from lipid implants. Proteins were lyophilised with trehalose in a ratio of 1:4 
(and with 0.05 % (w/v) polysorbate 80). Gel electrophoresis of reconstituted protein 
lyophilisates did not demonstrate any aggregated species potentially induced by the 
freeze drying process per se (residual moisture content ranging between 0.3 – 1.9 
%). These data verify protein integrity prior to implant manufacture.  
Protein loaded tristearin matrices were prepared with a 2.0 % protein load (i.e. 10% 
lyophilised protein) for all implants. Matrices were dissolved either in methylene 
chloride or in hexane followed by protein extraction with pH 7.4 isotonic 0.01 M 
phosphate buffer (PBS) and slight agitation. Each experiment comprised analysis of 
three individual samples (n=3). Results of recovered protein in the aqueous media 
after various time periods are shown in Fig. 11. 
Dissolving the matrices in methylene chloride resulted in a 5 % average recovery of 
G-CSF, 10 % for IFN α-2a and 50 % for BSA, respectively. In the case of G-CSF and 
IFN α-2a maximal values were reached after an agitation period of 2 hrs, but 
recovery values were lower when agitation was applied longer than that (Fig. 24A).  
Better results were yielded when hexane was used as solvent medium, i.e. values 
averaging 67 % for G-CSF and 47 % for IFN α-2a were found in the buffer media 
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after 8 hrs of agitation. However, BSA recovery (28 %) was lower than in the 
experiment with methylene chloride (Fig. 24B).  
 
Figure 24: Protein recovery after implant dissolving in (A) methylene chloride or in (B) hexane, 
resp., followed by extraction with buffer medium (average ± SD, n = 3). 
Protein integrity analysis unveiled that protein aggregation took place during the 
protein extraction by means of organic solvent/buffer (Fig. 25). For G-CSF, heavy 
destruction of protein molecules was observed when applying hexane, whereas 
apparently no G-CSF was extracted when methylene chloride was used as organic 
solvent.  
In contrast, IFN α-2a and BSA demonstrated to be extractable when methylene 
chloride was applied, though, the aggregation was more pronounced than for 
hexane/buffer extraction (Fig. 25). 
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Figure 25: Protein integrity after extraction from lipid implants via the organic solvent/buffer 
technique. (A) G-CSF – lane 1: MW marker, lane 2: protein standard, lane 3: extracted via 
hexane/buffer, lane 4: extracted via methylene chloride/buffer; (B) IFN α-2a – lane 1: MW 
marker, lane 2: extracted via hexane/buffer, lane 3: extracted via methylene chloride/buffer, 
lane 4: protein standard; (C) BSA – lane 1: protein standard, lane 2: MW marker, lane 3: 
extracted via hexane/buffer, lane 4: extracted via methylene chloride/buffer. 
Extracting proteins via organic solvent/buffer systems implies the formation of a 
water/organic solvent interface as well as diffusion processes of organic solvent and 
water molecules. In that respect, protein molecules can unfold and aggregate either 
due to adsorption to the water/organic solvent interface [165] or to destabilising 
effects of water-saturated organic solvent [109; 45]. Given the background of 
aggregated protein featuring an increased hydrophobicity, it may be argued that the 
extraction of protein - using an aqueous medium - may be somewhat incomplete. 
Strong aggregation provided, insufficient solubility of more hydrophobic aggregates - 
and thus the extraction method per se - may be deemed the primary cause for low 
recovery rates rather than parameters associated with the manufacture of the 
implants. 
Thoughts on an extraction technique avoiding the use of organic solvents led to the 
development of the extraction method II (refer to chapter III, 2.7.2). Here, the ground 
protein-loaded matrix mixtures were suspended in PBS. After gentle agitation, the 
lipid fraction was removed first by filtration.  
Whereas the suspension in pure buffer medium resulted in no protein recovery at all, 
the addition of polysorbate 20 in low concentrations (0.05 – 0.2 % (w/v)) already 
enabled recovery values of up to 70 %. A further increase of the polysorbate 20 
Chapter IV: Tentative experiments 74
content revealed that increasing surfactant concentrations appear to induce even 
higher protein recoveries.  
A non-ionic surfactant like polysorbate 80 features surface-activity and solubilising 
effects. Consequently, solid protein may be separated from lipid particles followed by 
protein dissolution in the buffer medium. However, non-ionic surfactants in higher 
concentration were described to inhere potential for protein destabilisation [103]. 
Though, the time the protein is exposed to the surfactant contact may play a key role 
in exerting detrimental effects on protein integrity. Protein recovery data in PBS with 
1 % (w/v) polysorbate 20 are illustrated in Fig. 26. Each experiment comprised 
analyses of three individual samples. In order to avoid protein loss due to filtration 
lipid fractions were now removed by centrifugation at 5000 G for 5 minutes. 
 
Figure 26: Protein recovery within the buffer media applying an extraction method without 
using organic solvents (average ± SD, n = 3). 
In average, recovery values of approximately 90 % could be reached for all proteins 
when samples were agitated for 2 hrs. Longer agitation periods were accompanied 
with a decrease of protein detectable in the buffer. This indicates aggregation 
presumably induced by present surfactant. However, the results clearly attribute this 
developed extraction method a higher potential than the organic solvent/buffer 
technique. 
Gel electrophoresis of extracted samples agitated over 2 hrs proved high protein 
purity (Fig. 27). For G-CSF, no bands of aggregated protein could be detected at all. 
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For IFN α-2a samples, marginal dimer and trimer specimen were identified. 
Generally, the quantification of the band intensities revealed that the aggregated 
fraction account for less then 1 % of overall band intensity.  
Extracted BSA revealed more pronounced aggregated bands than G-CSF and IFN α-
2a, but it is to be outlined that the BSA applied inhered substantial fraction of 
oligomers already in the standard (Fig. 27). 
1       2       3 1       2       3
IFN α-2aG-CSF BSA
1        2        3
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Figure 27: Protein integrity after extraction from lipid implants without using organic solvents 
for (A) G-CSF, (B) IFN α-2a and (C) BSA. Lanes 1: extracted proteins, lanes 2: protein 
standards, lanes 3: MW marker. 
The results indicated that the newly developed extraction method inheres only low 
influence on protein stability, if any. The detected protein loss of approximately 10 % 
may be a result of either the grinding process or incomplete separation of protein and 
lipid particles. An IFN α-2a aggregate fraction of less then 1 % can be deemed as 
acceptable for investigative purposes. The more, as lyophilised IFN α products even 
available on the market contain up to 1 % aggregate [20]. 
Finally, it could be demonstrated that the manufacturing process by compressing did 
not induce aggregate formation. Consequently, lipid implants being loaded almost 
exclusively with native protein before release studies were initiated. 
7. Summary and discussion 
In the course of the pilot surveys described in this chapter, stearic acid was 
shown to reveal constraints in its applicability as carrier material for the controlled 
delivery of protein drugs. Despite the existence of multiple polymorphic forms could 
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have been overlooked in the first experiments, protein aggregation within a time 
range of 3 – 7 days induced by eroded stearic acid products was enough reason to 
abandon the effort of developing a delivery system based on this material.  
Triglyceride systems featured only one polymorphic form after implant manufacture. 
However, the more important attainment of this pilot surveys was that protein integrity 
was not influenced by interactions with triglyceride material i.e. binding to erosion 
products or adsorption to lipophilic matrices. These findings were promising in terms 
of future protein release studies from these systems. The poor erosion behaviour of 
pure triglyceride systems namely excludes the control of protein liberation by the 
erosion process itself. However, a decelerated water uptake and the absence of 
degradation products may guarantee increased protein stability within triglyceride 
matrices during drug release. 
Homogeneity studies using methylene blue as model drug featured non-uniform drug 
distribution within the matrices. As already discussed before, these findings have to 
be taken into account during release experiments because a non-uniform protein 
distribution can result in fluctuations of the liberation curves. 
Moreover, the compressing process of protein/lipid mixtures was shown to work 
under relatively mild conditions. Protein integrity was retained during implant 
manufacture, what can be deemed as a major attainment - in contrast to results 
obtained with numerous PLGA devices [198; 184] – in terms of controlled protein 
delivery from lipophilic matrices. 
At this stage of the thesis work, protein concentration was determined with Lowry 
assay. However, it was shown that the assay inhered high standard deviations 
throughout the experiments. As a consequence, chromatographic methods (SE-
HPLC and RP-HPLC) were established for all further experiments for assessing 
protein concentration and stability. 
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The potential of triglycerides as compatible matrix materials for protein 
delivery, i.e. protein stability during manufacture, absence of degradation products 
influencing protein integrity during release etc. was framed in chapter IV. This 
chapter addresses basic approaches in the development of a protein delivery system 
which allows protein liberation over weeks in a linear mode. 
 
Proteins were lyophilised with trehalose in a weight ratio of 1:4 (and with 0.05 % (w/v) 
polysorbate 80). The residual moisture of the freeze-dried products (table 11) ranged 
between 0.3 % for G-CSF products and 1.9 % for BSA products. Normally, it is aimed 
to reduce moisture contents in freeze-dried protein formulations to values below 2 %. 
This was also achieved for the lyophilised proteins, though IFN α-2a and BSA 
products featured borderline values. 
 G-CSF products IFN α-2a products BSA products 
Residual moisture content 0.3 ± 0.3 % 1.7 ± 0.5 % 1.9 ± 0.2 % 
Table 11: Residual moisture contents of protein formulations lyophilised with trehalose in 1:4 
ratios and 0.05 % (w/v) polysorbate 20. 
 
Figure 28: Protein stability after reconstitution of the freeze-dried products. (A) G-CSF 
lyophilisate - lane 1: MW marker, lane 2: protein standard, lane 3: after reconstitution; (B) IFN 
α-2a lyophilisate - lane 1: after reconstitution, lane 2: protein standard, lane 3: MW marker; (C) 
BSA lyophilisate - lane 1: MW marker, lane 2: protein standard, lane 3: after reconstitution. 
A B C 
G-CSF IFN α-2a BSA 
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PAGE analysis of reconstituted protein lyophilisates did not detect any aggregated 
species induced by the freeze-drying process (Fig. 28). These data verify protein 
integrity prior to implant preparation. 
1. Influence of the drug load on protein release 
The formation of an interconnected pore network during implant manufacture 
by compressing and the corresponding protein release kinetics from non-
biodegradable matrices is reported to be mainly depending on the drug load [181; 
101; 182]. 
Therefore, initial in vitro release studies were performed from triglyceride matrices 
loaded with up to 30 % lyophilised protein formulations consisting of a protein/sugar 
mix in a 1:4 ratio (table 12). Accordingly, the protein itself represents one fifth of the 
lyophilised formulation. After implant preparation, in vitro release studies were 
performed as described in chapter III. Each experiment comprised the analysis of 
three individual samples (n=3).  
Triglyceride Lyoph. G-CSF 
formulation [%] 
Lyoph. IFN α-2a 
formulation [%] 
Lyoph. BSA 
formulation [%] 
90 % tristearin 10  10  10  
80 % tristearin 20  20  20  
70 % tristearin 30  30  30  
90 % trilaurin 10  10  10  
80 % trilaurin 20  20  20  
70 % trilaurin 30  30  30  
Table 12: Triglyceride matrix formulations of various proteins with varying protein loads.  
When implants were loaded with 10 % lyophilised G-CSF, less than 10 % of the 
incorporated protein were liberated after 3 weeks of incubation. Higher protein 
loadings substantially increased the total releasable amount of protein up to 23 %. 
However, this was associated with higher burst release of G-CSF, followed by non-
release and subsequent incomplete release after 1 month of incubation (Fig. 29). 
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Figure 29: Influence of the drug load on G-CSF release from tristearin matrices. Content of 
lyophilised G-CSF (with protein/sugar ratio being 1:4): 10 % ( ), 20 % ( ), 30 % ( ) (average ± 
SD, n = 3). 
For IFN α-2a, experimental data were comparable (Fig. 30).  
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Figure 30: Influence of the drug load on IFN α-2a release from tristearin matrices. Content of 
lyophilised IFN α-2a (with protein/sugar ratio being 1:4): 10 % ( ), 20 % ( ), 30 % ( ) (average 
± SD, n = 3). 
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Again, higher protein loads led to an increased burst release, but no extended protein 
liberation over the time could be achieved. Otherwise, 40 % of the incorporated IFN 
α-2a were liberated. 
For BSA matrices, in vitro release profiles are illustrated in Fig. 31. Whereas implants 
with a 30 % protein load caused a high burst release - e.g. 35 % BSA liberation 
within 24 hrs - the reduction of the drug load notably lowered BSA release rates. For 
example, devices with 10 % protein content came up with a sustained delivery over 
one month up to 40 % releasable protein. 
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Figure 31: Influence of the drug load on BSA release from tristearin matrices. Content of 
lyophilised BSA (with protein/sugar ratio being 1:4): 10 % ( ), 20 % ( ), 30 % ( ) (average ± 
SD., n = 3). 
Evaluating studies of trilaurin devices found no difference in protein release 
behaviour. Consequently, protein liberation was assumed to be independent from the 
fatty acid chain length of the triglycerides and thus from the lipophilic nature of the 
respective triglyceride. 
However, the variation of the drug load will not result in absolute controlling the 
protein release. In particular for implants with a higher drug load high burst effects up 
to 40 % protein delivery were observed within the first hours. Extended liberation 
over time only could be obtained from BSA systems with 10 % drug load. However, 
incomplete protein release was also to be detected from these matrices. 
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2. Influence of the compression force on protein release 
Packing arrangements of drug and matrix material particles can be affected by 
the compression force, which influences the pore characteristics and consequently 
protein release [101].  
Exerting a pressure of 2 tons during implant production yields triglyceride matrices 
with high physical stability, mirrored by breaking strengths of ∼27 N. Such 
compression forces configured a dense packaging arrangement wherein protein 
molecules were caught. Consequently, this may result in non-release or even in 
incomplete protein release. 
Evaluation studies whether or not the compression force influences protein release 
were solely performed with BSA/tristearin devices. The actual BSA load represented 
2 % (i.e. 10 % lyophilised protein formulation) of implant weight for all experiments. 
With a pressure below 1.2 tons no compact implants were obtained, i.e. the matrices 
broke apart when detached from the compacting tool. Therefore, implant 
manufacture was conducted by applying compression forces in a range from 1.2 – 2 
tons over 30 sec. 
Surprisingly, reduced compression forces (e.g. 1.2 and 1.5 tons) resulted in a lower 
protein release of about 20 % of the BSA initially incorporated (Fig. 32).  
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Figure 32: Influence of the compression force during implant manufacture on BSA release. 
Compression force: 1.2 t ( ), 1.5 t ( ), 1.7 t ( ), 2 t ( ) (average ± SD, n = 3). 
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When compared to matrices yielded with a pressure of 2 tons, the latter ones 
revealed release rates after 1 month of incubation of more than double that value.  
Based on these data, it could not be substantiated that incomplete protein release is 
caused by a too tight packaging. In contrast, minimal compression forces appear to 
be required for a suitable particle arrangement which leads to the formation of pores 
and void spaces where the dissolved protein molecules can diffuse through. 
3. Influence of various excipients on protein release 
In order to enhance drug release from inert matrices, the incorporation of 
additives such as pore forming substances or emulsifying agents has been discussed 
[17; 187; 186; 98]. 
3.1 Incorporation of hydrophilic excipients - polyethylene glycol derivatives 
Polyethylene glycol 6000 (PEG) and Poloxamer 188, an ABA block copolymer 
of ethylene glycol and propylene glycol, represent solid excipients easily miscible 
with the lipids in various ratios. Such additives are soluble in the release medium 
without inhering a swelling potential. Consequently, diffusion-driven protein release 
from triglyceride matrices can be increased by the formation of aqueous medium 
filled pores as a result of excipient dissolution [98]. In addition, these compounds 
feature a solubilising potential, and for PEG stabilising effects on proteins were 
noticed [43; 34]. 
Tristearin implants loaded with a varying amount of excipients were prepared 
(pressure = 2 tons). The actual protein load represented 2 % (i.e. 10 % lyophilised 
protein) of implant weight for all formulations (table 13).  
Formulation 
Lyophilised protein [%] - 
G-CSF, IFN α-2a or BSA 
(protein/sugar ratio 1:4) 
PEG 6000 
[%] 
Poloxamer 188 
[%] 
Tristearin [%] 
(Dynasan 118) 
I 10  - - 90  
II 10  2  - 88  
III 10  5  - 85  
IV 10  - 2  88  
Table 13: Tristearin matrix formulations with various excipients such as pore forming 
substances and emulsifiers with respect to their influence on protein release (n = 3). 
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For G-CSF experiments, the incorporation of PEG lowered protein liberation in 
comparison to the protein amount delivered from pure tristearin implants (Fig. 33). 
Only 5 % protein were released from such devices.  
When Poloxamer 188 was applied, more protein was liberated. However, still 88 % of 
the incorporated G-CSF retained unreleased after the incubation time (Fig. 33). 
Time (d)
0 5 10 15 20 25
C
um
ul
at
iv
e 
G
-C
S
F 
re
le
as
e 
(%
) 
0
2
4
6
8
10
12
14
16
 
Figure 33: Influence of pore forming substances on G-CSF release from tristearin implants. 
PEG content: 0 % ( ), 2 % ( ), 5 % ( ); Poloxamer 188 content: 2 % ( ) (average ± SD, n = 3). 
Poloxamer 188 also increased the total amount of releasable IFN α-2a and BSA up 
to 20 % and 42 %, respectively, when compared to matrices without that excipient 
(Fig. 34 A/B). However, the non-delivered fractions remaining within the matrices 
after incubation were still dominant. 
When PEG was applied, somewhat different effects for the particulate protein were 
observed (Fig. 34 A/B): compared to the excipient-free devices, IFN α-2a liberation 
slightly increased and was more sustained, but a lower total amount of BSA was 
delivered from such matrices.  
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Figure 34: Influence of pore forming substances on protein release from tristearin matrices. (A) 
IFN α-2a - PEG content: 0 % ( ), 2 % ( ), 5 % ( ); Poloxamer 188 content: 2 % ( ); (B) BSA – 
PEG content: 0 % ( ), 2 % ( ), 5 % ( ); Poloxamer 188 content: 2 % ( ) (average ± SD, n = 3). 
The addition of pore forming agents (e.g. PEG and Poloxamer 188) in contents of 2 - 
5 % of the implant weight did not accomplish the results anticipated. Neither a 
substantial increase of releasable protein nor a delivery control could be reported. 
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3.2 Incorporation of 1,2-Dioleyl-sn-Glycero-3-Phosphocholine (DOPC) 
Phospholipids like DOPC are commonly used as membrane constituents of 
liposomal delivery systems. While DOPC is insoluble in the release medium, it 
possesses an emulsifying and swelling potential. Thereby, the formation of a swollen 
structure with higher water content was expected during release which could result in 
increased protein liberation [105]. 
Tristearin implants with a protein load of 2 % (i.e. 10 % lyophilised protein 
formulation) and with a 5 % and 10 % DOPC content, respectively, were prepared. 
Thereby, a reduction in the compressibility of the mixture was notified. During 
incubation, matrices featured a distinctive water uptake followed by partial surface 
degradation of the implants. 
In Fig. 35 release profiles of G-CSF implants are demonstrated. The visible surface 
degradation effects were assumed to facilitate G-CSF release. In contrast, decreased 
levels of G-CSF delivery were observed when compared to matrices without DOPC 
charge (Fig. 35). 
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Figure 35: Influence of an emulsifying phospholipid (DOPC) on G-CSF release from tristearin 
matrices. DOPC content: 0 % ( ), 5 % ( ), 10 % ( ) (average ± SD, n = 3). 
Chapter V: Protein delivery from lipid implants: Providing grounds… 86
For IFN α-2a samples, the release profiles indicated that the addition of DOPC to 
tristearin matrix material resulted in a substantial change in protein release kinetics 
(Fig. 36).  
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Figure 36: Influence of an emulsifying phospholipid (DOPC) on IFN α-2a release from tristearin 
matrices. DOPC content: 0 % ( ), 5 % ( ), 10 % ( ) (average ± SD, n = 3). 
When compared to protein delivery rates from matrices without DOPC, implants 
containing such excipient featured extended protein releases. A 10 % DOPC load 
induced 30 % of the incorporated protein being continuously liberated for 12 days 
incubation. 
The effect of DOPC on BSA release was not comparable the findings presented 
above (Fig. 37). Only a marginal enhancement in delivered protein quantities was 
notified, and the release profiles were less sustained compared to those obtained 
from excipient-free matrices.  
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Figure 37: Influence of an emulsifying phospholipid (DOPC) on BSA release from tristearin 
matrices. DOPC content: 0 % ( ), 5 % ( ), 10 % ( ) (average ± SD, n = 3). 
In principle, DOPC as emulsifying compound increased the water uptake. 
Furthermore, surface degradation of the matrices was notified during release studies. 
This erosion behaviour resulted in a promising change of IFN α-2a release kinetics 
and moreover, in a prolonged IFN α-2a liberation for up to 2 weeks.  
4. Summary and discussion 
Generally, these basic in-vitro release studies demonstrated the potential of 
protein delivery from lipophilic triglycerides matrices. However, the release kinetics 
achieved were inappropriate. High burst release followed by non-release and 
subsequent incomplete protein release was noticed as hampering parameters.  
An extended liberation profile was neither obtained by drug load increase nor by the 
reduction of the compression forces. This results did neither overlap with what was 
expected, nor was the published information matched [117; 12; 101]. Langer et al. 
demonstrated BSA release from ethylene vinyl acetate matrices being proportional to 
the square root of time when very high protein loads (e.g. 30 – 50 %) were applied. 
With decreasing drug loads, the release curves were more concave and resulted in 
zero-order release at low protein load scenarios (e.g. 5 % - 10 % BSA load). The 
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change in the release kinetic was assumed to be the result of a considerable amount 
of entrapped protein at low drug loadings [181; 182]. 
Our results obtained from triglyceride matrices were not comparable to this 
theoretical model of macromolecule release from inert matrices. Higher protein loads 
resulted in higher burst release, however, protein liberation did not continue over time 
in the majority of cases. Only for BSA, a continuous liberation up to 1 month from 
tristearin matrices with a 10 % drug load could be obtained. Though, almost 60 % of 
the BSA remained within the implants after release experiments. A higher BSA load 
resulted in a higher burst release, but the total amount of releasable protein 
increased only slightly, if at all. Contrarily, the group of Benoit reported a 100 % BSA 
release from trimyristin matrices loaded with only 13 - 24 % protein [155]. 
Furthermore, it was demonstrated that protein release was almost independent of the 
used triglyceride itself. The fatty acid chain length of the triglyceride and 
consequently the lipophilic nature of the triglyceride did not impact protein release 
kinetics. That is consistent to erosion studies featuring no considerably increased 
water uptake of trilaurin devices in comparison to tristearin products. 
Incorporating hydrophilic release modifiers such as PEG and Poloxamer 188 
featured a moderate outcome with regards to an increased protein release. The 
additional excipients enhanced the amount of total releasable protein from tristearin 
implants marginally, if at all. For polyethylene glycol, G-CSF and BSA liberation rates 
decreased slightly when compared to the protein delivery from tristearin implants 
without any excipients added.  
Those side-effects of the hydrophilic compounds could be explained by excipient 
contents remaining under a certain effective concentration threshold. That means, 
the addition of 2 % pore forming excipient was too low in order to achieve a 
substantial influence on the formation of an interconnected pore network and, 
consequently, on the protein release. Jiang and Schwendeman reported that less 
than 45 % of BSA were released from PLGA microspheres when the PEG content 
was less than 10 % of the polymer weight. When the PEG content was raised to 20 
%, the amount of total protein released notably increased up to 75 % [98].  
Solid release modifiers like PEG may be involved in the formation of an 
interconnected pore network during implant manufacture. When the amount added is 
too low, the resulting network is incomplete, particularly when the drug load accounts 
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for only 10 % of implant weight. Consequently, both protein and excipient particles 
can be entrapped by lipophilic tristearin material. 
The addition of the amphiphilic 1,2-Dioleyl-sn-Glycero-3-Phosphocholine (DOPC) 
resulted in visible swelling and degradation effects, predominantly at the surface of 
the tristearin implants. Based on this surface erosion, the release kinetics of IFN α-2a 
changed substantially, as a continuous protein liberation for up to 2 weeks was 
achieved by adding 10 % DOPC. However, the amount of total releasable proteins 
was deemed still insufficient.  
Eroded material may be assumed to cause protein aggregation during release 
studies, but this hypothesis was not confirmed by gel electrophoresis. 
A further reason for incomplete release is that effective DOPC levels could not be 
reached. In the literature it is reported that only 40 % of the encapsulated BSA were 
liberated from cholesterol implants with a 30 % lecithin load. The raise in lecithin 
content up to 60 % was shown to enforce erosion rate of cholesterol/lecithin implants, 
and resulted in an increased protein release up to 100 % [105].  
However, it was not rendered possible to produce tristearin implants with higher 
DOPC contents (e.g. 30 – 50 %). The lubricious consistence of the mixtures caused 
a substantial decrease of material compressibility and resulted in the production of 
unformed, sticky implants. 
For G-CSF, no release higher than 23 % in relation to the incorporated protein 
content was achieved during all experiments. A great part of the G-CSF molecule 
consists of hydrophobic regions [133; 86], and consequently it was assumed G-CSF 
accumulating within the hydrophobic tristearin environment due to adsorption 
processes throughout the release studies. This effect may enormously hamper the 
development of a controlled G-CSF release system based on triglyceride material.  
Overall, new formulation strategies (e.g. variation of the lipid matrix) with respect to a 
sustained, controlled protein delivery from lipid implants were reconsidered so far. 
Furthermore, detailed analytical studies - applying gel electrophoresis or conducting 
long-term protein stability monitoring - appeared necessary to exclude protein 
instability as possible reason for incomplete drug release. 
The following chapters will outline how improvements in enhancing and controlling 
protein delivery from lipid implants have been realised. Thereby chapter VI 
addresses investigations performed with BSA as a model protein compound. In 
Chapter V: Protein delivery from lipid implants: Providing grounds… 90
chapters VII and VIII, the development of a controlled release system for IFN α-2a as 
pharmaceutically relevant protein is outlined. As a result of the basic investigations 
showed in this chapter, experimental work on G-CSF as protein compound was 
finalised at that state.  
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Chapter VI: Quickening the paces: BSA as model protein   
1. Alternative lipophilic matrix materials 
Tristearin implants were demonstrated to be very lipophilic and thus water 
repellent drug delivery systems. The extremely low water uptake into the matrices 
during release experiments potentially inhibits dissolution and subsequent diffusion 
processes of encapsulated proteins, what results in incomplete protein release. 
Therefore, mono-/diglycerides and polyglycerol esters, which inhere a less 
hydrophobic nature than triglyceride material, were investigated in terms of their 
applicability as sustained, controlled protein release devices.  
1.1 Mono– and diglyceride implants 
Sustained release features of monoglycerides for amphiphilic low molecular 
weight drugs are described in literature. Thereby, drug release followed the square-
root of time relationship during the initial release phase [35].  
Monoglycerides and diglycerides have an emulsifying potential. For example, 
glycerol monostearate with a hydrophilic-lipophilic balance (HLB) value of about 3.8 
is commonly used as lipophilic emulsifier in several cosmetic products.  
Thereby, water uptake and swelling power of such implant systems may be 
substantially increased in comparison to tristearin devices. Consequently, diffusion-
driven protein liberation could be facilitated. 
Monoglycerides (Myverol 18-04 K) and a composition of mono- and diglycerides 
(Admul MG 40-04 K) were investigated on both matrix material use and, in a 1:1 
combination excipient use with tristearin matrix material. All implants were loaded 
with 10 % lyophilised BSA (protein/sugar ratio 1:4), which corresponds to an actual 
protein load of 2 % of implant weight. 
The experimental results made obvious that monoglycerides as well as the 
composition of mono- and diglycerides are not feasible as matrix materials for 
sustained BSA release devices. Both formulations exhibited high burst release, with 
up to 55 – 65 % of the incorporated protein being delivered from the implants within 4 
days incubation (Fig. 38).  
As an example for excipient use, the 1:1 combination of monoglycerides and 
tristearin material is shown (Fig. 38). However, this formulation was also found to 
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feature an enormous burst, whereby a total of 45 % BSA were released within 4 
days.              
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Figure 38: BSA release from mono- and diglycerides devices. Matrix material: monoglycerides 
( ), composition of mono- and diglycerides ( ), 1:1 combination of monoglycerides and 
tristearin material ( ) (average ± SD, n = 3). 
Swelling and erosion of the matrices were not visible, therefore it is difficult to explain 
the increased but also accelerated BSA release from these systems in comparison to 
release profiles obtained when pure tristearin material was used (refer to chapter V).  
Nevertheless, the increased hydrophilic nature of mono- and diglyceride materials 
appears to be casting for this change, because an obvious reduction in total released 
protein was already notable when - instead of pure monoglycerides - the less 
hydrophilic mono-/diglyceride composition was applied.                      
1.2 Implants prepared with polyglycerol ester of fatty acids (PGEFs)   
The use of polyglycerol ester of fatty acids as sustained release dosage forms 
for proteins were first reported by Yamagata et al. [220]. In accordance to previous 
work with low molecular weight drugs such as theophylline, protein release was 
shown being a diffusion-controlled process dependent on the degree of fatty acid 
esterification and the chain length of the fatty acids [3; 220]. 
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Pilot studies with protein free devices featured compressed polyglycerol ester 
matrices swelling within hours. After a few days, this swelling was followed by a 
complete degradation of the implants during a 3 weeks incubation interval (Fig. 39).     
 
Figure 39: Swelling behaviour of polyglycerol ester implants during in vitro release studies. 
Left: implant immediately after incubation initiation, right: implant after 4 days incubation. 
That supposed both the diffusion-controlled process and the erosion to potentially 
contribute to optimisation of protein release.     
 
Figure 40: BSA release profile from polyglycerol ester implants. Matrices were completely 
eroded after 25 days of incubation ( ) (average ± SD, n = 3). 
Actually, polyglycerol ester matrices loaded with 10 % lyophilised BSA (protein/sugar 
ratio 1:4) showed a continuous BSA delivery for up to 25 days, whereby the burst 
release was reduced to 15 %.  
Time (d)
0 5 10 15 20 25 30
C
um
ul
at
iv
e 
BS
A 
re
le
as
e 
(%
)
0
10
20
30
40
50
60
70
Chapter VI: Quickening the paces: BSA as model protein 94
However, despite a complete degradation of the matrices within the monitored time 
period, only 55 % of the incorporated protein were detected in the release media by 
SE-HPLC (Fig. 40). 
SE-HPLC revealed a substantial drop in BSA monomer content down to 65 % after 4 
days of incubation (Fig. 41). At this time an additional peak was notified suggesting 
the occurrence of higher-order aggregate species. After 13 days of incubation this 
aggregate fraction already represented 20 % of total BSA content. In addition to that, 
BSA aggregation appeared to be linked with matrix swelling and erosion.  
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Figure 41: BSA monomer (%) and higher-order aggregate content (%) detected within the 
release media at different points of time during in vitro release studies (average ± SD, n = 3).     
As the matrices become completely hydrated the solid protein is exposed to 
increasing moisture. That results in an increase of protein mobility, possibly 
accelerating chemical reactions as well as protein denaturation and moisture-induced 
aggregation [48; 121].  
Therefore, it was assumed that the enormous water uptake of polyglycerol ester 
matrices increased the BSA aggregation tendency within the implant systems. 
Moreover, soluble aggregate species detected by SE-HPLC indicated also the 
potential formation of insoluble aggregate species during release experiments. Due 
to filtration of the release media prior to SE-HPLC investigations, these insoluble 
protein fractions, if present, were separated from the buffer samples and retained 
upon the filter material.       
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Besides, non-covalent and covalent interactions between eroded matrix material and 
protein molecules – as often described for PLGA devices [106; 50] – are assumed 
and such protein/lipid fractions also stuck upon the used filters. 
In order to specify the formation of insoluble aggregates as well as protein 
interactions with the lipid material, filter components used for sample preparation 
prior to SE-HPLC analysis were collected and incubated in each 2.0 mL SDS solution 
(2 % SDS (w/v)) at 37 °C over 24 hrs. High-concentrated SDS solutions enable the 
disruption of ionic interactions and non-specific protein adsorption. Furthermore, 
insoluble non-covalent aggregates can be dissociated by SDS [197; 144].  
Thus, protein species potentially removed by filtration may be dissolved in the SDS 
solution by incubating the filter material and consequently be available for analytical 
investigations (Fig. 42). 
 
Figure 42: BSA recovery in SDS solution after incubation of the filter material for 24hrs. Lane 1: 
BSA detected in the SDS solution, lane 2: protein standard, lane 3: MW marker.  
PAGE demonstrated BSA being present in the analysed supernatant solutions (Fig. 
42). The bands were less pronounced, but virtually similar to those in the standard 
preparation.  
Based on these data it was confirmed that polyglycerol ester matrices exhibited a 
detrimental effect on protein stability during in vitro release studies. This led to the 
formation of insoluble aggregates and/or to direct interactions between protein 
molecules with eroded lipid material. Consequently, the detected 45 % protein loss 
can be attributed to those BSA species.  
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1.3 Conclusion 
It was demonstrated that the use of mono-/diglycerides and polyglycerol ester 
of fatty acids (PEGFs) as alternative matrix systems to tristearin implants did not 
show the data expected. The total amount of releasable BSA was increased when 
mono- and diglycerides were applied, but the observed release patterns, featuring a 
high burst release of up to 65 %, followed by non-release and incomplete release, 
were insufficient.  
For PEGFs, the assessed BSA release was ongoing in a continuous manner over 25 
days, what initially appeared very promising. But then protein instability as a result of 
implant swelling and degradation was noticed - a hampering issue. Not only this 
resulted in a 45 % protein loss during in vitro release, but the liberation of higher-
aggregate species is intolerable in the light of potential immunogenical response of 
patients [41; 33].      
2. BSA release from tristearin matrices with higher amounts of PEG 
As already discussed, the use of polyethylene glycol as effective protein 
release modifier requires the incorporation of PEG in contents of at least 10 % of 
implant weight [98]. 
In a second survey, PEG contents in a range of 10 - 30 % were investigated in their 
influence on BSA release from tristearin matrices. Protein load was set to 10 % 
lyophilised BSA formulation (with protein/sugar ratio 1:4). 
Raising the PEG content led to a substantial enhancement in overall protein 
liberation. For example, by increasing the PEG amount from 5 % up to 10 % (Fig 43), 
approximately twice as much BSA was released from implant systems. The release 
kinetic indicated a sustained mode, featuring a continuous protein delivery for up to 1 
month.  
In contrast, when the PEG content was increased to 20 % or 30 %, respectively, an 
accelerated protein release was notable, resulting in high bursts of up to 70 % BSA 
liberation within 4 days (Fig. 43).         
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Figure 43: Effect of higher PEG contents on BSA release from tristearin matrices. PEG content: 
5% ( ), 10 % ( ), 20 % ( ), 30 % ( ) (average ± SD, n = 3).   
However, despite of an increased PEG content of up to 30 % implant weight, the 
BSA release obtained was still incomplete. Maximally, 70 % of the originally 
incorporated protein were liberated from the devices. SE-HPLC of the samples did 
not feature - as they did for polyglycerol ester matrices - higher-order aggregate 
species being evident in the release media. 
However, polyglycerol ester matrices eroded completely over time, whereby even 
higher-order aggregates were liberated. In contrast, from non-biodegradable implant 
systems, the release of aggregates and especially precipitates could be decelerated 
or even restricted due to the reduced solubility of aggregates or because of the pore 
sizes within the matrices [106; 216].  
In order to elucidate processes occurring within the matrices during release studies, 
the BSA portion, which remained in the devices after the 4 weeks release period was 
extracted and analysed by PAGE. 
BSA recovered from tristearin formulations containing 30 % PEG showed a band 
very similar to the standard BSA band. The quantification of the band intensities 
revealed for both the extracted protein and the standard about 79 % monomer, 17 % 
dimer, and 4 % trimer species (Fig. 44), what is comparable to the standard BSA.  
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However, it has to be mentioned that even if these results refer to high protein 
stability within the tristearin matrices during release, the formation of non-covalent 
aggregate species and potential insoluble aggregates can not excluded by these 
SDS-PAGE data. 
 
Figure 44: BSA stability within the matrices during in vitro release. Lane 1: BSA extracted from 
tristearin implants with a 30 % PEG content after incubation, lane 2: protein standard, lane 3: 
MW marker.       
The use of polyethylene glycol 6000 (PEG) as pore forming agent was demonstrated 
to be very promising: (I) the amount of releasable BSA was increased in comparison 
to PEG free implants; (II) BSA was delivered continuously from tristearin implants 
with a 10 % PEG content for 1 month, and (III) high protein stability within the 
matrices can be assumed. 
Nevertheless, a final conclusion explaining the incomplete protein release could not 
be drawn from these experiment data.  
As a consequence, it was tested whether a change of the freeze-dried formulation 
would enable a 100 % BSA delivery from tristearin implants containing PEG.              
3. Optimisation of the freeze-dried BSA formulation  
3.1 Stabilisation of proteins during freeze-drying 
Many proteins show conformational changes induced by the freeze-drying 
process [6]. Possible parameters affecting protein stability can be the formation of 
ice-water interfaces, freeze concentration of solutes and proteins, low temperature 
stress and potential pH changes due to selective precipitation of buffer components. 
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During the drying step, the loss of the protein hydration shell can induce protein 
instability [1]. To enhance the stability of freeze-dried products, usually excipients are 
added to the protein solution. Three mechanisms of protein stabilisation by additives 
during freeze-drying are discussed: (I) the Timasheff mechanism [8; 7], (II) the 
“glassy state” theory [67] and (III) the water replacement theory [51; 29; 28; 7]. 
Several excipients - e.g. sugars, amino acids, salts, polyols or polyethylene glycol - 
providing protein stability as cryoprotectants during the freezing step have been 
established in the formulation of freeze-dried protein products [214]. But only a few 
sugars such as sucrose and trehalose appear to be effective in protecting proteins 
from inactivation during the drying step [7; 30].  
Furthermore, non-ionic surfactants such as polysorbates in low concentrations of 
0.01 – 0.1 % are commonly added to protein formulations, in particular to inhibit 
protein unfolding as a result of ice/water interface adsorption during the freezing step 
and, secondly, to reduce protein aggregation tendency during later reconstitution [9]. 
3.2 Optimisation of the freeze-dried BSA formulation 
At the beginning of the thesis work, BSA (conc. 20 mg/mL in ultrapurified 
water) was lyophilised with trehalose in a ratio of 1:4 (and with 0.05 % polysorbate 
80). The analysis of the reconstituted samples by SE-HPLC did not indicate the 
freeze-drying process inducing BSA aggregation (table 14). Moisture content was 
found to be 1.9 %, achieving the maximal 2 % threshold of freeze-dried products 
commonly aimed for, and PAGE also did not exhibit further aggregated species (refer 
to chapter V). Though, the obtained lyo-cakes showed collapsed structures. 
SE-HPLC 
 
Recovery [%] Monomer [%] Dimer [%] Trimer [%] 
Water 
content [%] 
BSA raw material - 78.07 ± 1.31 16.60 ± 0.56 5.65 ± 0.89 - 
Lyophilised BSA after 
reconstitution  
(BSA/sugar ratio 1:4) 
99.13  ± 1.1 78.23 ± 0.45 16.05 ± 1.20 4.83 ± 1.52 1.9 ± 0.2 
Table 14: BSA integrity of freeze-dried products after reconstitution and determined water 
contents of the lyophilised products (average ± SD, n=3).  
Collapse is not necessarily detrimental to the long-term stability of freeze-dried 
proteins. For example, collapsed cake matrices of recombinant Factor VIII showed 
no difference in biological activity during storage at either 5 °C or ambient 
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temperature when compared to pharmaceutically acceptable products. At 40 °C 
storage, the stability of the collapsed products even appeared to be better than that 
of freeze-dried products with no collapse [208]. 
However, from a pharmaceutical point of view, collapsed freeze-dried formulations 
are unacceptable. Therefore new batches of BSA solutions with various levels of 
trehalose (and with 0.05 % polysorbate 80) were prepared. Conducting the freeze-
drying process resulted in collapsed structures for BSA samples lyophilised in 
protein/sugar ratios of 1:4 and 1:5, respectively, whereas formulations with 1:1, 1:2 or 
1:3 protein/sugar mixtures revealed amorphous cake structures (Fig. 45).  
1:4 1:3
 
Figure 45: Images of BSA freeze-dried with trehalose in various ratios. Left: 1:4 protein/sugar 
formulation resulting in collapsed freeze-dried products; right: 1:3 protein/sugar formulation 
resulting in amorphous freeze-dried products.       
A higher BSA content improved drying speed, and at the end of the primary drying 
such formulations were already ice-free. In contrast, the 1:4 and 1:5 mixtures 
contained residual ice at this state of the process and collapsed when shelf 
temperature was increased for secondary drying [97]. 
After reconstitution, BSA integrity in the amorphous products - i.e. 1:1, 1:2 and 1:3 
protein/sugar mixtures - was confirmed by SE-HPLC, revealing 79 % monomer, 16 % 
dimer and 5 % trimer in average. The residual moisture contents of non-collapsed 
lyophilisates were substantially lower when compared to the collapsed samples, 
ranging between 0.3 – 0.7 %. Generally, a moisture content of trehalose formulations 
below 1 % implicates Tg values well above room temperature, an important point with 
respect to long-term storage of freeze-dried pharmaceutics [1]. 
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3.3 Influence of the freeze-dried formulation on BSA release from tristearin 
implants 
The most promising matrix composition for controlled BSA release during the 
release studies conducted hitherto were tristearin implants containing PEG in a range 
of 10 - 30 %. Therefore, these matrix compositions were investigated again, 
employing non-collapsed freeze-dried BSA products.  
The sugar itself also can affect protein release from lipid implants by the formation of 
pores as a result of sugar dissolution in the release medium. Consequently, BSA 
samples lyophilised with trehalose in a ratio of 1:3 were chosen from the reservoir of 
new formulations in order not to substantially change the protein/sugar ratio within 
the implants when compared to previous matrix compositions.  
In Fig. 46, BSA release profiles of non-collapsed freeze-dried products (A) in 
comparison to profiles obtained from the collapsed products (B) are illustrated. 
Obviously, the freeze-dried formulation had a substantial impact on the release 
kinetics and on the amount of total releasable protein. Independent from the added 
PEG amount, more than 90 % of the incorporated BSA were delivered from tristearin 
implants over 12 days of incubation. Thereby, high burst release was observed, as 
70 – 80 % of BSA were liberated within 24 hours (Fig. 46A). 
Contrarily, when collapsed protein/sugar formulations were encapsulated, a 
continuous BSA liberation from tristearin matrices with a 10 % PEG content was 
achieved for up to one month (Fig. 46 B). However, the protein could not be released 
completely from the implants, even with higher PEG contents. After 1 month of 
incubation 30 - 50 % of the originally incorporated BSA retained within the matrices.  
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Figure 46: Influence of the freeze-dried BSA formulation on protein release from tristearin 
matrices containing PEG as additive. (A) Non-collapsed BSA/trehalose lyophilisates (ratio 1:3) - 
PEG content: 10 % ( ), 20 % ( ), 30 % ( ); (B) collapsed BSA/trehalose formulation (ratio 1:4) 
- PEG content: 10 % ( ), 20 % ( ), 30 % ( ) (average ± SD, n = 3). 
4. Summary and discussion 
The hampering issue of incomplete BSA release was reported in previous 
release studies. This phenomenon was independent from matrix composition, drug 
load and the addition of various excipients. Based on the investigations outlined in 
this chapter, the problem could be deemed resolved.  
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The use of collapsed freeze-dried formulations was responsible for remaining protein 
fractions within implant systems during release experiments. For this, two potential 
explanations can be stated:  
(I) Collapsed freeze-dried BSA formulations inhere an increased instability potential 
what leads to aggregation proceeding in the implant interior when water is present 
during release [32; 226]. Here, the formation of insoluble aggregates is 
predominantly suggested, since soluble aggregates have been detected by SE-
HPLC and PAGE studies described in the upper part.  
Insoluble aggregates per definition exhibit no solubility resulting in a restricted 
release of these species. In addition to that, pores and in particular the pore 
connecting channels throughout protein molecules must diffuse in order to be 
liberated from the inert matrices are known to be very narrow [106; 216]. 
Consequently, higher-order aggregate species may be inhibited from diffusion 
processes by getting stuck in the tortuous pore and channel net. 
(II) Collapse of freeze-dried formulations can reduce the solubility of the obtained 
products [2]. Consequently, encapsulating collapsed freeze-dried protein 
formulations within lipid implants may lead to slower dissolution and subsequent 
diffusion of protein molecules, and thus to the retardation of protein release from 
these matrices.  
Changing the freeze-dried formulation allowed the protein to be liberated almost 
completely from tristearin matrices charged with PEG as additive – more than 90 % 
of the originally incorporated BSA were detected in the release media. Being as 
important, the protein was found to be released in its native form.  
The formulation change also involved a substantial impact on the release kinetics. 
High burst release of up to 80 % BSA was observed within the first day and, 
moreover, the effect was independent from the PEG content. Nevertheless, the 
systems enabled protein release ongoing for several days.   
A high burst release of BSA encapsulated within implant systems was reported from 
several groups [98; 101; 202]. For example, trimyristate coated BSA microspheres 
liberated 80 % of the incorporated protein within 5 hrs, this with only a 15 % BSA 
load [156]. Vogelhuber et al. demonstrated trimyristate matrices containing gelatin as 
porogen being inadequate to control BSA burst release. Already the addition of 
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gelatin in the range of 1 – 5 % (w/w) led to pronounced BSA liberation of up to 60 % 
within the first day during release experiments [202].  
One reason for rapid BSA release from inert matrices may be the very high solubility 
BSA inheres within aqueous media (i.e. over 300 mg/mL). In the case of such highly 
water-soluble proteins it was demonstrated that all of the drug in the matrix pore 
spaces dissolves rapidly and protein release occurs by transient diffusion processes 
through the broad faces of matrix systems [182].  
Furthermore, Zhu and Schwendeman reported 15 % protein loading being sufficient 
for BSA to percolate effectively throughout PLGA implants. That results in a rapid 
protein release in particular with BSA loadings of beyond 15 % [226].  
Given that the incorporated polyethylene glycol may be involved in the formation of 
an interconnected network during the manufacture of the tristearin implants, it can be 
assumed that both the very high solubility of BSA and the complete network have an 
influence on the rapid BSA liberation observed from the tristearin matrices containing 
PEG as additive.                     
 
From the very first, bovine serum albumin (BSA) was deemed to serve as 
model protein compound, being available easily. Furthermore BSA inheres a higher 
physical stability than many other proteins (particularly hydrophobic proteins). 
Thereby, challenges in the development of compatible dosage forms are often 
reduced.  
BSA is not relevant as pharmaceutical drug and, consequently, it was not high 
priority to further optimise the results achieved, e.g. by spending efforts on burst 
release reduction. However, the gained know-how was important since it was used 
as platform for the development of a controlled release lipid implant system for the 
pharmaceutically relevant interferon α-2a. 
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Chapter VII: Development of a sustained release device for IFN alpha-2a  
In the early stages of this work, liberation profiles achieved from interferon α-
2a (IFN α-2a) implant systems which based on tristearin matrix material were 
insufficient and somewhat inappropriate (refer to chapter IV). In most cases, those 
profiles were characterised by initial burst effects followed by phases of non-release 
and eventually an incomplete IFN α-2a release. Solely the incorporation of the 
phospholipid DOPC in a 5 - 10 % content range resulted in continuous IFN α-2a 
delivery for up to 12 days, releasing 30 % of the encapsulated IFN α-2a.  
Though, this approach was not to be proceeded: as mentioned before, the 
compressibility of the mixtures substantially decreased with higher DOPC contents - 
i.e. 20 % and 30 % DOPC -, what consequently resulted in an impractical implant 
preparation via compressing.     
However, based on knowledge gained for BSA systems, new aspects in terms of the 
development of a controlled and sustained IFN α-2a delivery system were provided. 
1. Optimisation of the freeze-dried IFN α-2a formulation – first approach 
Freeze-dried IFN α-2a products (protein/sugar ratio 1:4) used in prior release 
studies featured collapsed structures in almost identical manner as demonstrated for 
the lyophilised BSA formulation. Based on data and conclusions derived from the 
BSA experiments (refer to chapter VI), these collapsed products  were assumed the 
reason for the observed incomplete IFN α-2a release from tristearin implants, even 
though stability data of the collapsed formulations did not indicate a loss in protein 
integrity due to the freeze-drying process per se.  
Freeze-drying experiments were performed with IFN α-2a formulated in various 
trehalose ratios (plus 0.05 % (w/v) polysorbate 80). In doing so, lyophilised products 
with a protein/sugar ratio of 1:3 yielded stable, amorphous cakes - an obvious quality 
improvement when compared to the collapsed 1:4 formulations. After reconstitution 
of these 1:3 products, almost 100 % of IFN α-2a were recovered in monomeric form.  
The residual moisture contents ranged between 0.3 – 0.5 %, being distinctively lower 
than those determined in the collapsed formulations with moisture contents of 1.7 % 
±  0.5 %. Consequently, long-term storage stability of the 1:3 lyophilisates may be 
improved [1]. 
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Tristearin implants loaded with 10 % lyophilisate were prepared from both non-
collapsed products and collapsed formulations. This results in an actual IFN α-2a 
load of 2.5 % for the non-collapsed and a 2 % load for collapsed formulations, 
respectively.   
During release experiments, the quality improvement of the freeze-dried formulation 
demonstrated a considerable impact on IFN α-2a release behaviour (Fig. 47). 
Whereas IFN α-2a release from implants containing collapsed products remained to 
show a 10 % burst level throughout the total timeframe monitored, the use of the 
non-collapsed formulation raised the liberation rate up to 40 % of total releasable IFN 
α-2a.  
Furthermore, the release profiles approached to mirror a curve shape aimed for: to 
overcome the burst effect and to realise an ongoing protein liberation over 3 weeks of 
incubation.                                       
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Figure 47: Influence of the lyophilisate formulation on IFN α-2a release from tristearin implants. 
Implants consisted of 10 % lyophilised protein and 90 % tristearin (average ± SD, n = 3). 
Besides the substantial enhancement in IFN α-2a being releasable totally, protein 
burst release was kept in a feasible range. That was very important as a starting 
basis with respect to the development of a controlled drug delivery device.  
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For various protein devices, high burst release phenomena were almost impossible 
to control [106; 202; 156], and in theory it may be deemed more difficult to reduce 
protein release than to increase the liberation rate. 
In contrast, starting from a 40 % IFN α-2a liberation level - with burst release 
encompassing about 20 % - will open the door to release optimisation from lipid 
implants, e.g. by variation of the matrix composition and by application of a wide 
range of apt additives. 
2. Variation of matrix composition 
2.1 Application of monoglycerides  
Despite the use of monoglycerides revealed a high burst release of the model 
protein compound BSA (refer to chapter VI), this does not mean these compositions 
are inappropriate for utilisation in protein drug delivery.  
Past experiments indicate the release behaviour of IFN α-2a being completely 
different from BSA release profiles. For example, the addition of the amphiphilic 
phospholipid DOPC notably impacted IFN α-2a liberation from tristearin matrices, 
whereas BSA release was almost not affected (refer to chapter V).         
Consequently, it was conceivable that the release of the more hydrophobic IFN α-2a 
can to be improved by the application of monoglyceridic compounds, also from the 
point of view that these compounds reveal similar physical properties as DOPC does 
(e.g. emulsifying potential). 
Evaluating studies of monoglycerides are listed in table 15. The IFN α-2a load of 2.5 
% of implant weight - i.e. using 10 % lyophilised IFN α-2a formulation - was constant 
for all implant formulations.  
Formulation Lyophilised IFN α-2a [%] 
(protein/sugar ratio 1:3) 
Monoglycerides [%]
(Myverol 18-04 K) 
Tristearin [%] 
(Dynasan 118) 
I 10  90  - 
II 10  70  20  
III 10  30  60  
IV 10  10  80  
V 10  - 90  
Table 15: Matrix formulations investigating monoglycerides as both matrix material and 
excipient (n=3).    
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The obtained release profiles indicated monoglycerides not to have a large potential 
as matrix compounds for sustained IFN α-2a delivery.  
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Figure 48: IFN α-2a release from implants containing monoglycerides and tristearin material. 
Monoglyceride content: 0 % ( ), 10 % ( ), 30 % ( ), 70 % ( ), 90 % ( ) (average ± SD, n = 3). 
For all formulations, within 7 days a high burst up to 50 % was observed. 
Furthermore, this burst release was followed by phases of almost non-release and 
consequently incomplete IFN α-2a release after a total 3 weeks incubation time (Fig. 
48).  
In addition to that, protein release decreased with higher monoglyceride content, 
leading to almost the same release profiles from pure monoglyceride matrices and 
pure tristearin matrices. Both implant systems liberated approximately 40 % of the 
incorporated protein within 3 weeks (Fig. 48).   
Contrarily, a 10 % monoglyceride content featured 55 % of protein being releasable 
and, furthermore, the release was more sustained when compared to all other 
formulations (Fig. 48).         
However, by applying monoglycerides an IFN α-2a release in linear mode during 
weeks could not be realised. High burst releases are to be considered a hampering 
issue.  
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2.2 Implants prepared with polyglycerol ester of fatty acids (PGEFs) 
As already discussed, polyglycerol ester matrices for sustained protein release 
were demonstrated as apt form allowing the incorporated protein to liberate in a 
diffusion-controlled manner. In the work of Yamagata et al., lyophilised IFN α-2a was 
encapsulated in PGEFs matrices by a heat extrusion technique. The bioavailability of 
IFN α-2a after subcutaneous implantation of the various matrix formulations was 
almost equivalent to that after injection of IFN α-2a solution. Therefore, IFN α-2a was 
concluded IFN α-2a to remain stable during the 12 days release period [220]. 
However, these results were in contrary to our results from previous release studies 
where BSA was used as protein compound (refer to chapter VI). Here, 45 % of the 
incorporated protein were lost in the course of the experiments. Moreover, it could be 
concluded that this loss has to be ascribed to extensive protein aggregation induced 
by the eroded matrix material.  
In awareness of this contradiction, polyglycerol ester material was re-investigated, 
but now with respect to its compatibility to IFN α-2a. Therefore, matrices with a 2.5 % 
IFN α-2a load (i.e. 10 % lyophilised IFN α-2a formulation) were prepared.  
 
Figure 49: IFN α-2a release from polyglycerol ester implants. Matrices were completely eroded 
after 22 days of incubation ( ) (average ± SD, n = 3).   
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IFN α-2a release was almost the same as observed for the BSA devices. The protein 
was liberated in a continuous manner over 16 days, delivering 50 % of the 
incorporated IFN α-2a (Fig. 49). Again, despite the fact that the matrices were 
completely eroded after 3 weeks of incubation, the remaining IFN α-2a fraction was 
not detectable in the release medium.        
PAGE analysis of the release media demonstrated covalent bounded aggregates 
being existent (Fig. 50). The major amount of such aggregated species originated 
from IFN α-2a dimer material. This dimer fraction was already detected after 24 hrs 
of incubation and became more pronounced with continuing incubation.  
 
Figure 50: IFN α-2a stability released from polyglycerol ester matrices. Lane 1: MW marker, 
lane 2: protein standard, lane 3: IFN α-2a released after 24 hrs, lane 4: IFN α-2a after 4 d, lane 5: 
IFN α-2a released after 7 d, lane 6: IFN α-2a released after 10 d, lane 7: IFN α-2a released after 
13 d, lane 8: IFN α-2a released after 16 d, lane 9: protein standard,  IFN α-2a dimer material.  
Generally, quantification of the band intensities revealed dimer aggregates 
accounting for more than 35 % of overall band intensity after 16 days of incubation. 
Later on, a further protein band was detected, which is due to the formation of IFN α-
2a trimer. This fraction represented another 4 % of overall band intensity in the 
monitored time period (Fig. 50). 
The occurrence of IFN α-2a aggregates was associated with the hydration of the 
PGEFs matrices. Consequently, the extensive water uptake of these matrices can be 
stated as reason for accelerated IFN α-2a aggregation proceeding within the 
matrices. Furthermore, interactions between protein molecules and the eroded 
material may be involved in the promotion of IFN α-2a aggregation. 
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The aggregates analysed are species which are soluble in the release media. Thus, 
these fractions did not account for the 50 % protein loss observed during release 
studies. However, their occurrence indicated that also the formation of insoluble 
aggregates as well as protein/lipid products can be assumed. Due to filtration of the 
release media prior to both SE-HPLC and PAGE studies, such fractions were 
separated and retained on the filter materials. These filters were collected and 
incubated in 2.0 mL SDS solution each (conc.: 2 % SDS (w/v)) at 37 °C over 24 hrs. 
SDS enables the dissociation of non-covalently bound insoluble protein aggregates 
and protein-polymer interactions to be disrupted.  
 
Figure 51: IFN α-2a recovered in SDS solution after incubating used filters at 37 °C over 24 hrs. 
Lanes 1 – 3: IFN α-2a detected in SDS solution, lane 4: protein standard, lane 5: MW marker.        
PAGE studies of the supernatant solutions exhibited a major amount of IFN α-2a 
being present in the solution (Fig. 51). Furthermore, the protein was considerably 
destructed, mirrored by the development of dimer and trimer material and further 
altered protein bands.  
These findings proved the extensive water uptake of PGEFs matrices as well as their 
erosion to cause protein instability during release studies. Here, the formation of 
insoluble aggregates and protein adsorption onto lipid erosion products can be 
assumed, leading to a 50 % IFN α-2a loss in the course of the experiments.  
The results were contrarily to data reported by Yamagata et al.. There, however, no 
definite statement was provided addressing the erosion behaviour of the matrices 
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presented, and maybe this is the lynchpin for protein being destabilised or not. This 
means, if the matrices demonstrated inhere a slower swelling and erosion – for 
example due to a different product quality -, IFN α-2a is thought to be more stable 
within these very devices versus within implants described in this thesis [220]. 
For the polyglycerol ester material available, protein instability was noticed as 
impeding fact. Already a small amount of aggregated species was discussed as 
major reason for immunogenic reactions in mice after subcutaneous injection of IFN 
α-2a formulations [20]. Consequently, PGEFs materials were considered to be 
inappropriate for further investigations. 
3. IFN α-2a release from tristearin implants containing PEG 
3.1 In vitro release studies 
When added in a content range between 10 – 30 %, polyethylene glycol 6000 
(PEG) was demonstrated as an effective excipient for BSA delivery from tristearin 
matrices.  BSA was liberated completely from these devices, whereby a high burst 
release has to be notified (refer to chapter VI). 
However, Siegel et al. demonstrated that the high solubility of BSA (i.e. 300 mg/mL) 
within aqueous media can be deemed a reason for the rapid release from inert 
matrices leading to transient diffusion processes. In contrast, proteins with lower 
solubilities such as IFN α-2a (solubility in a range of 25 mg/mL) are suggested to be 
liberated from such matrices according to the Higuchi equation [182; 174]. 
In awareness of this expected difference in the release kinetics of IFN α-2a 
compared to BSA, tristearin matrices containing a varying PEG ratio were evaluated 
in their applicability as delivery devices for a controlled IFN α-2a liberation. 
In table 16, the formulations investigated are illustrated. The IFN α-2a load 
represented 2.5 % of implant weight (i.e. 10 % lyophilised IFN α-2a formulation) in all 
experiments.  
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Formulation Lyophilised IFN α-2a [%] 
(protein/sugar ratio 1:3) PEG [%]  
Tristearin [%] 
(Dynasan 118) 
I 10  - 90  
II 10  5  85  
III 10  10  80  
IV 10  12  78  
V 10  14  76  
VI 10  16  74  
VII 10  18  72  
VIII 10  20  70  
IX 10  30  60  
Table 16: Tristearin matrix formulations with varying contents of polyethylene glycol 6000 
(PEG) as additive (n=3). 
In the first instance, formulations with 5 %, 10 %, 20 %, and 30 % PEG contents 
were evaluated (Fig. 52). The release profiles indicated that the addition of PEG 
resulted in two different features: in a substantial enhancement of IFN α-2a liberation, 
and secondly in an obvious change of the release kinetics. PEG-free matrices 
liberated 40 % of the incorporated protein over the monitored timeframe. However, 
the initial drug release accounted for almost 30 %, what led to a parabolic release 
profile (Fig. 52).  
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Figure 52: The effect of the PEG content on the release kinetics of IFN α-2a from tristearin 
implants. PEG content: 0 % ( ), 5 % ( ), 10 % ( ), 20 % ( ), 30 % ( ) (average ± SD, n = 3).  
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A protein release of up to 50 % in a steady manner over 17 days was achieved from 
implants containing 5 % PEG. Otherwise, implants containing 10 % PEG revealed a 
constant IFN α-2a liberation even over 3 weeks. After an initial drug release of about 
20 %, in the ongoing state another 50 % of protein were released. Thereby zero-
order kinetics were approached. Increasing the PEG content further on, e.g. 20 % 
and 30 %, resulted in a surge of IFN α-2a delivery of up to 80 %, yet the liberation 
succeeded faster and terminated after 10 days (Fig. 52). 
In further release studies, a content range of 10 – 20 % PEG was specified (Fig. 53). 
Time (d)
0 5 10 15 20 25
C
um
ul
at
iv
e 
IF
N
 a
lp
ha
-2
a 
re
le
as
e 
(%
) 
0
20
40
60
80
100
 
Figure 53: The effect of the PEG content on the release kinetics of IFN α-2a from tristearin 
implants. PEG content: 10 % ( ), 12 % ( ), 14 % ( ), 16 % ( ), 18 % ( ), 20 % ( ) (average ± 
SD, n = 3).  
The release profiles demonstrated that a stepwise raise of the PEG content did not 
result in gradually enhancing the total protein release. However, the profiles indicated 
that incorporated PEG contents higher than 14 % accelerated protein liberation. The 
addition of 12 % and 14 %, respectively, exhibited linear profiles for 3 weeks in 
accordance to the 10 % PEG formulation. In contrast, a higher PEG content - i.e. 16 
% and 18 % - approached non-linear profiles comparable to the 20 % PEG 
formulation (Fig. 53). 
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Based on this data set, it can be concluded that the additional incorporation of a 
solid, water soluble excipient contributes to the formation of an interconnected 
network [101]. 
Implants with a 10 % protein load and without PEG revealed only a slight increase in 
IFN α-2a liberation after initial burst effects. This suggests that most IFN α-2a 
particles are trapped within the matrix. Only the particles located directly at the 
surface or even close to it could be liberated.  
The release kinetics and the total amount of releasable protein changed substantially 
by adding 5 % PEG, even more distinct by 10 % PEG as solid excipient (Fig. 52). 
The continuous delivery after initial burst release up to 70 % IFN α-2a liberated after 
3 weeks of incubation supposed that dissolution and diffusion of non-surface IFN α-
2a molecules through pores and interconnected channels occurred. The comparison 
of implants containing 5 % PEG with 10 % PEG matrices confirmed this suggestion: 
by the addition of 5 % PEG, more protein particles could be trapped within the matrix 
because an incomplete network may be formed during compressing. This resulted in 
solely 50 % IFN α-2a delivery over time. An increase in the PEG content (e.g. 20 % 
or 30 % PEG) may yield in reduced tortuosity and in a greater porosity enabling 
diffusion, noticeable by the fast IFN α-2a from these devices. 
3.2 Protein stability during release 
A negligible water uptake of matrices made alone of triglycerides was 
demonstrated (refer to chapter IV). However, the formation of an interconnected 
network – as described in the preceding section – enables water uptake into the 
pores leading to a high concentrated protein solution. The hydration of the solid 
protein leads to a greater conformational flexibility of protein molecules and to a 
higher mobility of protein species, whereby protein aggregation in a highly 
concentrated solution may be preferred [48; 79; 121]. 
Consequently IFN α-2a aggregation proceeding within the matrices during release 
studies could be one possible reason for some protein loss. The extraction of the 
remaining IFN α-2a part from incubated implants with a 5 % and a 10 % PEG 
content, respectively, and following analysis of the samples by gel electrophoresis 
backed this suggestion. After three weeks of incubation, dimer and trimer fractions 
were estimated in dimensions of 3.5 % of total protein extracted from implants 
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containing 5 % PEG (Fig. 54). IFN α-2a extracted from incubated matrices with a 10 
% PEG content featured about 4 % higher-ordered aggregates, additionally to the 
dimer and trimer species. 
The inflow of the release medium caused proceeding aggregation of IFN α-2a within 
the matrices. One reason for the more distinct IFN α-2a aggregation extracted from 
implants containing 10 % PEG may be that the dissolution of PEG led to more 
porous matrices in the course of the release process. Concomitantly, the water 
content within the matrices increased, facilitating protein aggregation. 
 
Figure 54: IFN α-2a stability during in vitro release within tristearin matrices containing various 
ratios of PEG. Lane 1: IFN α-2a extracted from implants with a initial PEG content of 10 % after 
1 month of incubation, lane 2: IFN α-2a extracted from implants with a initial PEG content of 5 
% after 1 month of incubation, lane 3: protein standard, lane 4: MW marker.       
One further important question was whether aggregated species were liberated 
during release studies or not. For example, Morlock et al. published that 
erythropoietin (EPO) encapsulated in PLGA microspheres underwent moisture-
induced aggregation and that EPO aggregates did not release from the microspheres 
[129].  
Reversed phase HPLC did not indicate the existence of aggregated protein material 
in the release media, since 98.5 % of the detected IFN α-2a could be attributed to 
monomeric protein, even at stages of the release. The altered fraction can be 
ascribed to oxidised IFN α-2a species, whereby an average content of less then 2 % 
was present already in the bulk material.  
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In parallel to the assessment of protein concentration, the samples of all formulations 
were analysed by gel electrophoresis. The results for IFN α-2a released from 
implants containing 5 % PEG and 10 % PEG, respectively, are shown in Fig. 55 and 
Fig. 56 A/B. 
 
Figure 55: IFN α-2a released from tristearin matrices with an initial PEG content of 5 %. Lane 1: 
MW marker, lane 2: protein standard, lane 3: IFN α-2a released after 24 hrs, lane 4: IFN α-2a 
released after 4 d, lane 5: IFN α-2a released after 7 d, lane 6: IFN α-2a released after 10 d, lane 
7: IFN α-2a released after 13 d, lane 8: IFN α-2a released after 16 d.   
Generally, no dimer/trimer and higher aggregated species of IFN α-2a were 
assessed all along in the release media, neither when released from the 5 % PEG 
implants (Fig. 55) nor from the 10 % PEG matrices (Fig. 56 A/B). The comparison to 
IFN α-2a gel standard demonstrated identical bands of the samples and the 
standard. 
Consequently, the released IFN α-2a was rated to almost exclusively consist of pure, 
native monomer. 
Higher-ordered IFN α-2a could not liberate because a passive diffusion of 
aggregated protein species through the tortuous pores and channel network may be 
limited by the size of the pores [216]. Additionally, a higher molecular weight is 
associated with a smaller diffusion coefficient, thus also impeding liberation.            
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Figure 56: IFN α-2a released from tristearin matrices with an initial PEG content of 10 %.  
(A) Lane 1: protein standard, lane 2: IFN α-2a released after 24 hrs, lane 3: IFN α-2a released 
after 4 d, lane 4: MW marker, lane 5: IFN α-2a released after 7 d, lane 6: IFN α-2a released after 
10 d; (B) lane 1: protein standard, lane 2: IFN α-2a released after 13 d, lane 3: IFN α-2a released 
after 16 d, lane 4: IFN α-2a released after 19 d, lane 5: MW marker, lane 6: IFN α-2a released 
after 22 d. 
3.3 Summary and discussion 
Tristearin implants containing polyethylene glycol 6000 (PEG) as non-toxic, 
hydrophilic excipient enabled the development of a delivery system allowing the 
protein to be continuously released over weeks. For instance, with a 10 % PEG 
content, up to 70 % of the incorporated protein could be delivered in a linear manner 
over a 1 month period. Moreover, released protein consisted almost exclusively of 
monomeric IFN α-2a.  
It was further shown that varying the amount of PEG allows the control of protein 
liberation: whereas the addition of 20 % exhibited a 70 % IFN α-2a release within 10 
days in non-linear mode, implants containing 10 % also released 70 % of the 
incorporated protein, but in a linear way within three weeks. 
However, even with a 30 % PEG content, only 85 % of the incorporated protein could 
be liberated from these devices. That incomplete IFN α-2a liberation was not to be 
expected because the percolation threshold, i.e. the drug loading enabling the 
network to be coherent, was claimed for a 33.8 % loading [101]. Furthermore, a 15 % 
protein load was demonstrated to achieve a complete percolation of BSA when 
encapsulated in PLGA microspheres [226]. 
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The extraction of the remaining IFN α-2a part exhibited some protein being existent 
as covalent aggregated species. However, non-covalently bound aggregates within 
the extracted samples may be dissociated upon dilution with SDS buffer medium and 
subsequent heating prior to PAGE analysis.  
Therefore, it was the objective of further investigations to specify potential reasons 
for the incomplete protein release and, moreover, to minimise or even eliminate 
these parameters in order to achieve a complete protein liberation from the tristearin 
devices containing PEG. 
4. Potential parameters causing incomplete IFN α-2a release  
4.1 Studies on IFN α-2a stability in aqueous solution 
Since it has been shown in tentative experiments (refer to chapter IV) that 
Lowry assay data reveal considerable variability, some of the stability experiments 
were repeated as far as IFN α-2a data are pertained. In doing so, assay data are 
substantiated by using chromatographic methods. 
4.1.1 IFN α-2a formulated in pH 7.4 isotonic 0.01 M phosphate buffer (PBS)  
In the previous chapter protein release was discussed as the result of 
dissolution and diffusion processes through pores and channels. Thus, the 
incorporated protein is exposed to the infiltration of PBS medium over a 1 month 
incubation period.  
In order to evaluate whether the buffer environment itself or the elevated temperature 
of 37 °C promoted protein aggregation as well as chemical degradation pathways 
such as oxidisation throughout incubation, long-term stability studies of IFN α-2a 
were performed.  IFN α-2a solutions (0.2 mg/mL) formulated in PBS with 0.05 % 
(w/v) NaN3 were prepared and 2.0 mL each were incubated at 37 °C over time 
periods up to 2 months (stirring 40 rpm). At predetermined points of time protein 
concentration as well as protein integrity were characterised by SE-HPLC and RP-
HPLC (Fig. 57 A/B). 
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Figure 57: Alteration of IFN α-2a concentration and stability in PBS/0.05 % (w/v) NaN3 over 2 
months of incubation. (A) Results of SE-HPLC; (B) results of RP-HPLC (average ± SD, n=3).    
Chromatographic analysis featured a substantial decrease in IFN α-2a concentration 
after 3 days of incubation. The protein loss ranged between 10 - 20 % detected by 
both SE-HPLC and RP-HPLC. However, for SE-HPLC studies the monomer content 
remained almost constant on a 100 % level over 10 days, following by a slight 
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decrease with incubation continuing and finally resulting in 95 % monomeric IFN α-2a 
after 2 months. The monomer loss could be attributed to dimer and trimer species 
which were detectable in the solutions after 2 weeks of incubation (Fig. 57 A).  
Otherwise, chemical protein degradation was not observed over 1 month of 
incubation. RP-HPLC analysis demonstrated a constant 98 % monomer level. The 
remaining 2 % protein portion originated from oxidised IFN α-2a already existent in 
the protein bulk solution. Within the following month of incubation, the oxidative 
modified protein amount increased up to 5 % (Fig. 57 B).   
In order to exclude the formation of insoluble aggregates causing the detected 15 % 
protein loss, these data were backed by light obscuration measurements (table 17). 
The 10 days values were not to be generated because of device-related problems. 
Incubation time [d] Numbers of 
particles per 
mL with µm 
dimensions of 
Before 
incubation 3 15 17 22 30 60 
> 1 865 1,510 3,329 3,341 3,400 1,514 7,646 
> 4.1 107 363 512 903 671 242 1,429 
> 10 13 60 147 78 23 40 270 
 IFN α-2a 
formulated in 
PBS with  
0.05 % (w/v) 
NaN3 
> 25 0 0 0 0 0 2 4 
Table 17: Light obscuration measurements of IFN α-2a solutions incubated over 2 months (n=3, 
data in cumulative presentation).    
According to the European Pharmacopoeia, particle requirements for parenteral 
liquid dosage forms (Ph.Eur. 2.9.19) of not more than 6,000 particles ≥ 10 µm with a 
spherical diameter and/or 600 particles with diameters ≥ 25 µm were not exceeded in 
IFN α-2a solutions, nor were they after 2 months of incubation. An incipient formation 
of insoluble aggregates may cause the increased particle numbers in the solutions 
incubated for 2 months. However, based on this data it can be excluded that the 
formation of insoluble aggregates accounted for decreasing protein recoveries 
detectable in the solutions after 3 days of incubation.  
4.1.2 Influence of PEG on IFN α-2a stability formulated in PBS 
Polyethylene glycol 6000 (PEG) is soluble in aqueous release media. 
Consequently, this incorporated excipient will be dissolved during release 
experiments when buffer penetrates into the lipid devices. Thus, both solved protein 
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and PEG components will coexist in the interior of the matrices. Moreover, PEG 
diffusion processes throughout the matrix interior will occur simultaneously with 
protein diffusion.  
For polyethylene glycols, stabilising effects on proteins in aqueous media have been 
reported [43; 44]. However, stabilisation effects seem to be dependent on protein 
type and PEG sizes. Human serum albumin (HSA) was stabilised in the presence of 
PEG 8000 and PEG 10000, respectively, showing negative preferential interaction. 
On the other hand, PEGs with lower molecular weight (e.g. Mw 1000 and 4000) 
interacted favourable with the hydrophobic side chains when the protein was 
unfolded and eventually led to a stabilisation of the unfolded state [64]. 
In order to characterise potential IFN α-2a-PEG interactions, tristearin implants with a 
10 % PEG content were prepared. Stability studies were conducted by incubating the 
implants in 2.0 mL of a IFN α-2a solution (0.2 mg/mL) formulated in PBS/0.05 % 
(w/v) NaN3 at 37 °C over 2 months. The samples were agitated at 40 rpm. Protein 
concentration and protein integrity were assessed by SE-HPLC and RP-HPLC at 
predetermined points of time. In order to examine insoluble aggregates, samples 
were analysed by light obscuration. Fig. 14 illustrates determined protein recoveries 
and IFN α-2a monomer contents versus time. 
The results mirrored almost the same effects as faced in IFN α-2a stability studies 
without any PEG-lipid implants. Within the first days, a considerable decrease in the 
protein concentration detectable was notified, ending up in protein recovery rates of 
approximately 87 %. However, no further substantial protein loss was detected over 
the monitored incubation time (Fig. 58).  
Again, IFN α-2a monomer content remained on a high constant level for 1 month, i.e. 
a 97 % monomer fraction was detected by SE-HPLC, resembling the 98 % monomer 
content assessed via RP-HPLC. These data indicated that neither a pronounced 
formation of soluble aggregated species nor of oxidised IFN α-2a caused the 
detected protein loss.  
Furthermore, it can be concluded that PEG released from the lipid implants is not 
compromising protein stability. Though in contact with the hydrophilic additive, high 
IFN α-2a stability was maintained throughout 2 months of incubation.       
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Figure 58: Influence of polyethylene glycol 6000 (PEG) on IFN α-2a stability formulated in PBS/ 
0.05 % (w/v) NaN3 over 2 months of incubation. (A) Results of SE-HPLC; (B) results of RP-HPLC 
(average ± SD, n=3).      
Light obscuration measurements confirmed these data by excluding the formation of 
insoluble aggregates in IFN α-2a solutions during this 2 months period. Detectable 
particle numbers in the solutions were distinctively below the Ph.Eur. requirements 
(table 18) and showed no trending towards increasing particles counts over time.       
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Incubation time [d] Numbers of 
particles per mL 
with µm 
dimensions of 
Before 
incubation 3 15 17 22 30 60 
> 1 627 3,150 5,925 1,804 1,679 1,252 1,643 
> 4.1 90 363 678 337 248 210 240 
> 10 27 94 181 30 27 32 40 
IFN α-2a 
formulated in 
PBS plus 
PEG-
tristearin 
implant  
> 25 1 0 5 2 0 2 7 
Table 18: Light obscuration measurements of IFN α-2a solutions in PBS/0.05 % (w/v) NaN3 
containing one PEG-lipid matrix. Samples were incubated over 2 months (n=3, data in 
cumulative presentation).    
4.2 Protein adsorption upon packaging material 
Adsorption of protein upon glass surfaces is a well-known and extensively 
described phenomenon. Surface adsorption may result in protein loss and/or 
destabilisation of proteins. For example, at 1 µg/mL conditions the adsorption of 
acidic fibroblast growth factor on surfaces of various container materials (untreated 
glass, siliconised glass, sulphur-treated glass, Purcoat glass, polyester, 
polypropylene and nylon) was accounting for a 20 – 40 % loss [203]. Protein surface 
adsorption is usually dependent on protein concentration and may reach a maximum 
above a certain concentration-surface ratio [24]. Furthermore, the type of the 
container material mainly influences protein adsorption to its surface [77]. 
Schwarzenbach et al. measured IFN α-2a interactions with glass vial surfaces by 
atomic force microscopy. It was shown that the adhesion force on coated borosilicate 
glass (Schott Fiolax Type I plus®) was reduced down to 40 % of the total adhesion 
force measured on standard type I borosilicate glass [175]. 
In order to specify a potential protein adsorption upon the borosilicate glass vials, 
which were used for preceding in vitro release studies, the recovery of IFN α-2a bulk 
solutions (protein concentration 0.2 mg/mL and 1.0 mg/mL, resp.) formulated in PBS 
with 0.05 % (w/v) NaN3 was evaluated by spectroscopic measurements. 
Furthermore, potential adsorption upon the lipid implants was investigated by adding 
one pure tristearin matrix to IFN α-2a solutions. Besides these evaluations with 
untreated glass, experiments using siliconised glass (2R) and TopPac® vials (10R), 
made of a cycloolefin copolymer, were performed. The sample volumes were 2.0 mL 
consistently, and each experiment comprised analysis of three individual samples. 
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Samples were incubated at 37 °C and agitated with 40 rpm. Protein concentration 
was determined at 280 nm wavelength after 24 hrs and 3 days, respectively.  IFN α-
2a solutions with known concentrations (0.1 mg/mL – 1.0 mg/mL) were used to 
generate calibration curves.  
Fig. 59 A/B illustrates the amount of IFN α-2a recovered, depending on the used 
package material, the initial protein concentration, and the incubation duration. 
Generally, not more than 86 % of the initial IFN α-2a concentration was measured in 
the solutions incubated in untreated, borosilicate glass. The notable protein loss was 
determined after 24 hrs, followed by a slight decrease, if any, within the next two 
days. Furthermore, the higher concentrated IFN α-2a solution exhibited a lower 
protein recovery (Fig. 59 A/B). 
Based on comparable IFN α-2a recoveries in the pure protein solutions and in 
solutions containing additionally one tristearin matrix (Fig. 59 A/B), it could be 
concluded that the protein did not adsorb on the surface of the lipid implants. This 
was an important attainment of the lipid systems, since for various polymeric devices 
a substantial protein loss as a result of surface adsorption after protein release has 
been discussed [198]. 
When using siliconised glass vials as package material, higher protein concentrations 
were detected in the media. This advancement was more pronounced for the higher 
concentrated IFN α-2a solutions, and the protein loss occurred again within 24 hrs. 
But, as a matter of fact, a complete inhibition of protein adsorption processes could 
not be realised (Fig. 59 A/B).       
From the cycloolefin copolymer vials (TopPac®), approximately 98 % of IFN α-2a 
were recovered and that result was independent from the initial protein concentration 
and the incubation period. Consequently, the plastic materials featured a high 
potential as package material for future in vitro release studies (Fig. 59 A/B). 
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Figure 59: Protein adsorption upon package material. IFN α-2a stock solutions were incubated 
in various containers at 37 °C over 3 days (average ± SD, n=3).    
In order to confirm the protein loss as a consequence of adsorption upon the 
package material, protein had to be removed from the surfaces. Therefore, the vials 
were rinsed with water after 3 days of incubation. Then, 2% (w/v) SDS-solution – with 
SDS enabling the disruption of non-specific adsorption - was filled into the vials. After 
incubation at 37 °C for 24 hrs, the supernatant solutions were analysed by PAGE 
(Fig. 60).  
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Figure 60: IFN α-2a removed from the surfaces of various containers by supernatant SDS at 37 
°C after 24 hrs. Lane 1: protein removed from untreated glass vials, lane 2: MW marker, lane 3: 
protein removed from siliconised glass vials, lane 4: protein removed from TopPac® vials, lane 
5: protein standard.      
Monomeric IFN α-2a was detected in the supernatant solutions incubated in 
untreated glass vials and in siliconised glass (Fig. 60). Thereby, the protein band 
intensity was more pronounced in samples from untreated glass. This implicates that 
more protein was removed from these glass surfaces, in accordance with the 
increased protein loss of the samples, as determined by spectroscopic 
measurements.              
From the surfaces of the cycloolefin copolymer vials, no protein was removed at all 
by the supernatant SDS substantiating the approximately 98 % IFN α-2a recovery 
value detected by UV. 
The quantification of the removed protein by spectrophotometric measurements 
revealed recoveries corresponding to only 5 – 7 % of the initial protein concentration, 
what can be attributed to an incomplete removal of the protein by the supernatant 
SDS [205]. 
4.3 Optimisation of the lyophilised protein formulation – second approach 
As outlined above, the quality improvement of the freeze-dried IFN α-2a 
formulation can be deemed as crux of the matter in protein delivery from lipid 
implants, and the first approach done in this field was proven by a considerable 
increase in total releasable IFN α-2a. Moreover, this optimisation enabled the 
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development of an IFN α-2a delivery system based on tristearin implants containing 
PEG, which allows a 70 % continuous protein release over a 1-month period. 
Hence, one alternative optimisation approach by varying the applied cryo- and 
lyoprotective excipients, the cake masses, and the formulation pH was considered to 
further optimise the quality of the freeze-dried formulation - and consequently to 
improve the protein release behaviour (refer to chapter III, 2.1.1.3 B/C).  
Besides the commonly used trehalose, the polymers dextran 60 and hydroxypropyl-
ß-cyclodextrin (HP-ß-CD) were investigated on their efficiency in protein stabilisation 
during freeze-drying and subsequent solubilisation.  
After reconstitution, hitherto used lyophilised IFN α-2a formulations had a pH of 5.6, 
which is a pH close to the isoelectric point of IFN α-2a. This may implicate an 
increased sensitivity of this formulation against freezing and subsequent dehydration 
stress, what could result in an accelerated aggregation tendency after protein 
resolvation [6; 226]. Generally, protein solubility within aqueous media is lowest at 
the isoelectric point. Here, it was assumed that portions of the protein could have 
remained unsolved within the lipid implants during release experiments.     
Table 19 summarises the experimental design of these investigations, the pH of the 
formulations after reconstitution, and the determined residual moisture contents in 
the freeze-dried products. 
After the freeze-drying process, all formulations showed elegant amorphous cake 
structures, and no obvious difference was visible among the various products. The 
determined water contents were below 1 %, ranging from 0.3 – 0.9 %. Here, the 
increased solid content of the formulation was accompanied by a decrease of the 
residual moisture contents (table 19).       
Protein solutions adjusted to a pH of 4.2 exhibited slightly increased pH values in a 
range of 4.3 - 4.8 after the freeze-drying process. However, this formulation pH can 
be considered to guarantee a high physical and chemical IFN α-2a stability during 
storage and upon resolubilisation [224; 214]. In contrast, solutions of pH 7 resulted in 
a pH drop to values of 6.0 - 6.2 after lyophilisation - a pH close to the isoelectric point 
(table 19). 
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Formulation Excipient 
Mass of the freeze-
dried cake, protein 
sugar ratio of 1:3 
[mg]  
Adjusted pH pH after reconstitution 
Water 
content [%] 
I  
(hitherto 
used) 
trehalose 16 - 5.53 0.81 
II trehalose 16 4.2 4.80 0.76 
III trehalose 16 7.0 6.14 0.78 
IV trehalose 64 4.2 4.54 0.39 
V trehalose 64 7.0 6.08 0.57 
VI dextran 60 16 - 5.19 0.91 
VII dextran 60 16 4.2 4.80 0.70 
VIII dextran 60 16 7.0 6.00 0.70 
IX dextran 60 64 4.2 4.33 0.41 
X dextran 60 64 7.0 6.12 0.47 
XI HP-ß-CD 16 - 5.31 0.79 
XII HP-ß-CD 16 4.2 4.64 0.75 
XIII HP-ß-CD 16 7.0 6.16 0.81 
XIV HP-ß-CD 64 4.2 4.31 0.27 
XV HP-ß-CD 64 7.0 6.10 0.54 
Table 19: Evaluating studies on the stability of IFN α-2a freeze-dried formulations. Listed are 
various formulations, pH values (with 2 N acetic acid or 0.05 N NaOH, resp.) before 
lyophilisation, and pH values after reconstitution as well as determined residual moisture 
contents.  
After reconstitution, IFN α-2a stability was monitored for 7 days. The reconstituted 
formulations were incubated at 37 °C, stirred with 40 rpm and finally analysed by SE-
HPLC after 2 days and 7 days of incubation, respectively.  
Figs 61 – 63 illustrate the detected protein recoveries with regards to formulation pH, 
the employed excipient, and the incubation time. 
Using trehalose as stabilisation excipient in combination with a formulation pH of 4.2 
assured the protein to be stable throughout incubation. Approximately 98 % of IFN α-
2a were recovered after 7 days (Fig. 61), and only a marginal dimer fraction 
accounting for less than 1 % of overall protein concentration was detected.  
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Figure 61: IFN α-2a stability of trehalose freeze-dried formulations with different pH values after 
reconstitution and incubation at 37 °C (40 rpm).  
In contrast, formulations used hitherto with a pH of 5.6 featured almost 100 % 
recovery directly after reconstitution, but after 2 days only 60 % of the initial protein 
was found. This drop in protein recovery was associated by noticeable turbidity of the 
solutions what indicated protein aggregation and precipitation proceeding. 
Consequently, it was assumed that the lyophilisation process itself exerted more 
stress on IFN α-2a when formulated close to its isoelectric point around pH 6 than 
formulated at a pH of 4.2 (Fig. 61).  
For the pH 7 formulation, protein precipitation was already visible during sample 
reconstitution, and that mirrored in only 60 % IFN α-2a recovery. The detectable 
protein amount further decreased to 30 % over the 7 days incubation period (Fig. 61). 
As demonstrated above, the pH of this formulation decreased to a pH of 6.1 during 
freeze-drying which may exhibit a destabilising impact on the protein structure and, 
consequently, resulted in a high degree of aggregate formation after reconstitution. 
Because of a pH at the isoelectric point, a reduced solubility of these products can be 
considered as further parameter leading to protein precipitation after reconstitution.  
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Figure 62: IFN α-2a stability of dextran 60 freeze-dried formulations with different pH values 
after reconstitution and incubation at 37 °C (40 rpm).  
Employing dextran 60 as stabilising excipient revealed a similar dependency of 
protein stability on the formulation pH before freeze-drying. Only the formulation 
adjusted to a pH of 4.2 exhibited a high IFN α-2a stability throughout incubation (Fig. 
62).  
However, in comparison to the trehalose formulation, IFN α-2a recovery was 
obviously lower already after reconstitution. Only 90 % of the initial protein amount 
were detected, which was 9 % protein less than determined in trehalose products. 
Moreover, aggregated protein species were notified as early as after reconstitution.  
These experimental data confirmed the discussion around dextrans´ efficiency in 
protein lyoprotection, during which dextrans were demonstrated to form elegant 
amorphous cakes, but fail in protein protection due to steric hindrance [6; 1]. 
In contrast to dextran, the polymer hydroxypropyl-ß-cyclodextrin (HP-ß-CD) featured 
a potential in IFN α-2a lyoprotection comparable to trehalose. When formulated at pH 
4.2, approximately 100 % protein were recovered in the reconstituted formulation 
throughout the 7 days incubation. However, the stabilisation potential was also 
limited to the acidic formulations. All other freeze-dried HP-ß-CD products exhibited 
decreasing protein recoveries over time, in particular the pH 7 formulations (Fig. 63). 
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Figure 63: IFN α-2a stability of HP-ß-CD freeze-dried formulations with different pH values after 
reconstitution and incubation at 37 °C (40 rpm).  
4.4 Summary and discussion 
Based on stability data, high IFN α-2a stability in formulations of pH 7.4 
isotonic 0.01 M phosphate buffer (PBS) was verified. After 2 months of incubation, 95 
% of IFN α-2a almost exclusively consisted of native monomer. Moreover, this high 
protein stability was also provided by the addition of a PEG-lipid matrix substantiating 
that polyethylene glycol 6000 (PEG) exhibited no destabilising effects on IFN α-2a. 
For future release studies that means PEG as release modifier is not anticipated to 
detract from IFN α-2a stability within the tristearin matrices.      
The detected protein loss during stability experiments could be explained by protein 
adsorption upon the used package materials. It was demonstrated that a major 
amount of IFN α-2a – up to 15 % of the initial protein dose – has been adsorbed to 
the borosilicate glass vials during previous stability experiments and as a conclusion 
during previous release studies. Hence, this protein dose was liberated from the lipid 
implants, but could not be detected in the release media. 
However, it could also be demonstrated that this problem can be solved by the use of 
cycloolefin copolymer vials. This package material enabled an almost complete 
inhibition of IFN α-2a adsorption, what can be ascribed to a different surface integrity 
in comparison to glass materials. Consequently, it was assumed that by changing the 
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package material during future release studies the total release may be in the 
ballpark of 85 % values for IFN α-2a implants containing 10 % PEG. 
Stability studies of freeze-dried protein formulations showed that the hitherto used pH 
5.6 IFN α-2a/trehalose formulations still lack protein stability when reconstituted and 
incubated at 37 °C. It can be suggested that the freeze-drying process detracts from 
IFN α-2a stability leading to an accelerated protein aggregation/precipitation 
tendency when these products were exposed to rehydration stress and/or elevated 
temperature during incubation.  
Freeze-dried IFN α-2a/trehalose products adjusted to a pH of 4.2 before 
lyophilisation revealed high protein stability. Approximately 100 % of the initial protein 
were recovered in the reconstituted formulations after 7 days of incubation. Neither 
the freeze-drying process per se nor subsequent active stress parameters (e.g. 
rehydration and elevated temperature) compromised IFN α-2a stability. 
Consequently, it was suggested that this highly stable lyophilised protein will be 
released to a greater amount from the lipid implants than a protein that already has 
experienced considerable stress. For future release experiments, that means 
previously incomplete protein release can potentially be reduced or eliminated by 
using the pH 4.2 lyophilised IFN α-2a/trehalose formulations – i.e. with cake masses 
of 16 mg and 64 mg, respectively. 
Moreover, HP-ß-CD used as lyoprotective excipient inhered a high efficiency in 
protein stabilisation during freeze-drying. After reconstitution, approximately 100 % of 
the initial IFN α-2a were recovered in the acidic formulations after 7 days of 
incubation. The lyoprotective effect of HP-ß-CD is addressed to protein complexing, 
thereby shielding the protein in its native form [87]. For future release experiments 
the applicability of HP-ß-CD formulations should be exploited. Therefore, the pH 4.2 
formulation with the higher cake mass of 64 mg was chosen.  
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After extensively discussing the potential parameters being accountable for 
incomplete IFN α-2a release from tristearin matrices containing PEG as additive, the 
following chapter will relate to improvements attained in protein liberation by using 
new freeze-dried formulations and, moreover, by changing the repositories during 
release experiments. Detailed information concerning lipid modification, protein 
stability issues, and implant morphology throughout release studies are shown. As 
mentioned before, the pH 4.2 trehalose lyophilisates featured the same protein/sugar 
ratio, but differ in the mass of the freeze-dried cakes – i.e. 16 mg and 64 mg cake 
mass, respectively. In the following, these lyophilisates will be referred to as 
trehalose lyophilisates A (mass of 16 mg) and B (64 mg). For HP-ß-CD, lyophilisates 
with a higher mass (64 mg) were chosen. The investigated matrix formulations are 
listed below (table 20).      
Formulation 
IFN α-2a/ 
trehalose lyoph. 
A [%]   
IFN α-2a/ 
trehalose lyoph. 
B [%]   
IFN α-2a/ 
HP-ß-CD lyoph. 
 [%]   
PEG 
[%] 
Tristearin 
[%] 
1 10 - - 0 90 
2 10 - - 5 85 
3 10 - - 10 80 
4 10 - - 12 78 
5 10 - - 14 76 
6 10 - - 16 74 
7 10 - - 18 72 
8 10 - - 20 70 
9 - 10 - 0 90 
10 - 10 - 5 85 
11 - 10 - 10 80 
12 - 10 - 12 78 
13 - 10 - 14 76 
14 - 10 - 16 74 
15 - 10 - 18 72 
16 - 10 - 20 70 
17 - - 10 0 90 
18 - - 10 5 85 
19 - - 10 10 80 
20 - - 10 14 76 
21 - - 10 16 74 
22 - - 10 18 72 
23 - - 10 20 70 
Table 20: Design of various matrix formulations; for each formulation, three implants were 
investigated (n=3). The drug load was calculated from implant weight, whereby constantly 2.5 
% of implant weight accounted for the IFN α-2a dose. 
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1. Characterisation of lipid modifications 
Tentative experiments featured that lipid modifications are not influenced by 
implant compression (refer to chapter IV). However, these data only mirrored cases 
of pure tristearin implants. In order to clarify whether the lyophilised protein per se 
induced modification changes, previous differential scanning calorimetric data (DSC) 
were completed by investigations on that. Therefore, implants with a 10 % drug load 
were prepared and analysed in comparison to unprocessed tristearin bulk as well as 
to pure tristearin implants (Fig. 64). 
 
Figure 64: DSC analysis of (A) tristearin bulk, (B) pure tristearin implants by compressing, (C) 
tristearin implants containing 10 % IFN α-2a/trehalose lyophilisate A, and (D) tristearin implants 
containing IFN α-2a/HP-ß-CD lyophilisate (the plots are displaced vertically for better 
visualisation).      
Unprocessed tristearin bulk (A) demonstrated one single endothermic peak at  
72.3 °C, which is assigned to the melting of the stable ß-modification. The 
thermogram of both tristearin implants (B) and implants containing 10 % IFN α-2a/ 
trehalose lyophilisate A (C) illustrate similar data, as one endothermic DSC peak was 
detected at 73.6 °C and 73.1 °C, respectively. As already discussed, the 
displacement of the peak maxima towards lipid bulk is considered as an effect 
caused by different particle sizes of the ground implants [23]. In addition, implants 
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with a 10 % IFN α-2a/HP-ß-CD lyophilisate charge (D) showed also identical results 
compared to bulk material (one single endothermic peak at 73.0 °C). 
In order to verify DSC data, wide-angle X-ray scattering (WAXS) was performed (Fig. 
65). 
 
Figure 65: X-ray diffraction patterns of (A) tristearin bulk, (B) pure tristearin implants, (C) 
tristearin implants containing 10 % IFN α-2a/trehalose lyophilisate A and (D) tristearin implants 
with 10 % IFN α-2a/HP-ß-CD lyophilisate. The numbers correspond to the short spacings in nm 
of the peak maxima (the plots are displaced vertically for better visualisation). 
The diffraction pattern of both implants comprising pure tristearin material (B) and 
implants containing 10 % lyophilised protein – i.e. 10 % IFN α-2a/trehalose 
lyophilisate A (C) and 10 % IFN α-2a/HP-ß-CD lyophilisate (D), respectively - 
resembled that of the bulk material (A). The visible short spacings at 0.46, 0.38 and 
0.37 nm, respectively, correspond to short spacings typical for the stable ß-
modification [217]. Only very weak reflections were detected at 0.42 nm (ß` 
polymorph: short spacings at 0.38 and 0.42 nm). 
DSC and WAXS results suggested that both the amount of protein load and the 
manufacturing process per se have no direct impact on lipid modification. Moreover, 
lipid implants are consisting mainly of stable ß-modification after preparation. 
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2. Influence of the manufacturing process on the protein stability 
Protein stability was assessed after implant manufacture applying the 
extraction technique without using organic solvents (refer to chapter IV). In each 
case, two implants consisting of 10 % IFN α-2a/trehalose lyophilisates (lyophilisate A 
and B) and 10 % IFN α-2a/HP-ß-CD lyophilisate, respectively, and 90 % tristearin 
were compressed. After extraction, the buffer media – containing the protein drug – 
were analysed by gel electrophoresis. In comparison, lyophilised IFN α-2a samples 
were reconstituted with PBS/0.05 % (w/v) NaN3 containing 1 % (w/v) polysorbate 20 
(PBST) and used as IFN α-2a standard (Fig. 66). 
 
Figure 66: Influence of the manufacturing process on protein stability. IFN α-2a was extracted 
from the implants subsequent to compressing. (A) Implants performed with IFN α-2a/trehalose 
lyophilisates A and B - lanes 1, 2: extracted samples (lyophilisate B), lane 3: lyophilisate A 
reconstituted in PBST, lanes 4, 6: extracted samples (lyophilisate A), lanes 5: MW marker, lane 
7: lyophilisate B reconstituted in PBST; (B) implants performed with IFN α-2a/HP-ß-CD 
lyophilisates, lane 1: lyophilisate reconstituted in PBST, lanes 2, 4: extracted samples, lane 3: 
MW marker.        
The results confirmed that the compression process of protein/lipid mixtures did not 
detract from protein stability, thus works under mild conditions. Implants prepared 
from IFN α-2a/trehalose lyophilisates (Fig. 66 A) did not exhibit any IFN α-2a 
aggregates. Samples derived from IFN α-2a/HP-ß-CD lyophilisates were shown to 
marginally contain aggregated protein (Fig. 66 B). However, the identified dimer 
A B 
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species were also notified when analysing the reconstituted lyophilisates, and thus 
are not be attributed to the manufacture process. 
Generally, such dimer fractions accounted less then 2 % of overall protein. Such an 
approach can be deemed acceptable for investigative purposes. As earlier 
discussed, even lyophilised IFN α-2a products available on the market contain up to 
1 % aggregates [20]. 
As a conclusion, for assessing data of release studies described below, one can 
assume that the lipid matrices were loaded almost exclusively with native IFN α-2a 
before release studies were initiated.   
3. In vitro release studies 
Initially, IFN α-2a release from tristearin matrices without additives was 
investigated. As shown in Fig. 67 A, implants loaded with 10 % IFN α-2a/trehalose 
lyophilisate A liberated 84 % of the incorporated protein. However, the initial drug 
release accounted for almost 45 % of the total protein load, and after 4 days as much 
as 70 % of IFN α-2a were liberated. 
Evaluation studies on implants prepared with 10 % IFN α-2a/trehalose lyophilisate B 
(Fig. 67 B) featured comparable release profiles. Overall, obtained liberation rates 
were lower for this formulation, only 60 % of the encapsulated IFN α-2a were 
released. 
In order to maximise IFN α-2a release and to control the release profile, varying 
amounts of tristearin were replaced by PEG (table 20). Selected liberation curves are 
illustrated in Fig. 67 A/B. 
As demonstrated by the release profiles the addition of PEG 6000 caused a 
considerable alteration of the release kinetics. This was in accordance with previous 
release experiments when PEG was used as release modifier (refer to chapter VII). 
Moreover, a notable decrease of about 25 % in the initial burst release was shown for 
the PEG containing formulations.   
For IFN α-2a/trehalose lyophilisates A (Fig. 67 A), implants containing 5 % PEG and 
10 % PEG, respectively, revealed a continuous and sustained protein liberation for 
up to 1 month. The total amount of released IFN α-2a did not change substantially in 
comparison to the formulations without PEG, i.e. 83 % and 89 % of the incorporated 
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protein, respectively, were liberated. Increasing the PEG content further on, e.g. 16 
% and 20 %, resulted in liberation profiles approaching a 95 % protein release level. 
However, the liberation succeeded faster and terminated after 2 weeks of incubation. 
 
 
 
Figure 67: Effects of lyophilisate formulation and PEG content on release kinetic of IFN α-2a. 
(A) Release profiles of implants performed with IFN α-2a/trehalose lyophilisates A - PEG 
content: 0 % ( ), 5 % ( ), 10 % ( ), 16 % ( ), 20 % ( ); (B) Release profiles of implants 
performed with IFN α-2a/trehalose lyophilisates B - PEG content: 0 % ( ), 5 % ( ), 10 % ( ), 16 
% ( ), 20 % ( ) (average ± SD, n=3).  
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Implants manufactured with IFN α-2a/trehalose lyophilisates B and a variation of 
PEG contents (Fig. 67 B) led to lower protein releases compared to implants 
containing the lyophilisate A formulations. But, in general, the profiles obtained were 
identical, meaning low PEG contents achieved a continuous IFN α-2a release for up 
to 1 month. With higher amounts of PEG an enhanced but also accelerated protein 
liberation occurred.  
In Fig. 68, the release profiles of matrices formulated with IFN α-2a/HP-ß-CD 
lyophilisates are illustrated. The addition of PEG to these implants caused an 
enhancement of total released IFN α-2a up to 97 %, facing a 75 % release from 
matrices without any PEG. Moreover, with PEG the release behaviour appeared to 
be more sustained, and again burst effects were lowered. An optimal content of 10 % 
PEG was assessed. By that, 95 % of the initial incorporated protein were delivered 
continuously over 1 month, approaching zero-order kinetic within the very first 2 
weeks.  
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Figure 68: Effect of lyophilisate formulation and PEG content on the release kinetic of IFN α-2a. 
Release profiles of implants performed with IFN α-2a/HP-ß-CD lyophilisates - PEG content: 0 % 
( ), 5 % ( ), 10 % ( ), 16 % ( ), 20 % ( ) (average ± SD, n=3).   
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It can be concluded that both the lyophilisate formulation per se and the addition of 
PEG impacted the liberation profile, the total drug release, and the release 
mechanism.  
The continuous drug release over a period of 1 month suggested that dissolution and 
diffusion of IFN α-2a occurs through pores and interconnected channels, formed by 
PEG and protein particles during the manufacturing process. Here, the raise in PEG 
content from 10 % up to 20 % did not result in a considerable enhancement of total 
drug delivery, but the liberation periods were considerably reduced from implants 
with higher PEG contents. It can be assumed that the increase in the PEG content – 
i.e. 16 % up to 20 % - led to easier accessible pathways (reduced tortuosity) and to a 
greater porosity within the interior of the lipid implants. Consequently, protein release 
was accelerated from such matrices. 
Generally, IFN α-2a release was faster and more complete from implants formulated 
with IFN α-2a/HP-ß-CD lyophilisates, what can be ascribed to the solubilising and 
stabilising potential of HP-ß-CD for proteins as well as by drug complexing features 
[21; 192].                                       
4. Protein stability during release 
IFN α-2a aggregation proceeding within the matrices can be deemed a 
possible reason for residual protein remaining in the matrix after incubation (refer to 
chapter VII).  
Fig. 69 A/B shows the result of IFN α-2a extraction from incubated implants produced 
with IFN α-2a/trehalose lyophilisates. In comparison to the samples extracted directly 
after compressing, higher-ordered aggregates were now detected in all samples.  
For the IFN α-2a/trehalose lyophilisates A (Fig. 69 A), aggregation occurred more 
pronounced within implants containing a higher amount of PEG: the aggregate 
fraction increased from approximately 1 % (for PEG free matrices) to 7 % (for a 10 % 
PEG content). Here, a difference in the protein aggregates detected in the two 
samples extracted from 10 % PEG implants was to be noted (Fig. 69 A, lane 1 and 
2). The stated value of 7 % of aggregated species matches to the sample showing a 
more pronounced aggregation (Fig. 69 A, lane 2). Considering the initial incorporated 
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IFN α-2a, 0.7 % - 1.4 % of the protein can be suggested being existent within the 
implants as higher-ordered aggregates after 1 month of incubation.    
 
Figure 69: IFN α-2a stability within the matrices during in vitro release, effect of the lyophilisate 
formulation on protein stability during release. (A) Extracted from IFN α-2a/trehalose 
lyophilisate A implants after 1 month of incubation - lanes 1, 2: 10 % initial PEG content, lanes 
3, 4: 5 % initial PEG content, lanes 5, 6: 0 % initial PEG content, lane 7: protein standard, lane 8: 
MW marker. (B) Extracted from IFN α-2a/trehalose lyophilisate B implants after 1month - lanes 
1, 2: 10 % initial PEG content, lanes 3, 5: 5 % initial PEG content, lane 4: MW marker, lanes 6, 7: 
0 % initial PEG content, lane 8: protein standard. 
PAGE studies of IFN α-2a samples extracted from IFN α-2a/trehalose lyophilisate B 
implants (Fig. 69 B) after 1 month of incubation featured more intense protein 
aggregation than samples extracted from IFN α-2a/trehalose lyophilisate A matrices. 
Besides higher-order oligomer fractions, a considerable amount of dimer and trimer 
species was detected in the buffer media containing the extracted protein drug. The 
quantification revealed protein aggregated species accounting for more than 30 % of 
overall band intensity. This event was independent from the initial PEG content of the 
implants. Based on these PAGE data the extensive protein aggregation in the 
matrices during release experiments could be shown to reason the reduced and 
incomplete protein liberation from such IFN α-2a/trehalose lyophilisate B implants. 
As visualised in Fig. 70, samples extracted from IFN α-2a/HP-ß-CD lyophilisate 
matrices also contained higher-order aggregates, yet the total amount of aggregates 
(≤ 3 %) was considerably lower compared to samples extracted from IFN α-
2a/trehalose implants. Moreover, it can be claimed that only 0.15 % - 0.3 % of the 
A B 
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initial incorporated protein are existent as higher-order IFN α-2a species within the 
implants after 1 month of incubation.  
 
Figure 70: IFN α-2a stability within the matrices during in vitro release, effect of the lyophilisate 
formulation on protein stability during release. IFN α-2a extracted from IFN α-2a/HP-ß-CD 
implants after 1 month of incubation - lane 1: MW marker, lanes 2, 3: 0 % initial PEG content, 
lanes 4, 5: 5 % initial PEG content, lanes 6, 7: 10 % initial PEG content, lane 8: protein standard. 
As presented before, HP-ß-CD demonstrates a stabilising effect on various peptides 
and proteins [192; 21]. Consequently, it can be assumed that IFN α-2a can be 
protected by HP-ß-CD within lipid matrices during the release process by minimizing 
aggregation phenomena.  
Contrarily, the released IFN α-2a appears almost exclusively in monomeric form. SE-
HPLC marginally revealed aggregated protein with less than < 1 % within the release 
media over all the incubation period, and RP-HPLC demonstrated a constant 1.5 % 
level of oxidised IFN α-2a species.  
PAGE studies of samples drawn from implant studies conducted with IFN α-
2a/trehalose lyophilisates A and a 10 % PEG content are illustrated in Fig. 71 A/B. 
Only a minor amount of trimer specimen notified after 16 days of incubation mirrored 
protein aggregation. Data obtained from implants using IFN α-2a/trehalose 
lyophilisates B or IFN α-2a/HP-ß-CD lyophilisates showed comparable results (data 
not shown).  
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Figure 71: Stability of IFN α-2a released from the matrices. (A, B) IFN α-2a liberated from 
implants using IFN α-2a/trehalose lyophilisates A with a 10 % PEG content - (A) lanes 1, 6: MW 
marker, lane 2: protein standard, lane 3: IFN α-2a released after 24 hrs, lane 4: IFN α-2a 
released after 4 d, lane 5: IFN α-2a released after 7 d, lane 7: IFN α-2a released after 10 d, lane 
8: IFN α-2a released after 13 d; (B) lanes 1, 6: MW marker, lane 2: protein standard, lane 3: IFN 
α-2a released after 16 d, lane 4: IFN α-2a released after 19 d, lane 5: IFN α-2a released after 22 
d, lane 7: IFN α-2a released after 25 d, lane 8: IFN α-2a released after 28 d, ( ) Occurrence of 
trimer species material.            
In accordance to chapter VII, these data confirmed the liberation of higher-order 
aggregate species being limited from the lipid implants because of their lower 
diffusion coefficients or due to the pore sizes within the implants. Moreover, it can be 
concluded 85 % - 95 % of IFN α-2a to be released in form of native monomer as well 
as aggregated dimer and trimer species to be liberated only marginally.  
5. Implant morphology 
Even with higher PEG contents, tristearin implants revealed a high physical 
stability during release. No erosion was visible after 1 month of incubation (Fig. 72). 
before incubation after 1 month of   
incubation  
Figure 72: Implants consisting of 10 % IFN α-2a/trehalose lyophilisate A, 10 % PEG and 80 % 
tristearin before and after 1 month of incubation. 
A B
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Due to this physical stability and the lack of erosion phenomena, the protein was 
assumed to be liberated through pores. After preparation of matrices containing 10 % 
lyophilisate, 10 % PEG and 80 % tristearin, implant surfaces appeared smooth and 
with only low ruggedness (Fig. 73 A/B).      
 
Figure 73: SEM images of (A) implant from 10 % IFN α-2a/trehalose lyophilisate A/10% 
PEG/80% tristearin and (B) implant from IFN α-2a/HP-ß-CD lyophilisate/10% PEG/80% tristearin 
– both before incubation. 
Fig. 74 A - C illustrates SEM images of implants manufactured with 10 % IFN α-
2a/trehalose lyophilisate A and a different amount of PEG after 1 month incubation. 
A small number of pores were formed on the surface of implants containing 5 % PEG 
as additive (Fig. 74 A). With a higher PEG amount, the pore number and the pore 
sizes increased (Fig. 74 B/C). Pores with up to 100 µm in diameter were visible on 
such implant surfaces. Data obtained from IFN α-2a/trehalose lyophilisate B implants 
were comparable in data.     
 
Figure 74: SEM images of implants consisting of 10 % IFN α-2a/trehalose lyophilisate A and 
different levels of PEG after 1 month of incubation. PEG content: 5 % (A), 10 % (B) and 20 % (C) 
(images with 50x magnification). 
As visualised in Fig. 75 A – C, implants performed with IFN α-2a/HP-ß-CD 
lyophilisate and different PEG levels also exhibited pore formation after 1 month of 
100 µm 100 µm 100 µm 
A B C 
B A 
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incubation. The diameters visible at up to 100 µm were comparable to those of the 
IFN α-2a/trehalose matrices. However, a dependency of both pore number and pore 
sizes on the initial PEG amount could not be asserted for the IFN α-2a/HP-ß-CD 
implants. 
 
Figure 75: SEM images of implants consisting of 10 % IFN α-2a/HP-ß-CD lyophilisate and 
different levels of PEG after 1 month of incubation. PEG content: 5 % (A), 10 % (B) and 20 % (C) 
(images with 500x magnification). 
SEM results were backed by mercurial porosimetry measurements in order to 
evaluate the inner surface of the implants after 1 month of incubation. The 
determined total intrusion volumes and calculated porosities of incubated implants 
are listed as a function of the initial PEG content in table 21. Dry implants revealed a 
total intrusion volume of 0.0446 mL/g. That can be attributed to a small number of 
pores located on matrix surfaces as a result of the compressing process. 
Initial PEG content [%]  10 % IFN α-2a/trehalose 
lyophilisate A implants 5 10 14 16 18 20 
Total intrusion volume (mL/g) 0.1387 0.1651 0.2469 0.2662 0.3453 0.3650 
Porosity (%)  9.68 11.02 17.70 18.78 23.04 22.74 
    
Initial PEG content [%] 10 % IFN α-2a/HP-ß-CD 
lyophilisate B implants 10 14 16 18 20 
Total intrusion volume (mL/g) 0.1605 0.2685 0.3246 0.3743 0.3919 
Porosity (%)  11.13 17.05 21.42 22.33 24.76 
Table 21: Results of mercury porosimetry measurements. Implants were analysed after 1 
month of incubation. 
Porosimetry data demonstrated a considerable enhancement in the final pore volume 
of 1 month incubated implants, when compared to dry matrices. Moreover, with 
higher levels of initial incorporated PEG these final pore volumes increased, e.g. a 
50 µm 50 µm 50 µm
A B C 
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rise from 0.1387 mL/g for IFN α-2a/trehalose lyophilisate A implants and a 5 % PEG 
content up to 0.3650 mL/g for a 20 % PEG load could be determined.  
Such an effect was also mirrored by the calculated porosities. IFN α-2a/trehalose 
lyophilisate A implants with a 5 % PEG charge resulted in porosity values well below 
10 %. Increasing the PEG content, e.g. up to 18 % and 20 %, led to a surge of 
implants porosity up to double values, what means that porous structures such as 
pores and channels account for over 20 % of the implant volume after 1 month of 
incubation.   
Incubated matrices manufactured with IFN α-2a/HP-ß-CD lyophilisates and different 
PEG contents featured the same dependency of implant porosity on the initial PEG 
amount: higher PEG levels generated more porous structures during release 
experiments. For 10 % PEG matrices, porosity was determined being around 11 %, 
increasing constantly up to 25 % for matrices with a 20 % PEG content.  
The data verified the formation of water-filled pores and channels within the lipid 
implants during release experiments. Given the background that only 10 % of implant 
weight is due to lyophilised protein and that tristearin matrices themselves do not 
erode at all, it can be assumed that this effect was the result of both PEG and IFN α-
2a dissolution and diffusion. Consequently, protein liberation from the lipid implants 
appeared to be a result of pore diffusion and, moreover, was influenced by the initial 
incorporated PEG amount.  
6. IFN α-2a storage stability within lipid implants containing PEG  
Depending on the lyophilisate formulation, up to 95 % of the incorporated IFN 
α-2a could be liberated continuously over a 1 month period from tristearin implants 
with a 10 % PEG content. Moreover, the protein was released almost exclusively in 
its monomeric form.  
However, the storage stability of drug dosage forms can be influenced by 
environmental conditions such as temperature, oxygen, light, and humidity. In this 
relation, the term stability refers to the time frame from initial preparation and 
packaging during which the dosage form continues to comply with quality and purity 
requirements.  
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As a result of the marginal storage stability of many proteins, long-term storage of 
protein dosage forms often goes along with conformational changes of the protein 
drugs incorporated and, consequently, purity requirements can not be fulfilled any 
longer [6]. 
In order to evaluate storage stability of IFN α-2a within lipid implants, tristearin 
matrices with 10 % lyophilised protein and a PEG content of 10 % were prepared. 
Subsequently, implants were deposited into borosilicate glass vials and overlayed 
with nitrogen before sealing in order to reduce potential detrimental effects of 
atmospheric oxygen. Samples were stored at 4 °C and room temperature (with 33 % 
relative humidity) over 3 months and 6 months, respectively. After the expiration of 
these terms, implants were transferred into TopPac® vials and release studies were 
conducted at 37 °C (40 rpm) over a 1 month incubation period. 
6.1 Release studies after 3 months and 6 months of implant storage 
As visualised in Fig. 76 A, matrices formulated with IFN α-2a/trehalose 
lyophilisates A and a 10 % PEG content yielded a decrease of total drug liberation 
after 3 month storage. When compared to release studies performed immediately 
after implant preparation, only 80 % of the incorporated protein were liberated from 
the implants – in contrast to a 90 % protein liberation rate of unstored implants. 
However, the release kinetics did not notably change, since IFN α-2a still was 
liberated continuously over 1 month. For implants stored at 4 °C reduced liberation 
rates were demonstrated in early release phases, but after incubation for 1 month the 
same total drug release was achieved as it was with implants stored at room 
temperature.  
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Figure 76: Influence of storage conditions on IFN α-2a release from tristearin matrices 
formulated with trehalose lyophilisates and with 10 % PEG. Implants were stored over 3 
months and 6 months at 4 °C and room temperature (33 % rel. humidity), respectively, before 
release studies were initiated. (A) Implants performed with IFN α-2a/trehalose lyophilisates  A – 
before storage ( ), stored for 3 months at 4 °C ( ) and RT ( ), stored for 6 months at 4 °C ( ) 
and RT ( ); (B) Implants performed with IFN α-2a/trehalose lyophilisates B - before storage 
( ), stored for 3 months at 4 °C ( ) and RT ( ), stored for 6 months at 4 °C ( ) and RT ( ) 
(average ± SD, n=3). 
The extension of the storage period up to 6 months led to a further reduction of total 
drug liberation. Only 70 % of the incorporated protein could be liberated from 
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implants stored at room temperature. Moreover, protein delivery in early release 
stages appeared to be accelerated in comparison to IFN α-2a liberation from 
implants before storage as well as after 3 month storage. Consequently, release 
profiles approached parabolic forms.          
For implants performed with IFN α-2a/trehalose lyophilisates B and with PEG, no 
correlation of protein release with storage conditions was notified (Fig. 76 B). After a 
3 month and 6 month storage, the attained liberation levels of up to 85 % protein 
were identical to that of matrices before storage. Also, the protein was delivered from 
stored implants in a virtually linear manner during a 1 month incubation period. 
Fig. 77 illustrates IFN α-2a liberation profiles from implants formulated with IFN α-2a/ 
HP-ß-CD lyophilisates and with 10 % PEG.    
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Figure 77: Influence of storage conditions on IFN α-2a release from tristearin matrices 
formulated with HP-ß-CD lyophilisates and with 10 % PEG. Implants were stored over 3 months 
and 6 months at 4 °C and room temperature (33 % rel. humidity), respectively, before release 
studies were conducted - before storage ( ), stored for 3 months at 4 °C ( ) and RT ( ), 
stored for 6 months at 4 °C ( ) and RT ( ) (average ± SD, n=3).    
Generally, more than 95 % of the incorporated protein could be liberated from the 
matrices even after 6 month storage. This indicated protein stability within such 
implants not to be affected during storage. Moreover, the kinetic of release was 
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identical to that before storage, once more revealing a faster IFN α-2a release than 
out of implants comprising trehalose lyophilisates (Fig. 77). 
6.2 Protein stability after 3 months and 6 months of implant storage    
In Fig. 78, IFN α-2a dimer and trimer fractions of total released protein 
(release studies of implants stored at 4 °C over 3 months) are exemplified versus the 
parameter incubation time. Apparently, IFN α-2a liberated from implants containing 
IFN α-2a/trehalose lyophilisates A and PEG revealed a considerable amount of dimer 
and trimer species (> 3 %) as early as after 10 days of incubation. Aggregation 
unambiguously became more extensive with continuing incubation, since the 
aggregate fraction accounted for more than 8 % after 19 days of incubation.  
Time (d)
0 5 10 15 20
D
im
er
 a
nd
 tr
im
er
 a
gg
re
ga
te
s 
(%
)  
0
2
4
6
8
10
 
Figure 78: IFN α-2a dimer and trimer species detected in the release media during in vitro 
release studies; implants were stored at 4 °C over 3 months before release studies were 
conducted. IFN α-2a released from implants performed with ( ) IFN α-2a/trehalose 
lyophilisates A and 10 % PEG, ( ) IFN α-2a/trehalose lyophilisates B and 10 % PEG, ( ) IFN α-
2a/HP-ß-CD lyophilisates and 10 % PEG (average ± SD, n=3). 
In contrast, protein released from implants manufactured with IFN α-2a/trehalose 
lyophilisates B and IFN α-2a/HP-ß-CD lyophilisates also comprised dimer and trimer 
species, yet the total amount of aggregates remained below 2 % throughout the 
incubation period.    
Chapter VIII: Continuous release of IFN alpha-2a from a lipid implant system 152
Furthermore, RP-HPLC analysis of the different samples exhibited a slightly 
increased amount of oxidised IFN α-2a species when the protein was released from 
the trehalose lyophilisate implants, e.g. in a range of 4 – 6 % in comparison to 
standard material (where oxidised protein was around 2 %). Contrarily, IFN α-2a 
liberated from HP-ß-CD lyophilisate matrices demonstrated levels of oxidised protein 
below 2 %.         
After 6 month storage, approximately 15 % of total IFN α-2a released from implants 
manufactured with IFN α-2a/trehalose lyophilisates A and PEG had to be ascribed to 
dimer and trimer protein (Fig. 79). 
The mass of the species released from IFN α-2a/trehalose lyophilisate B implants 
and from IFN α-2a/ HP-ß-CD lyophilisate matrices, respectively, remained constantly 
below 2 % total released protein over the timeframe monitored (Fig. 79).                       
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Figure 79: IFN α-2a dimer and trimer species detected in the release media during in vitro 
release studies. Implants were stored at 4 °C over 6 months before release studies were 
conducted. IFN α-2a released from implants performed with ( ) IFN α-2a/trehalose 
lyophilisates A and 10 % PEG, ( ) IFN α-2a/trehalose lyophilisates B and 10 % PEG, ( ) IFN α-
2a/HP-ß-CD lyophilisates and 10 % PEG (average ± SD, n=3). 
When IFN α-2a was liberated from implants processed with trehalose lyophilisates 
and PEG, oxidised protein was detected to an extent of 10 – 15 % in the release 
media after 6 month storage. In contrast, protein released from the HP-ß-CD 
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matrices remained at a 2 - 3 % level of chemically altered species throughout 
incubation.      
Based on these storage stability data it can be concluded that the high amount of 
dimer and trimer aggregates released from the IFN α-2a/trehalose lyophilisate A 
implants refers to protein instability effects proceeding within the matrices during 
storage. Consequently, higher-order aggregates may also be assumed in the implant 
interior. These species may cause the notable decrease in total protein release 
compared to drug release from the same implants before storage. 
Release experiments of implants formulated with IFN α-2a/trehalose lyophilisates B 
and with 10 % PEG exhibited an incomplete protein liberation of 80 % total 
releasable IFN α-2a before storage. This incomplete liberation was ascribed to 
aggregation proceeding within the matrices during release (refer to this chapter, 
paragraph 4). However, neither total drug liberation nor the release kinetic changed 
when implants were stored over 3 months and 6 months, respectively, prior to 
release experiment initiation. Moreover, the released dimer and trimer species 
remained below 2 % throughout the incubation time. On the other hand, an increased 
amount of oxidised protein species was notable.  
Total protein liberation from implants formulated with IFN α-2a/HP-ß-CD lyophilisates 
and 10 % PEG remained on a 95 % release level also after 6 month implant storage. 
Moreover, the protein was released almost completely in its monomeric form. Here, 
protein liberation generally occurred faster than from implants manufactured with 
trehalose lyophilisates. These data verified HP-ß-CD inhering a solubilising and 
particularly stabilising potential for proteins encapsulated within lipid matrices during 
both storage and release process. 
7. Summary and discussion 
In chapter VII, parameters potentially causing an incomplete IFN α-2a release 
from lipid implants containing PEG as additive were discussed. Based on the 
resulting conclusions and consequences thereof - i.e. the change of the lyophilised 
protein formulation, and the quality improvement associated herewith, as well as the 
change of the containers used during release experiments - the development of a 
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delivery system which allows an almost complete and sustained protein release was 
realised.  
Initially, tristearin implants composed of IFN α-2a/trehalose lyophilisates A and 10 % 
PEG exhibited a high potential as compatible protein delivery devices. Up to 90 % of 
the incorporated protein were released as native monomer in a steady mode over 1 
month. However, long-term storage of such implants appeared to be detrimental for 
the stability of the incorporated protein, apparent by both the reduction of the 
achieved total drug release and the liberation of a high amount of dimer and trimer 
species. Moreover, chemically altered protein molecules were detected. It can be 
supposed that the mixture of protein, trehalose, PEG and tristearin material per se 
somewhat fosters IFN α-2a instability within the matrices during storage and 
subsequent release. That means lipid-protein interactions being possible especially 
during an extended time of storage, and trehalose lyophilisates A appear not to be 
effective to provide a full protein protection. Consequently, this may lead to both 
protein aggregation as well as to an increase in overall tendency for IFN α-2a to 
remain within the lipid matrix due to non-covalent interactions. 
Not more than 83 % of the incorporated protein could be liberated from implants 
manufactured with IFN α-2a/trehalose lyophilisate B matrices and with 10 % PEG 
during all release experiments. This incomplete release may also implicate that 
trehalose did not protect the incorporated IFN α-2a sufficiently from aggregation 
and/or from lipid-protein interactions.  
Otherwise, the total amount of releasable protein and the release kinetics did not 
alter due to the precedent long-term storage. Moreover, the amount of released 
dimer and trimer species remained below 2 % throughout incubation. Thus, it can be 
suggested that the protein/trehalose lyophilised B formulation appears to be more 
effective in IFN α-2a stabilisation within the tristearin implants over time than the 
lyophilisate A formulation.  
In contrast, 95 % of the initially incorporated IFN α-2a could be liberated continuously 
during a 1 month period from tristearin implants manufactured with IFN α-2a/HP-ß-
CD lyophilisates and PEG, even after 6 month storage of the implants. In addition to 
that, protein was released from such implants almost in its native monomeric form, 
whereas aggregated species were liberated only marginally.  
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This obviously indicates the high potential of HP-ß-CD in protein stabilisation and 
solubilisation within the matrix during both storage and release processes. It can be 
hypothesised that HP-ß-CD reduces the hydrophobic interactions of protein and lipid 
matrix material by complexing the protein in its native or potentially in its (partly) 
denatured form. Thereby, the overall tendency for IFN α-2a to remain in the lipid 
matrix due to non-covalent interactions may be substantially lowered.           
Moreover, it was shown that polyethylene glycol 6000 (PEG) enabled the control of 
IFN α-2a release from such implants. Whereas implants without PEG showed a fast 
and high protein delivery during early release phases, the addition of PEG reduced 
the burst below 25 % and protein liberation lasted over 1 month, with release 
proceeding in almost linear manner within the very first two weeks. By increasing the 
PEG levels (> 14 %), protein liberation succeeded faster and terminated after 2 
weeks. 
Based on Fick`s laws and the Higuchi equation, the release of macromolecules from 
inert matrices (e.g. wax matrices or non-biodegradable polymeric matrices) is usually 
discussed being a diffusion-controlled process through water-filled pores and 
channels. That means diffusion to be the rate limiting factor in drug release, even 
when specific models are normally necessary to take factors into account such as 
drug solubility, the dependence of the diffusion coefficient on drug concentration and 
the mass transfer per se [12; 182; 113].  
As a result of the release data presented in this chapter, it can be reported that IFN 
α-2a liberation from tristearin matrices without PEG can also be described as 
diffusion-controlled process. The obtained release profiles matched well the 
mathematical models for diffusion-controlled drug release from cylindrical dosage 
forms [183].  
However, the addition of PEG appears to inhere an obvious influence on the release 
mechanism from the tristearin implants. At this state of the thesis, a pure diffusion-
controlled process could be excluded, since the mathematical model describing this 
procedure failed, even with a low amount of PEG having been added. On the other 
hand, SEM and mercurial porosimetry evidenced porous structures within the 
matrices, thus confirming dissolution and diffusion progression of PEG and protein 
particles to happen during release experiments. 
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PEG featured a distinctive effect on the arrangement of particles while compressing. 
This was apparent by the more compact matrices as a result of a denser packaging. 
The density of the implants increased step by step with higher amounts of PEG – i.e. 
a rise of 1.35 % in density for a 5 % PEG content compared to implants without PEG 
and up to 4.26 % for a 20 % PEG content was determined. Consequently, the denser 
packaging of PEG containing matrices can be asserted as one explanation for the 
sustained IFN α-2a liberation in early release phases.  
A further explanation for the altered release mechanism with PEG can be given when 
assuming reversible IFN α-2a precipitation caused by PEG within the matrices during 
release. Sharma and Kalonia demonstrated that the solubility of IFN α-2a decreased 
with an increase in PEG concentration and, also, with an increase of the PEG 
molecular weight. For a 5 % (w/v) PEG 1450 solution IFN α-2a solubility at 25 °C, pH 
6.5, was 0.8 mg/mL. Employing a 5 % (w/v) PEG 4600 solution led to a decrease in 
protein solubility below 0.4 mg/mL and with 10 % PEG solubility values around 0.05 
mg/mL were determined. It was also shown that the occurring precipitation was 
reversible and affected the tertiary structure of the protein only marginally [180]. 
Of course, these literature data can not be transferred principally to the processes 
occurring within the lipid implant systems during release, but it is noticeable that a 
protein precipitation process can be suggested to explain the altered release 
mechanism and the sustained IFN α-2a liberation from tristearin matrices with PEG. 
Specified investigations on that are in progress in order to further elucidate the 
different scenarios. 
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Chapter IX: Final summary, conclusions, and prospective 
The development of sustained and controlled injectable systems can be 
considered as the most promising strategy in protein parenteral delivery. However, 
over the last few years it has become obvious that the encapsulation of proteins in 
polymeric devices – in particular in PLGA systems – is hampered by substantial 
protein degradation occurring during both manufacturing and release [45; 130; 144; 
225]. 
In the search for alternative biomaterials for use in controlled protein release systems 
natural lipophilic products such as fatty acids, glycerides and waxes appeared on the 
radar screen. Unambiguously inhering high potential in protein delivery, these 
materials took a back seat over the last years, mainly because it was focused on 
veterinary applications [211; 154; 188; 105]. It was the aim of this thesis to develop a 
protein delivery system based on lipid implants for human and animal use which 
allows the protein to be continuously released in its native form. 
 
In the theoretical section (Chapter I), protein release devices in general are 
introduced. Backgrounds of degradation of proteins encapsulated in polymeric 
biodegradable devices are presented as well as basic improvements and prosperities 
when using those systems. Furthermore, it is dealt with the development of protein 
release devices based on lipophilic materials. Various manufacturing techniques, 
principles of sustained and controlled release from such systems and several 
promising features already attained in the use of lipid materials are presented. A 
summary of the theoretical principles and the aim of this thesis are outlined in 
Chapter II. Chapter III lists the materials and methods used in this work, where three 
different protein drugs were employed – granulocyte colony stimulating factor (G-
CSF), interferon α-2a (IFN α-2a) and bovine serum albumin (BSA).    
 
Chapter IV addresses tentative investigations for the characterisation of pure lipid 
implants in terms of their polymorphic behaviour, erosion properties, and basic 
applicability as delivery systems for protein drugs. Here, stearic acid was tested and 
constraints in its applicability were revealed: (I) A notable polymorphic transition of 
stable stearic acid material to instable forms during implant manufacturing could 
potentially influence the stability of the dosage forms, and (II) proteins were 
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demonstrated to interact with erosion products of stearic acid material what results in 
denaturation and intense aggregation within a few days. 
In contrast, triglyceride materials could be illustrated to reveal a high potential as 
compatible delivery systems for protein drugs. These products remained in stable ß-
modification during implant compressing and, moreover, protein integrity was not 
affected by the triglyceride implant systems themselves. 
In order to render investigations on the influence of the manufacturing process on 
protein stability possible, a novel method for protein extraction was developed. 
Without using organic solvents during extraction, this method avoids the detraction 
from protein stability due to extraction process per se.   
Implant manufacture by compressing was demonstrated to work under mild 
conditions, retaining protein integrity during the preparation of the lipid devices. As a 
consequence, lipid matrices were loaded almost exclusively with native protein – 
thus, assessment of data of subsequent release studies could be performed on a 
meaningful basis and in an accurate way.    
 
In Chapter V, grounds were provided for protein delivery from tristearin implants. 
Parameters such as drug load and compression force, which can potentially 
influence protein release, were scrutinised and optimised from a feasibility 
perspective.  
In general, release profiles achieved during these first in vitro release experiments 
were characterised by initial burst effects followed by a phase of non-release and 
eventually incomplete protein release from the lipid implants. Only for BSA, sustained 
protein liberation could be realised - i.e. 40 % of the incorporated BSA were 
continuously released over 1 month from tristearin matrices with a 10 % drug load.         
The application of various excipients as release modifiers was examined. 
Polyethylene glycol 6000 (2 % - 5 % range) and Poloxamer 188 (2 % content) have 
not shown any effects what was attributed to insufficient levels of the added 
components.  
The phospholipid 1,2-Dioleyl-sn-Glycero-3-Phosphocholine (DOPC), on the other 
hand, was demonstrated to inhere a high potential in particular for a sustained IFN α-
2a release – when 10 % DOPC were added. A continuous liberation of up to 30 % 
protein was achieved over 12 days. But mixtures with higher DOPC levels, e.g. 20 % 
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and 30 %, suffered from their substantially reduced compressibility, thus implants 
could not be prepared by compressing. 
Alternatively, throughout all experiments G-CSF delivery could not be enhanced 
above a total of 23 % releasable protein. Based on these study data, investigations 
on G-CSF as a model drug were abandoned up at this state. 
For BSA and IFN α-2a, special attempts in terms of enhancing and controlling protein 
delivery from lipid implants are outlined in Chapter VI and VII.  
    
For BSA (Chapter VI), employing monoglyceride and diglyceride material in protein 
drug delivery resulted in high burst effects of up to 60 % BSA release within 4 days. 
This burst phase was followed by almost non-release and thus incomplete BSA 
release from the devices.   
It was further demonstrated that polyglycerol ester matrices allow a sustained protein 
delivery approaching zero-order kinetics, but intense aggregation as a result of matrix 
swelling and erosion was to be noted as drawback. 
The addition of 10 % or more PEG to tristearin material overcame previous problems 
of low total drug release and protein instability. Nevertheless, complete BSA 
liberation could not be achieved. As a consequence, it was tested whether a change 
in the freeze-dried formulation would enable a 100 % BSA delivery from tristearin 
implants containing PEG. By this, a full release of BSA was allowed within 4 days.  
         
This improvement by solely the lyophilised formulations alone was deemed as crux of 
the matter in protein delivery from lipid implants and this was proven by a substantial 
increase in total releasable IFN α-2a (Chapter VII).  
Protein release from devices containing monoglycerides and/or diglycerides were 
studied, but found to perform badly due to high initial burst effects.  
Polyglycerol ester matrices resulted in intense IFN α-2a aggregation because of 
implant swelling and erosion. 
On the other hand, tristearin implants containing PEG 6000 enabled the development 
of a delivery system allowing the protein to be continuously released over weeks. For 
instance, a PEG content of 10 % achieved an almost linear IFN α-2a liberation up to 
70 %, delivered over a 1 month period. Moreover, liberated protein consisted virtually 
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completely of monomeric protein. Higher PEG amounts accelerated protein liberation 
but did not offer a positive influence on the total amount of releasable IFN α-2a.  
A high IFN α-2a adsorption upon the used glass repositories during release 
experiments was assessed, leading to the conclusion that actually more protein was 
released from the implants than detected in the buffer media. This problem was 
solved by using cycloolefin containers (TopPac®) in later experiments.  
Moreover, specified stability studies showed that the IFN α-2a/trehalose lyophilised 
formulation used hitherto was still suboptimal for protein stabilisation, when 
rehydrated and incubated at 37 °C. As a consequence, the formulation stability was 
further improved by (I) changing the trehalose formulation pH prior to freeze-drying 
and (II) replacing trehalose by hydroxypropyl-ß-cyclodextrin (HP-ß-CD) as cryo- and 
lyoprotectant, with concomitant pH adjustment.                                    
 
The experience gained so far was finally used for the successful development of an 
IFN α-2a delivery system based on tristearin material (Chapter VIII). This system 
allows 95 % protein liberation in a continuous manner over a 1 month period, 
whereby a control of protein release was achieved by the addition of polyethylene 
glycol 6000 as pore forming agent. Initial burst release was reduced to values below 
25 % - and low burst effects are considered a cachet in this field. Moreover, IFN α-2a 
was liberated almost exclusively in its native monomeric form.    
A substantial impact of the applied lyophilised protein formulation on the stability of 
the dosage form during long-term storage has been notified. Trehalose featured to be 
less effective in the protection of encapsulated IFN α-2a, what resulted in reduced 
total drug release rates as well as in the liberation of aggregated protein species (i.e. 
dimer and trimer protein) from such lipid matrices after 6 month storage.  
In contrast, HP-ß-CD can be considered a very valuable excipient providing IFN α-2a 
protection within the lipid implants during storage and during the release process. 
Even after an extended storage period of the dosage forms, the incorporated IFN α-
2a was liberated in its native form in a sustained way over 1 month from IFN α-
2a/HP-ß-CD lyophilisate tristearin devices containing PEG. 
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Conclusions and prospective:  
The use of synthetic, biodegradable polymers is prevalently considered state-of-the-
art in the development of controlled release systems for protein drugs. However, 
unveiled risks of protein inactivation during manufacturing and release represent a 
bottleneck in the final success of these systems over the last years [197; 176]. 
In this thesis, a sustained release implant device based on lipid materials for 
interferon α-2a (IFN α-2a) was developed, which provides high protein stability during 
implant preparation, storage, and drug release. Thus, the known problems of immune 
response associated with higher-order aggregate formation in proteinic drugs can be 
overcome. Adjustment of the lyophilisate formulation as well as of PEG and lipid 
qualities and quantities allow to control the release rate in order to realise the dosing 
schedule aimed for. Consequently, this device can be used as a very promising 
platform to deliver large pharmaceutical proteins for periods up to 1 month and even 
beyond.          
 
Several studies addressed the poor erosion phenomena of triglyceride implants in 
vivo what can be attributed to the size, the compact geometry, and the reduced 
specific surface of implant devices [125; 141; 211]. Based on these literature data 
and on the notable lack of in vitro erosion properties, the option of fostering in vivo 
biodegradation by lipases might questionable for the developed lipid implants.  
 
For human use, non-biodegradability would limit the application of this delivery 
device. However, in vivo studies monitored a timeframe of maximal one month after 
administration [211]. Consequently, it is conceivable that triglyceride implants 
undergo in vivo biodegradation, but with a substantial gap between the drug release 
period and the erosion process. Even in case the lipid matrices would degrade in vivo 
as late as after half a year, grave side effects are not to be expected due the high 
biocompatibility of these materials inhere [211]. Moreover, the option to isolate the 
release process from matrix degradation can be deemed advantageous in terms of 
protein liberation control. Therefore, it has to be the objective of further investigations 
to evaluate the in vivo biodegradation of the developed lipid implants and to 
especially clarify the role of lipases thereby. 
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Otherwise, the influence of the geometry - i.e. the use of smaller implants and 
microparticles - is to be illuminated with respect to a potential biodegradability and, 
furthermore, the chance of an improved patient compliance.  
The in vivo degradation of triglyceride microparticles within 7 days was already 
demonstrated [154], and solid lipid nanoparticles (SLNs) were shown to erode in vitro 
by adding various quantities of a lipase/colipase assay [139]. These studies indicate 
that the effect of lipases seems to be impacted by the surface area the delivery 
system provides.  
Additionally, the SLN degradation studies revealed matrices with lower crystallinity to 
exhibit a faster degradation rate than devices processing highly crystalline products 
[140]. Consequently, it can be assumed that the use of mixed-acid triglycerides, 
which inhere lower crystalline properties, may improve the biodegradability of the 
lipid implants [169; 127]. 
One further interesting approach may be the direct incorporation of lipase/colipase 
into the lipid implants before drug release already at the stage of manufacture. It is 
possible that the implant erosion might be triggered from the interior after 
administration. 
 
For the veterinary market, the protein-lipid dosage form developed in this work can 
be applied without any doubt, since comparable lipid implant systems exhibited a 
high biocompatibility in vivo and did not cause severe side-effects or immune 
response due to implant size or the non-biodegradability [105; 141; 211].  
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Chapter X: Near-Infrared Spectroscopy (NIRS) as non-destructive analytical 
tool for protein quantification within lipid implants 
1. Background 
Currently, great interest is put on the encapsulation of biologically active 
proteins in sustained release devices such as PLGA particles or, as focused on in 
this thesis as lipid implant carriers. In order to determine the actual drug load and 
drug distribution after encapsulation, for most analytical methods the protein first is to 
be extracted from the matrices. That implicates a potential protein loss or, in case of 
extraction with organic solvents, protein aggregation, which is often induced by such 
methodical procedures (refer to Chapter IV). It is to be noted, that during release 
studies protein quantification measurements are generally indirect. That means the 
liberated protein quantity is detected in the release medium, for example by 
chromatographic techniques. Consequently, the protein fraction remaining in the 
devices is calculated by subtraction. 
Therefore, it would be advantageous to have a method available for performing such 
analysis directly within the controlled release device and thus without destructing the 
carrier system. In this respect, the successful use of (Fourier-transform) spectroscopy 
in the determination of protein conformation within PLGA microparticles was reported 
by van de Weert et al. [200].  
One other technique amenable to non-destructive analysis of such systems is Near- 
Infrared Spectroscopy (NIRS). An introduction in NIRS technique, measurements 
and spectra interpretation is provided by Schoenbrodt et al. [170; 171]. Although 
NIRS has been used for many decades, it never was established as a common 
analytical and physical tool as so many other spectroscopic techniques [111]. With 
the development of novel imaging systems (e.g. focal plane array detection 
technology), it is now possible to rapidly collect high contrast images of large 
samples. That suggests considerable value of NIRS for the chemical and functional 
characterisation of complex solid pharmaceutical dosage forms including sustained 
protein release devices [152].  
For example, Reich et al. demonstrated non-destructive NIRS monitoring of matrix 
hydration, polymer hydrolysis and free carboxylic end group ionisation of PLGA 
microparticles. Furthermore, drug-polymer interactions and drug release kinetics 
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were visualised [151]. In a later work, chemical mapping of the distribution and 
relative abundance of a model protein in polymer matrix tablets - immediately after 
processing and during the release phase - was shown [152]. 
That promising results obtained from polymeric devices exhibited the potential 
application of NIRS measurements for protein content determination within lipid 
implants. 
2. The potential of NIRS for protein quantification in lipid matrices     
The following investigations base upon a close collaboration with the Institute 
of Pharmaceutical Technology in Heidelberg, Germany, where NIRS measurements 
were conducted. For all experiments, a NIRTab® spectrometer (Büchi AG, Flawil, 
Switzerland) was used. Spectra analysis was performed with NIRCal® software 
package version 3.0 and 4.21 (Büchi AG, Flawil, Switzerland).     
 
Initially, the general ability of NIRS for dosage forms based on lipid material was 
evaluated. In this realm, investigations were performed which should clarify to what 
extent the implant shaping potentially can influence the optical properties of the 
matrices and, consequently, the NIR spectra.  
The first set of lipid implants was prepared with varying levels of lyophilised G-CSF 
(protein/sugar ratio of 1:4) and with tristearin material. This implant batch was 
characterised by diameters of 13 mm, but matrices varied in weights between 82 – 
196 mg with height dimensions of 0.6 – 1.5 mm.  
The spectra showed enormous scattering in transmittance intensity, what was 
ascribed to the sample geometry. Generally, implants were very flat with low optical 
density. The heterogeneity in implant dimensions resulted in different optical 
properties of the matrices. As a consequence, a quantitative calibration of 
transmittance spectra was not to be rendered possible. On the other hand, spectra 
measured in diffuse reflectance mode allowed good quantitative calibrations using 
principle component regression (PCR) and partial least squares regression (PLSR). 
Regression coefficients ranged between 0.994 – 0.997 [173; 172].  
As a result, these first experiments showed the basic ability of NIRS to determine the 
protein content in lipid matrices. Due to the scattering in transmittance intensity, the 
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sample geometry was modified for further investigations, and implants with a 
diameter of 5 mm and height dimensions of about 3 mm were prepared. 
The second approach should demonstrate that only the protein and not the sugar 
component of the incorporated freeze-dried formulation was spectroscopically 
detected. Therefore, two implant sets were prepared with BSA as protein drug 
compound: (I) BSA was lyophilised in different ratios with trehalose (protein/sugar 
ratios of 1:1 –1:5). However, the drug load of the implants was kept constant at 10 % 
(w/w) for all formulations. This resulted in actual BSA charges in a range of 1.66 - 5 
% of implant weight. (II) Implants were prepared with pure BSA (lyophilised without 
additives) in content ranges between 2 - 10 % (w/w). 
Analysis of transmittance spectra obtained from the first BSA implant set (I) yielded a 
calibration regression coefficient of 0.992. The standard value of prediction (SEP – 
appreciation value for the quality of the predicted calibration model) was 0.16 mg and 
BIAS failure, as parameter for the mean deviation of two data sets, was – 0.04 mg. 
Given the narrow calibration area as well as the low number of implant samples, the 
obtained calibration data were acceptable. Moreover, the calibration obviously was 
based on spectral information derived from the protein, due to the fact that the 
implants contained varying contents of protein and sugar [173; 172]. 
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Figure 80: BSA content in lipid implants. PLSR of transmittance spectra of implants containing 
pure BSA in various contents, 4 calibration factors, second derivative, 6000 – 11520 cm-1 (n=24) 
[172].   
As visualised in Fig. 80, transmittance measurements of implants loaded with 
different levels of pure BSA exhibited good quantitative calibrations with regression 
coefficient of 0.994 (validation) and 0.996 (calibration), respectively. The SEP value 
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once showed 0.16 mg, but the BIAS failure substantially decreased to – 0.009 mg, 
what proved calibration to be of good acceptance [173; 172]. 
Based on these two experimental results, it could be demonstrated that calibration 
models really based on spectral features of the incorporated protein and not on the 
sugar component [173; 172].  
 
In further investigations, the promising results obtained for BSA lipid implants should 
be transferred on IFN α-2a, a pharmaceutically relevant protein. Since the developed 
IFN α-2a delivery device based on tristearin matrices and contained PEG as release 
modifier (refer to chapter VII), the influence of PEG on NIRS calibration was to be 
specified. Two implant sets containing IFN α-2a lyophilised with trehalose in a ratio of 
1:3 were prepared: (I) the drug load was varied between 10 - 30 % lyophilised protein 
and, (II) in addition to the different drug load the second implant batch contained 10 
% PEG as additive. This experimental design resulted in IFN α-2a loads in a range of 
1070 – 3700 µg protein per implant. 
Fig. 81 illustrates the calibration of the transmittance spectra obtained from both IFN 
α-2a implants without PEG and matrices containing 10 % PEG. 
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Figure 81: IFN α-2a content in tristearin implants with and without PEG as additive. 
Transmittance spectra, PLSR, 7 calibration factors, first derivative and normalisation, 6000 – 
11520 cm-1 (n=24) [172].          
The calibration model apparently demonstrated NIRS enabling also the determination 
of the IFN α-2a load within lipid implants. The standard value of prediction was 176 
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µg and acceptable calibration coefficients (Fig. 81) were reached. Furthermore, 
calibration and validation curves were almost identical [172]. 
Moreover, these results suggested that the addition of PEG had no impact on the 
calibration at all, since both implants with and without PEG were included in this 
model system. 
On the other hand, cluster analysis revealed qualitative spectral differences between 
implant systems with and without PEG (Fig. 82). However, the principle component 
analysis (PCA) mirrored a factor 4, what indicated the influence of PEG on the 
spectra data to be considered as marginally [172]. 
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Figure 82: Cluster analysis of IFN α-2a/tristearin implants with ( ) and without ( ) PEG. 
Transmittance spectra, cluster, first derivative, 7000 – 8000 & 9000 – 10000 cm-1 [172].       
It can be concluded that protein quantification will not be affected by the amount of 
PEG. This was important with respect to the application of NIRS as tool for analysis 
of protein liberation during release experiments, because the PEG amount can 
change within the matrices during release. 
  
Based on these encouraging data, the aptitude of NIRS to determine the protein 
content in the lipid implants during release was evaluated. Tristearin matrices loaded 
with 10 % lyophilised IFN α-2a (protein/sugar ratio of 1:3) and PEG contents of 5 % 
and 10 %, respectively, were prepared. In addition, implants with a protein load of 20 
% and 10 % PEG were used as delivery systems, potentially allowing an accelerated 
and more complete protein release. Before this release studies, the actual protein 
load ranged between 915 – 1270 µg for implants loaded with 10 % lyophilised 
protein, and between 1600 – 2095 µg for the 20 % IFN α-2a/trehalose lyophilisate 
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matrices. Implants were incubated in 2.0 mL PBS (pH 7.4 with 0.05 % NaN3) over 
various time periods (i.e. 1, 3, 5, 7, 9, 12, 15, 18 and 21 days). 
IFN α-2a was continuously liberated from matrices with a 5 % and a 10 % PEG 
content. This resulted in remaining IFN α-2a fractions in a range of 200 – 1020 µg 
per implant after incubation. Implants loaded with 20 % lyophilised protein and with 
10 % PEG led to an accelerated IFN α-2a release, delivering approximately up to 90 
% protein over 6 days. Consequently, the remaining protein amount within the 
implants was between 70 – 380 µg. After the respective incubation time, implants 
were removed from the buffer media and were dried at room temperature as far as a 
constant weight was measurable. Then, transmittance spectra were taken.    
As visualised in Fig. 4, NIRS allowed the prediction of the IFN α-2a content within the 
lipid implants, independent from the protein load before incubation. A calibration with 
a standard of prediction value (SEP) of 57 µg and a calibration regression coefficient 
of 0.987 was achieved. Moreover, even low protein contents of 100 – 200 µg could 
be addressed [172].  
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Figure 83: IFN α-2a release from tristearin implants containing PEG. Before incubation, 
implants were loaded with 10 % and 20 % lyophilised protein, respectively. Implants were 
incubated over various time periods, dried and subjected before NIRS measurements. 
Transmittance spectra, PLSR, 5 calibration factors, MCS & second derivative, 6000 – 9000 cm-1, 
(n=47) [172].          
These study data can be deemed a major attainment considering the complexity of 
the investigated delivery system. Despite the presence of lipid, sugar and PEG 
material, plus the considerable alteration of matrix composition and porosity during 
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release, NIRS still allows the determination of the protein content within the implant 
systems. 
3. Summary 
The ability of Near Infrared spectroscopy as non-destructive analytical tool for 
protein quantification in lipid implants was investigated. 
Tentative experiments featured diffuse reflectance being useful for the determination 
of the drug load in very flat implants (height: 0.6 – 1.5 mm). In contrast, for protein 
determination in implants with base heights greater than 1.5 mm – as presented in 
this thesis work – transmittance measurements can be considered appropriate. 
Based on this, a good calibration model was achieved. 
It was demonstrated that the protein per se and not the incorporated sugar 
accounted for the spectral information. BSA content measurements in both implants 
with varying protein/sugar ratios and implants loaded with different levels of pure 
BSA demonstrated this set-up to be a good calibration model. 
In further investigations, the determination of the IFN α-2a content in tristearin 
matrices containing polyethylene glycol (PEG) as additive was evaluated. It could be 
shown that NIRS can be used as a tool for content determination of various proteins, 
since transmittance spectra proved the good calibration also for IFN α-2a 
measurements. Moreover, the influence of PEG was shown being negligible for IFN 
α-2a quantification by NIRS. 
During release experiments, NIRS allows a good prediction of the IFN α-2a content 
remaining in the lipid implants. This results in a calibration regression coefficient of 
0.987. In addition to that, minor protein amounts could also be determined 
demonstrating a low detection limit of NIRS. 
Generally, calibration models for protein quantification mainly based on vibrations of 
the N-H bands in protein molecules [172]. 
 
In summary, these study data demonstrated NIRS to be a promising technique for 
the quantification of the protein content in sustained delivery systems such as lipid 
implants. As a non-destructive method, NIR enables to determine the protein load of 
implants without complicated protein extraction steps, subsequent to implant 
manufacture, and also during release experiments. 
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